Epigenetics Congress 2018 Book

September 2018 | Volume 7
conferenceseries.com ISSN: 2161-1041

Hereditary Genetics: Current Research
Proceedings of
4th International Congress on
EPIGENETICS
& CHROMATIN
September 03-05, 2018
London, UK
Conference Series llc LTD - UK

47 Churchfield Road, London, W3 6AY
Exhibitors Toll Free: +1-800-014-8923

Scientific Program
EPIGENETICS 2018
Page 2
conferenceseries.com
DAY-1
September 03, 2018
Meeting Hall: Bleriot 1
09:00-09:30 Registrations
Opening Ceremony 09:30-09:55

Keynote Forum
09:55-10:00 Introduction
Title: DNA analogues for CRISPER/CAS fidelity and exon skipping

10:00-10:40
Marvin H Caruthers, University of Colorado, USA
Title: Maternal exposure to environmental particles leads to transgenerational epigenetic

10:40-11:20 transmission of asthma risk
Alexey V Fedulov, Alpert School of Medicine of Brown University - Rhode Island Hospital, USA
Group Photo, Networking & Refreshments 11:20-11:50 @ Foyer
Title: ChIPmentation: An innovative technology for fast and high quality ChIP-seq
11:50-12:15
Anne Clémence Veillard, Diagenode, Belgium
Sessions: Epigenetics | Cancer Epigenetics | DNA Methylation
Chair: Michelle M. Hanna, Ribomed Biotechnologies, USA

Co-Chair: Charles De Smet, De Duve Institute - University of Louvain, Belgium
Introduction
Title: Evaluating drug-chromatin interactions using novel methods for target engagement studies
12:15-12:40
Marta Rucka, Promega, UK
Title: Targeting a lncRNA – epigenetic factor complex to inhibit colon cancer metabolism
12:40-13:05
Maria Hatziapostolou, Nottingham Trent University, UK
Lunch Break 13:05-14:05 @ Hotel Restaurants
Title: Epigenetic regulation of leukemia

14:05-14:30
Andreas Lennartsson, Karolinska Institute, Sweden
Title: Methylation pattern switch between low and high grade cervical intraepithelial neoplasia:
14:30-14:55 implications for progression models, robust triage and cancer risk
Belinda Nedjai, Barts and the London School of Medicine and Dentistry - Queen Mary University, UK
Page 3
Special Session | Title: The genetics of common diseases

14:55-15:20
Kari Stefansson, deCODE Genetics, Iceland
Title: Generation of long acting therapies using glycosylated linkers

15:20-15:45
Abdulrahman Alshehri, University of Sheffield, UK
Title: Synergistic pharmacology: targeting two epigenetic enzyme targets in a protein complex
15:45-16:10
Sriram Raja Gopal, Jubilant Drug Discovery and Development Center, India
Networking & Refreshments 16:10-16:30 @ Foyer
Title: Alterations of DNA methylation seem to be an early event in the development of tumors from
16:30-16:55 the upper aerodigestive tract
Sheila Coelho Soares Lima, Brazilian National Cancer Institute, Brazil
Title: Robust joint statistical tests for DNA methylation data

16:55-17:20
Xiaogang Steven Wang, York University, Canada
Title: Role of DNA methylation in sperm nuclear-encoded of oxidative phosphorylation pathway

17:20-17:45 regulation and embryo development
Mahmoud Hashemitabar, Ahvaz Jundishapur University of Medical Sciences, Iran
Panel Discussion
DAY-2
September 04, 2018
Keynote Forum
Title: Simultaneous measurement of MGMT methylation and determination of IDH1 R132H and
CpG Island Methylator Phenotype (CIMP) in Gliomas using Coupled Abscription PCR Signaling
10:05-10:45
(CAPS)
Michelle M. Hanna, Ribomed Biotechnologies, USA
Title: The histone H3K79 methyltransferase DOT1L regulates gene transcription and promotes
10:45-11:25 neuroblastoma tumourigenesis
Tao Liu, Histone Modification Group Children's Cancer Institute, Australia
Networking & Refreshments 11:25 -11:45 @ Foyer
Title: Identification of DNA methylation of distal regulatory regions with causal effect on
11:45-12:05 tumoriginesis
Jiangwen Zhang, University of Hong Kong, Hong Kong
Page 4
Sessions: Epigenetics | Chromatin
Chair: Marvin H Caruthers, University of Colorado, USA

Co-Chair: Xiaogang Steven Wang, University of Colorado, USA
Introduction
Title: The centenarian epigenome: DNA methylation and chromatin formation of the oldest old
12:25-12:50
Danielle Gutman, University of Haifa, Israel
Title: Activation of epigenetics pass way for improving traits in different cultivars
12:50-13:15
Avner Shenfeld, Epigenetics Ltd, Israel
Title: Epigenetic editing in the promoter of CXCL11 gene

14:15-14:40
Alexey V. Fedulov, Brown University, USA
Title: Transcriptional regulation by histone modifications using yeast model

14:40-15:05
Jung Shin Lee, Kangwon National University, South Korea
Poster Presentations 15:05-16:05

Poster Judge: Charles De Smet, De Duve Institute - University of Louvain, Belgium
Title: Valproic acid effects on DNA methylation during the cell cycle of HeLa cells
EC01
Marina Amorim Rocha, University of Campinas, Brazil
Title:Writing about epigenetics for allied health professionals in gerontology

EC02
Celia Mary Ross, Delaware Gerontology Institute, LLC, USA
Title: Role of DNA methylation in resistance to platinum-based chemotherapy in ovarian cancer

EC03 cells
Marcela Chmelarova, University Hospital Hradec Kralove, Czech Republic
Title: Heterogeneity, phenotypic and genotypic instability of the primary tumor and its metastasis
EC04
Nawel Agher, University Hospital of Sidi Bel Abbés, Algeria
Title: Doxorubicin induces large-scale histone redistribution in live cells

EC05
Péter Nánási, University of Debrecen, Hungary
Title: H2A.Z: stable or not stable that is the question

EC06
László Imre, University of Debrecen, Hungary
Title: Metastasis-associated protein 2 (MTA2) as a regulator of NF-kB in lung cancer

EC07
Nefertiti El-Nikhely, Institute of Graduate Studies and Research, Alexandria University, Egypt
Title: Emerging role of histone Lysine Methyltransferase SETDB1 and repressive

EC08 histone marks H3K9me3, H4K20me3, H3K4me3 in pediatric brain tumors
Alexia Klonou, Kapodistrian University of Athens Medical School, Greece
Networking & Refreshments 16:05-16:25 @ Foyer
Page 5
Panel Discussion
DAY-3
September 05, 2018
Keynote Forum
Title: Transcriptional overlap links DNA hypo-methylation and hyper-methylation of contiguous
10:05-10:45 promoters in cancer
Charles De Smet, De Duve Institute - University of Louvain, Belgium
Title: The decline of the prevalence of cancers during organism senescence

10:45-11:25
Alvaro Macieira Coelho, French National Institute of Health, France
Networking & Refreshments 11:25-11: 45 @ Foyer
Sessions: Genomics | Biomarkers | Histone Proteins
Chair: Jiangwen Zhang, University of Hong Kong, Hong Kong

Co-Chair: Tao Liu, Histone Modification Group Children’s Cancer Institute, Australia
Introduction
Title: Detection of tumor-related DNA methylation biomarkers in liquid biopsies from metastatic
11:45-12:10 castration resistant prostate cancer patients to improve treatment decisions
Madonna R Peter, University of Toronto, Canada
Title: Emergence of novel CpG islands and genomic imprinting in mammalian evolution
12:10-12: 35
Shunsuke Suzuki, Shinshu University, Japan
Title: TRF1 suppresses Break Induced Replication and early onset of ALT induction
12:35 -13:00
Jean-Baptiste Vannier, Imperial College London, UK
Awards & Closing Ceremony
Bookmark your Dates

Epigenetics & Chromatin

August 22-23, 2019 | Vienna, Austria
E: epigenetics@oncologyseries.com; epigenetics@conferenceseries.net
Website: epigenetics.conferenceseries.com
Page 6
List of Open Access Journals
Agri, Food & Aqua Immuno Chemistry: Open Access -
Advances in Crop Science and Technology 2329-8863 Industrial Chemistry: Open Access -
Advances in Dairy Research 2329-888X International Journal of Applied Biology and Pharmaceutical
0976-4550
Technology
Agrotechnology 2168-9881
International Journal of Drug Development & Research 0975-9344
Aquaculture Research & Development 2155-9546
Arabidopsis C. Elegans and Zebrafish - Mass Spectrometry: Open Access -
Biofertilizers & Biopesticides 2155-6202 Medicinal Chemistry 2161-0444
Crop Research 2454-1761 Modern Chemistry & Applications 2329-6798
Experimental Food Chemistry - Natural Products Chemistry & Research Journal 2329-6836
Fisheries & Livestock Production 2332-2608 Neuro Chemistry: Open Access -
Fisheries and Aquaculture Journal 2150-3508
Organic & Inorganic Chemistry -
Fisheriessciences 1307-234X
Organic Chemistry: Current Research 2161-0401
Food & Industrial Microbiology -
Food & Nutritional Disorders 2324-9323 Pharmaceutical Analytical Chemistry: Open Access -
Food Processing & Technology 2157-7110 Physical Chemistry & Biophysics 2161-0398
Food: Microbiology, Safety & Hygiene - RROIJ: Medicinal Chemistry -
Forest Research 2168-9776 Structural Chemsitry & Crystallography Communication -
Horticulture 2376-0354 Trends in Green Chemistry -
International Biodiversity, Bioprospecting and Development 2376-0214
Vitamins & Minerals 2376-1318
Marine Science: Research & Development 2155-9910
Medicinal & Aromatic Plants 2167-0412 Clinical
Nutrition & Food Sciences 2155-9600
Ageing Science 2329-8847
Plant Pathology & Microbiology 2157-7471
Ancient Diseases & Preventive Remedies 2329-8731
Poultry, Fisheries & Wildlife Sciences 2375-446X
Anesthesia & Clinical Research 2155-6148
Probiotics & Health 2329-8901
Annals of Clinical and Laboratory Research 2386-5180
Research & Reviews: Journal of Agriculture and Allied Sciences 2347-226X
Arrhythmia: Open Access -
Research & Reviews: Journal of Food and Dairy Technology 2321-6204
Atherosclerosis: Open Access -
Rice Research 2375-4338 Cell Biology: Research & Therapy 2324-9293
Traditional Medicine and Clinical Naturopathy (Homeopathy & Ayurve- Cellular & Molecular Pathology -
-
dic Medicine-2167-1206)
Clinical & Experimental Cardiology 2155-9880
Business & Management Clinical & Experimental Dermatology Research 2155-9554
Clinical & Experimental Nephrology -
Accounting & Marketing 2168-9601
Clinical & Experimental Oncology 2324-9110
Arabian Journal of Business and Management Review 2223-5833
Clinical & Experimental Ophthalmology 2155-9570
Business & Financial Affairs 2167-0234
Clinical & Experimental Orthopaedics -
Business & Hotel Management 2324-9129
Clinical & Experimental Pathology 2161-0681
Business and Economics Journal 2151-6219
Clinical & Molecular Endocrinology -
Defense Studies & Resource Management 2324-9314
Clinical and Experimental Psychology -
Entrepreneurship & Organization Management 2169-026X
Clinical and Experimental Transplantation -
Global Economics 2375-4389
Clinical Case Reports 2165-7920
Hotel & Business Management 2169-0286
Clinical Depression -
International Journal of Accounting Research -
Clinical Dermatology Research Journal -
International Journal of Economics and Management Science 2162-6359
Clinical Diabetes & Practice -
Internet Banking & Commerce 1204-5357
Clinical Nutrition & Dietetics -
Review of Public Administration and Management 2315-7844 Clinical Oncology and Practice -
Stock & Forex Trading 2168-9458 Clinical Pediatrics -
Tourism & Hospitality 2167-0269 Clinical Pediatrics & Dermatology -
Chemical Engineering Clinical Psychiatry

Clinical Research & Bioethics
-
2155-9627
Advanced Chemical Engineering 2090-4568 Clinical Research On Foot & Ankle 2329-910X
Bioprocessing & Biotechniques 2155-9821 Clinical Respiratory: Open Access -
Chemical Engineering & Process Technology 2157-7048 Clinical Toxicology 2161-0495
Thermodynamics & Catalysis 2157-7544 Clinical Trials 2167-0870
Chemistry
Clinics in Mother and Child Health 2090-7214
Cosmetology & Orofacial Surgery -
Analytical & Bioanalytical Techniques 2155-9872 Cosmetology & Trichology -
Analytical & Electrochemical Insights - Dermatitis -
Bioenergetics: Open Access 2167-7662 Diabetes Case Reports -
Chemical Informatics - Dialysis and Clinical Practice -
Chemical Sciences Journal 2150-3494 Drug Intoxication & Detoxification : Novel Approaches 2327-4557
Chromatography & Separation Techniques 2157-7064 Dual Diagnosis: Open Access -
Clinical & Medical Biochemistry: Open Access - Eye & Cataract Refractive Surgery -
Clinical Chemistry: Open Access - Forensic Toxicology & Pharmacology 2325-9841
Environmental & Analytical Toxicology 2161-0525 Glaucoma: Open Access -
Environmental Analytical Chemistry - HIV & Retro Virus -
Glycobiology 2168-958X Immunooncology -
Herbal Medicine: Open Access - Insights in Pediatric Cardiology -
Page 7
Intensive and Critical Care - International Journal of Advanced Research in Electrical, Electronics
2278-8875
International Journal of Anesthesiology & Pain Medicine - and Instrumentation Engineering
International Journal of Cardiovascular Research 2324-8602 International Journal of Advancements in Technology 0976-4860
International Journal of Digestive Diseases - International Journal of Biomedical Data Mining 2090-4924
International Journal of Ophthalmic Pathology 2324-8599 International Journal of Innovative Research in Computer and
2278-1021
- Communication Engineering
Interventional Cardiology: Open Access
2376-0311 International Journal of Innovative Research in Science, Engineering
JBR Journal of Clinical Diagnosis and Research 2319-8753
and Technology
Optometry: Open Access -
International Journal of Sensor Networks and Data Communications 2090-4886
Phonetics & Audiology -
International Journal of Swarm Intelligence and Evolutionary
Speech Pathology & Therapy - 2090-4908
Computation
Stem Cell Research & Therapy 2157-7633
Irrigation & Drainage Systems Engineering 2168-9768
Toxicology: Open Access -
Lasers, Optics & Photonics -
Vasculitis -
Lovotics 2090-9888
Earth & Environmental Sciences Membrane Science & Technology 2155-9589

Molecular Imaging & Dynamics 2155-9937
Advances in Recycling -
Nuclear Energy Science & Power Generation Technology 2325-9809
Astrobiology & Outreach 2332-2519
Research & Reviews: Journal of Engineering and Technology 2319-9873
Biodiversity & Endangered Species 2332-2543
Steel Structures & Construction -
Biodiversity Management & Forestry 2327-4417
Telecommunications System & Management 2167-0919
Bioremediation & Biodegradation 2155-6199
Textile Science & Engineering 2165-8064
Biosafety 2167-0331
Climatology & Weather Forecasting 2332-2594 General Science
Coastal Zone Management -
Computer Science & Systems Biology Journal 0974-7230
Earth Science & Climatic Change 2157-7617
Ergonomics 2165-7556
Ecosystem & Ecography 2157-7625
Research and Development -
Entomology, Ornithology & Herpetology 2161-0983
International Journal of Advance Innovations, Thoughts & Ideas 2277-1891
Expert Opinion On Environmental Biology 2325-9655
Metrology -
Fundamentals of Renewable Energy and Applications 2090-4541
Research & Reviews: Journal of Botanical Sciences 2320-0189
Geography & Natural Disasters 2167-0587
Research & Reviews: Journal of Chemistry 2319-9849
Geoinformatics & Geostatistics: An Overview 2327-4581
Tomography -
Geology & Geosciences 2329-6577
Geophysics & Remote Sensing 2169-0049 Genetics & Molecular Biology
Hydrogeology & Hydrologic Engineering 2325-9647
Advanced Techniques in Biology & Medicine 2379-1764
Hydrology: Current Research 2157-7587
Advancements in Genetic Engineering 2169-0111
Industrial Pollution Control -
Advances in Molecular Diagnostics -
Innovative Energy Policies 2090-5009
Biochemistry & Analytical Biochemistry 2161-1009
International Journal of Evolution 2324-8548
Biochemistry & Molecular Biology Journal -
International Journal of Waste Resources 2252-5211
Biochemistry & Physiology 2329-9029
Marine Biology & Oceanography 2324-8661
Biological Systems 2329-6577
Oceanography: Open Access 2332-2632
Biotechnology & Biomaterials 2155-952X
Oil & Gas: Open Access -
Bipolar Disorder: Open Access -
Petroleum & Environmental Engineering 2157-7463
Cell & Developmental Biology 2168-9296
Plant Physiology & Pathology 2329-955X
Cell Science & Therapy 2157-7013
Pollution Effects & Control 2375-4397
Cell Signaling -
Research & Reviews: Journal of Ecology and Environmental Sciences -
Cellular & Molecular Medicine: Open Access -
EEE Chemical Biology & Therapeutics -

Clinical Epigenetics -
Electrical & Electronic Systems 2332-0796
Cloning & Transgenesis 2168-9849
Electrical Engineering & Electronic Technology 2325-9833
Current Synthetic and Systems Biology 2332-0737
Engineering Cytology & Histology 2157-7099

Down Syndrome & Chromosome Abnormalities -
Advances in Automobile Engineering 2167-7670 Electronic Journal of Biology -
Advances in Robotics & Automation 2168-9695 Enzyme Engineering 2329-6674
Aeronautics & Aerospace Engineering 2168-9792 Fertilization: in Vitro 2375-4508
Applied Bioinformatics & Computational Biology 2329-9533 Fungal Genomics & Biology 2165-8056
Applied Mechanical Engineering 2168-9873 Gene Technology 2329-6682
Architectural Engineering Technology 2168-9717 Genetic Syndromes & Gene Therapy 2157-7412
Automatic Control of Physiological State and Function 2090-5092 Hereditary Genetics: Current Research 2161-1041
Biochips & Tissue Chips 2153-0777 Human Genetics & Embryology 2161-0436
Bioengineering & Biomedical Science 2155-9538 Insights in Cell Science -
Biomusical Engineering 2090-2719 Insights in Stem Cells -
Biosensors & Bioelectronics 2155-6210 International Journal of Genomic Medicine 2332-0672
Biosensors Journal 2090-4967 Metabolomics: Open Access 2153-0769

Metabonomics & Metabolites 2325-9736
Civil & Environmental Engineering 2165-784X
Microbial & Biochemical Technology 1948-5948
Computer Engineering & Information Technology 2324-9307
Microbial Methods & Assays Open Access -
Computer Engineering and Information Technology 2324-9307
Molecular and Genetic Medicine 1747-0862
Defense Management 2167-0374
Molecular Biology 2168-9547
Fashion Technology & Textile Engineering 2329-9568
Molecular Biomarkers & Diagnosis 2155-9929
Global Journal of Technology and Optimization 2229-8711 2325-9787
Molecular Cloning & Genetic Recombination
Global Research in Computer Science 2229-371X Nanomedicine & Biotherapeutic Discovery 2155-983X
Industrial Engineering & Management 2169-0316 Next Generation: Sequencing & Applications -
Information Technology & Software Engineering 2165-7866 Phylogenetics & Evolutionary Biology 2329-9002
Page 8
Physiobiochemical Metabolism 2324-8793 Aerobics & Fitness -
Plant Biochemistry & Physiology 2329-9029 Aesthetic & Reconstructive Surgery -
Proteomics & Enzymology - Aids & Clinical Research 2155-6113
Single Cell Biology 2168-9431 Air and Water Borne Diseases 2167-7719
Tissue Science & Engineering 2157-7552 Alternative & Integrative Medicine 2327-5162
Transcriptomics: Open Access 2329-8936 Analgesia & Resuscitation : Current Research 2324-903X
Translational Biomedicine 2172-0479 Anaplastology 2161-1173
2161-0940
Health Care
Anatomy & Physiology: Current Research
Andrology & Gynecology: Current Research 2327-4360
Diversity and Equality and Health and Care 2049-5471 Andrology 2167-0250
Health Care: Current Reviews 2375-4273 Angiology: Open Access 2329-9495
Health Science Journal 1791-809X Annals of Behavioural Science -
Pregnancy & Child Health 2376-127X Applied and Rehabilitation Psychology: Open Access -
Primary Health Care 2167-1079 Archives in Cancer Research 2254-6081
Quality in Primary Care 1479-1072 Archives of Medicine 1989-5216
Tropical Diseases & Public Health 2329-891X Archives of Surgical Oncology -
Women'S Health, Issues & Care 2325-9795 Archivos De Medicina 1698-9465
Immunology
Arthritis 2167-7921
Asthma and Bronchitis -
Advances in Antibiotics & Antibodies - Athletic Enhancement 2324-9080
Allergy & Therapy 2155-6121 Autacoids & Hormones 2161-0479
Autoimmune Diseases: Open Access - Biology and Medicine 0974-8369
Clinical & Cellular Immunology 2155-9899 Biomedical Engineering & Medical Devices -
Cytokine Biology - Biomedical Sciences 2254-609X
Immunobiology - Bioterrorism & Biodefense 2157-2526
Immunogenetics: Open Access - Blood -
Immunome Research 1745-7580 Blood & Lymph 2165-7831
Immunotherapy: Open Access - Blood Disorders & Transfusion 2155-9864
Infectious Diseases & Immunological Techniques 2325-9752 Blood Pressure: Open Access -
Inflammatory Bowel Diseases & Disorders - Bone Marrow Research 2329-8820
Innate Immunity & Immunological Disorders - Bone Reports & Recommendations -
Interdisciplinary Journal of Microinflammation - Brain Tumors -
Lupus: Open Access - Breast Cancer: Current Research -
Molecular Immunology - Cancer Biomarkers -
Osteoarthritis - Cancer Clinical Trials -
Reproductive Immunology - Cancer Diagnosis -
Rheumatology: Current Research 2161-1149 Cancer Medicine & Anticancer Drugs -
Sarcoidosis - Cancer Science & Therapy 1948-5956
Vaccines & Vaccination 2157-7560 Cancer Surgery -
Informatics
Carcinogenesis & Mutagenesis 2157-2518
Cardiovascular Diseases & Diagnosis 2329-9517
Data Mining in Genomics & Proteomics 2153-0602 Cardiovascular Pathology: Open Access -
Glycomics and Lipidomics 2153-0637 Celiac Disease: Open Access -
Health & Medical Informatics 2157-7420 Cervical Cancer: Open Access -
Proteomics & Bioinformatics 0974-276X Chemotherapy 2167-7700
Theoretical and Computational Science 2376-130X Chest Diseases -
Materials Science
Childhood & Developmental Disorders -
Childhood Obesity -
Bioceramics Developments and Applications 2090-5025 Chronic Obstructive Pulmonary Disease: Open Access -
Material Sciences & Engineering 2169-0022 Colorectal Cancer: Open Access -
Nano Research & Applications - Communication Disorders, Deaf Studies & Hearing Aids 2375-4427
Nanomaterials & Molecular Nanotechnology 2324-8777 Community Medicine & Health Education 2161-0711
Nanomedicine & Nanotechnology 2157-7439 Complex Diseases and Treatment -
Plastic & Polymer Sciences - Contraceptive Studies -
Powder Metallurgy & Mining 2168-9806 Critical Care Obstetrics & Gynecology -
Research & Reviews: Journal of Material Sciences 2321-6212 Current Trends in Gynecologic Oncology -
Mathematics
Dental Health: Current Research -
Dental Implants and Dentures: Open Access -
Applied & Computational Mathematics 2168-9679 Dentistry 2161-1122
Biometrics & Biostatistics 2155-6180 Depression and Anxiety 2167-1044
Generalized Lie Theory and Applications 1736-4337 Dermatology Case Reports -
Physical Mathematics 2090-0902 Diabetes & Metabolism 2155-6156
Research & Reviews: Journal of Statistics and Mathematical Sciences - Diabetes Medication and Care -
Medical
Diabetic Complications and Medicine -
Drug Abuse -
Abnormal and Behavioural Psychology - Emergency Medicine 2165-7548
Acta Psychopathologica - Endocrinology & Diabetes Research -
Acta Rheumatologica - Endocrinology & Metabolic Syndrome 2161-1017
Addictive Behaviors , Therapy & Rehabilitation 2324-9005 Epidemiology: Open Access 2161-1165
Adenocarcinoma - Evidence based Medicine and Practice -
Advances in Cancer Prevention - Family Medicine & Medical Science Research 2327-4972
Advances in Genetic Engineering & Biotechnology - Forensic Biomechanics 2090-2697
Advances in Weight Loss Management & Medical Devices - Forensic Medicine -
Page 9
Forensic Nursing: Open Access - Neonatal Studies -
Forensic Odontology - Neonatal Medicine -
Forensic Psychology - Neoplasm -
Forensic Research 2157-7145 Nephrology & Therapeutics 2161-0959
Gastrointestinal & Digestive System 2161-069x Neurobiotechnology -
Gastrointestinal Cancer and Stromal Tumors - Neuroinfectious Diseases 2314-7326
General Medicine 2327-5146 Neurooncology: Open Access -
General Practice 2329-9126 Neurosurgery & Cardiac Surgery -
Genetic Disorders & Genetic Reports 2327-5790 Novel Physiotherapies 2165-7025
Genital System & Disorders 2325-9728 Nuclear Medicine & Radiation Therapy 2155-9619
Geriatric Psychiatry - Nutritional Disorders & Therapy 2161-0509
Gerontology & Geriatric Research 2167-7182 Obesity & Eating Disorders -
Gynecology & Obstetrics 2161-0932 Obesity & Weight Loss Therapy 2165-7904
Gynecology & Obstetrics- Case Report - Occupational Medicine Health Affairs 2329-6879
Haematology & Thromboembolic Diseases 2329-8790 Omics Journal of Radiology 2167-7964
Hair: Therapy & Transplantation 2167-0951 Oncology & Cancer Case Reports -
Head and Neck Cancer Research - Oncology Translational Research -
Health & Medical Economics - Oral Health and Dental Management 2247-2452
Health Care Communications - Oral Health Case Reports -
Health Economics & Outcome Research: Open Access - Oral Hygiene & Health 2332-0702
Health Education Research & Development (Biosafety & Health Edu- Orthodontics & Endodontics -
-
cation: Open Access-2332-0893) Orthopedic & Muscular System: Current Research 2161-0533
Health Systems and Policy Research 2254-9137 Orthopedic Oncology -
Heart Transplant and Surgery - Osteoporosis & Physical Activity 2329-9509
Heavy Metal & Chelation Therapy - Otolaryngology:Open Access 2161-119X
Hepatology and Gastrointestinal Disorders - Otology & Rhinology 2324-8785
Hospital & Medical Management - Pain & Relief 2167-0846
Hypertension- Open Access 2167-1095 Pain Management & Medicine -
Hypo & Hyperglycemia 2327-4700 Palliative Care & Medicine 2165-7386
Imaging and Interventional Radiology - Pancreatic Disorders & Therapy 2165-7092
Medical Implants & Surgery - Pediatric Care -
Informatics and Data Mining - Pediatric Dental Care -
Insights in Biomedicine - Pediatric Emergency Care and Medicine- Open Access -
Insights in Medical Physics - Pediatric Nephrology Practice -
Integrative Oncology 2329-6771 Pediatric Neurology and Medicine -
Internal Medicine 2165-8048 Pediatric Nursing: Open Access -
International Journal of Clinical & Medical Imaging 2376-0249 Pediatric Oncology: Open Access -
International Journal of Collaborative Research on Internal Medicine Pediatric Physiotherapy -
-
& Public Health -
Pediatric Psychology and Psychiatry
International Journal of Emergency Mental Health and Human Resil- 2161-0665
1522-4821 Pediatrics & Therapeutics
ience
Periodontics and Prosthodontics: Open Access -
International Journal of Mental Health & Psychiatry 2327-4654
Pigmentary Disorders 2376-0427
International Journal of Pediatric Neurosciences -
Prevention Infection Control: Open Access -
International Journal of Physical Medicine & Rehabilitation 2329-9096
Preventive Medicine -
International Journal of Public Health and Safety -
Primary & Acquired Immunodeficiency Research 2324-853X
International Journal of School and Cognitive Psychology -
Prostate Cancer -
Interventional Pediatrics -
Psoriasis & Rosacea Open Access -
Invasive Cardiology Future Medicine -
Psychiatry 2378-5756
JBR Journal of Interdisciplinary Medicine and Dental Sciences 2376-032X
Psychological Abnormalities in Children 2329-9525
Kidney -
Psychology & Psychotherapy 2161-0487
Kidney Transplant -
Pulmonary & Respiratory Medicine 2161-105x
La Prensa Medica 0032-745X
Rare Disorders & Diseases -
Laser Surgery and Therapy -
Regenerative Medicine 2325-9620
Leukemia 2329-6917
Reproductive Endocrinology & Infertility -
Liposuction -
Reproductive System & Sexual Disorders 2161-038x
Liver 2167-0889
Liver: Disease & Transplantation 2325-9612 Research & Reviews: Journal of Dental Sciences 2320-7949
Lung Cancer Diagnosis & Treatment - Research & Reviews: Journal of Medical and Health Sciences 2319-9865
Lung Diseases & Treatment - Research Journal of Biology 2322-0066
Malaria Control & Elimination 2090-2778 Sleep Disorders & Therapy 2167-0277
Maternal and Pediatric Nutrition - Sleep Disorders : Treatment & Care 2325-9639
Medical & Surgical Pathology - Spine 2165-7939
Medical & Surgical Urology 2168-9857 Spine & Neurosurgery 2325-9701
Medical and Clinical Reviews - Spine Research -
Medical Case Reports - Sports Medicine & Doping Studies 2161-0673
Medical Diagnostic Methods 2168-9784 Sports Nutrition and Therapy -
Medical Toxicology and Clinical Forensic Medicine - Steroids & Hormonal Science 2157-7536
Melanoma and Skin Diseases - Stroke Research & Therapy -
Mental Health in Family Medicine 2327-4972 Journal of Surgery [Jurnalul de Chirurgie] 1584-9341
Mental Illness and Treatment - Surgery: Current Research 2161-1076
Metabolic Syndrome 2167-0943 The Headache Journal -
Molecular & Medical Histology - The International Journal of Apitherapy -
Molecular Medicine & Therapeutics 2324-8769 The Pancreas 1590-8577
Neonatal Biology 2167-0897 Therapeutic Care and Physical Rehabilitation -
Page 10
Thrombosis and Circulation - Pharmaceutical Sciences
Thyroid Disorders & Therapy 2167-7948
Advances in Pharmacoepidemiology & Drug Safety 2167-1052
Translational Medicine 2161-1025
Alcoholism & Drug Dependence 2329-6488
Transplant Reports : Open Access -
Bioanalysis & Biomedicine 1948-593X
Transplantation Technologies & Research 2161-0991
Biochemistry & Pharmacology: Open Access Journal 2167-0501
Trauma & Acute Care -
Bioequivalence & Bioavailability 0975-0851
Trauma & Treatment 2167-1222
Biomarkers in Drug Development 2327-4441
Traumatic Stress Disorders & Treatment 2324-8947
Biomarkers Journal -
Tropical Medicine & Surgery 2329-9088
Biomolecular Research & Therapeutics 2167-7956
Tumor Diagnostics and Reports -
Cardiovascular Pharmacology: Open Access 2329-6607
Universal Surgery 2254-6758
Clinical & Experimental Pharmacology 2161-1459
Vascular Medicine & Surgery 2329-6925
Clinical Pharmacology and Biopharmaceutics 2167-065X
Vitiligo & Dermatomyositis -
Current Trends in Nutraceuticals -
Voice Medicine & Surgery -
Developing Drugs 2329-6631
Women’s Health Care 2167-0420
Diagnostic Techniques & Biomedical Analysis -
Wound Medicine and Tissue Repair -
Drug Designing: Open Access 2169-0138
Yoga & Physical Therapy 2157-7595
Drug Metabolism & Toxicology 2157-7609
Microbiology in Silico & in Vitro Pharmacology -
Molecular Enzymology and Drug Targets -
Advances in Influenza Research -
Molecular Pharmaceutics & Organic Process Research 2329-9053
Antimicrobial Agents -
Pharmaceutica Analytica Acta 2153-2435
Antivirals & Antiretrovirals 1948-5964
Pharmaceutical Care & Health Systems 2376-0419
Applied Microbiology: Open Access -
Pharmaceutical Microbiology -
Archives of Clinical Microbiology 1989-8436
Pharmaceutical Regulatory Affairs: Open Access 2167-7689
Bacteriology and Parasitology 2155-9597
Pharmaceutical Sciences & Emerging Drugs -
Clinical Infectious Diseases & Practice -
Pharmaceutics & Drug Delivery Research 2325-9604
Clinical Microbiology: Open Access 2327-5073
Pharmacoeconomics: Open Access -
Colitis & Diverticulitis -
Pharmacogenomics and Pharmacoproteomics 2153-0645
Emerging Infectious Diseases -
Pharmacognosy & Natural Products -
Fermentation Technology 2167-7972
Pharmacokinetics & Experimental Therapeutics -
Fibromyalgia: Open Access -
Pharmacological Reports -
Forensic Pathology -
Pharmacovigilance 2329-6887
Hepatitis -
Research & Reviews: Journal of Hospital and Clinical Pharmacy -
Human Papillomavirus -
Research & Reviews: Journal of Pharmaceutical Analysis 2320-0812
Infectious Diseases and Diagnosis -
Research & Reviews: Journal of Pharmaceutical Quality Assurance -
Infectious Diseases and Therapy 2332-0877
Research & Reviews: Journal of Pharmaceutics and Nanotechnology 2347-7857
Medical Microbiology & Diagnosis 2161-0703
Research & Reviews: Journal of Pharmacognosy and Phytochemistry 2321-6182
Medical Mycology: Open Access -
Research & Reviews: Journal of Pharmacy and Pharmaceutical
Meningitis - 2320-1215
Sciences
Mycobacterial Diseases 2161-1068 Virology & Antiviral Research 2324-8955
Pediatric Infectious Diseases: Open Access -
Research & Reviews: Journal of Microbiology and Biotechnology 2320-3528 Physics
Research & Reviews: Journal of Inflammation - Astrophysics & Aerospace Technology 2329-6542
Research & Reviews: Journal of Pathology & Epidemiology - Research & Reviews: Journal of Pure and Applied Physics 2320-2459
Virology & Mycology 2161-0517 Vortex Science and Technology 2090-8369
Neuroscience
Addiction Research & Therapy 2155-6105
Social & Political Sciences
Alzheimers Disease & Parkinsonism 2161-0460 Anthropology 2332-0915
Autism-Open Access 2165-7890 Arts and Social Sciences Journal 2151-6200
Brain Disorders & Therapy 2168-975X Civil & Legal Sciences 2169-0170
Child & Adolescent Behavior 2375-4494 Forensic Anthropology -
Clinical & Experimental Neuroimmunology - Global Media Journal 1550-7521
Dementia & Mental Health - Intellectual Property Rights: Open Access 2375-4516
Epilepsy Journal - Mass Communication & Journalism 2165-7912
Insights in Clinical Neurology - Political Science & Public Affairs 2332-0761
International Journal of Neurorehabilitation 2376-0281 Research & Reviews: Journal of Educational Studies -
Multiple Sclerosis 2376-0389 Research & Reviews: Journal of Social Sciences -
Neurological Disorders 2329-6895 Socialomics 2167-0358
Neurology & Neurophysiology 2155-9562 Sociology & Criminology 2375-4435
Neurology and Neuroscience 2171-6625
Neuropsychiatry - Veterinary Sciences
Neuroscience & Clinical Research -
Animal Nutrition -
Schizophrenia Journal -
Primatology 2167-6801
Health Care & Nursing Research & Reviews: Journal of Veterinary Sciences -
Research & Reviews: Journal of Zoological Sciences 2321-6190
Advanced Practices in Nursing -
Veterinary Science & Medical Diagnosis 2325-9590
Community & Public Health Nursing -
Veterinary Science & Technology 2157-7579
Nursing & Care 2167-1168
Nursing & Clinical Research -
Patient Care -
Perioperative & Critical Intensive Care Nursing -
Research & Reviews: Journal of Nursing and Health Sciences -
Page 11
Impact
ImpactFactors*
Factors* (IF)(IF)
Impact Oral Health and Dental Management Oral Health Dent Manag 1.23
Journal Name Pubmed Short Name
Factor International Journal of Advancement
Int J Adv Tech 5.08
Biological Systems: Open Access Biol Syst Open Access 0.76 technology
Journal of Biotechnology & Biomaterials J Biotechnol Biomater 1.94 Translational Medicine Transl Med (Sunnyvale) 1.312
Journal of Psychology & Psychotherapy J Psychol Psychother 1.3 Air Water Borne
Air and Water Borne Diseases 0.6
Advanced Techniques in Biology & Medicine Adv Tech Biol Med 1.08 Diseases
AIDS & Clinical Research J AIDS Clin Res 2.7 Journal of Coastal Zone Management J Coast Zone Manag 0.54
Autism Open Access Autism Open Access 3.52 Biology and Medicine Biol Med (Aligarh) 3.07
Biochemistry & Physiology: Open Access Biochem Physiol 1.03 Journal of Bioterrorism and Biodefense J Bioterror Biodef 0.38
Divers Equal Health Journal of Tropical Diseases & Public Health J Trop Dis 0.83
Diversity Equality in Health & Care 2.49
Care Journal of Surgery
Journal of Surgery 0.08
Drug Designing: Open Access Drug Des 6 [Jurnalul de chirurgie]
Fungal Genomics & Biology Fungal Genom Biol 1.15 Nephrology & Therapeutics J Nephrol Ther 0.318
International Journal of Genomic Medicine Int J Genomic Med 0.67 Journal of Fundamentals of Renewable J Fundam Renewable
1.41
Journal of Addiction Research & Therapy J Addict Res Ther 2.86 Energy and Applications Energy Appl
Journal of Alzheimers Disease & J Alzheimers Dis Advances in Pharmacoepidemiology & Drug Adv Pharmacoepidemiol
1.18 1.37
Parkinsonism Parkinsonism Safety Drug Saf
Journal of Fertilization: In Vitro JFIV Reprod Med Genet 1 Bioanalysis & Biomedicine J Bioanal Biomed 1.67
Journal of Genetic Syndromes & Gene J Genet Syndr Gene Biochem Pharmacol
2.34 Biochemistry & Pharmacology: Open Access 2.09
therapy Ther (Los Angel)
Journal of Microbial & Biochemical J Microb Biochem Bioequivalence & Bioavailability J Bioequiv Availab 1.88
2.5
Technology Technol Biomolecular Research & Therapeutics J Biomol Res Ther 1.67
Journal of Nursing & Care J Nurs Care 1.6 Cardiovascular Pharmacology: Open Access Cardiol Pharmacol 1.77
Journal of Osteoporosis and Physical Activity J Osteopor Phys Act 0.66 Clinical & Experimental Pharmacology Clin Exp Pharmacol 1.83
Journal of Yoga & Physical Therapy J Yoga Phys Ther 1.17 Clin Pharmacol
Clinical Pharmacology & Biopharmaceutics 1.69
Molecular Biology Mol Biol 1.85 Biopharm
Neurology & Neurophysiology J Neurol Neurophysiol 0.77 J Data Mining Genomics
Data Mining in Genomics & Proteomics 2
Primary health care Prim Health Care 1 Proteomics
Quality in Primary Care Qual Prim Care 3.88 Drug Metabolism & Toxicology J Drug Metab Toxicol 1.37
Tissue Science & Engineering J Tissue Sci Eng 2.72 Ergonomics J Ergonomics 1.38
Biochemistry & Analytical Biochemistry Biochem Anal Biochem 2.6 Glycomics & Lipidomics J Glycomics Lipidomics 1.82
Molecular and Genetic Medicine J Mol Genet Med 2.89 Health & Medical Informatics J Health Med Inform 1.98
Advancements in Genetic Engineering Adv Genet Eng 1 Metabolomics (Los
Metabolomics: Open Access 3.03
Angel)
Enzyme Engineering Enz Eng 2.3
J Nanomedine
Depression and Anxiety J Depress Anxiety 1 Nanomedicine & Biotherapeutic Discovery 2.69
Biotherapeutic Discov
Human Genetics & Embryology Human Genet Embryol 1.2
OMICS Journal of Radiology OMICS J Radiol 0.54
Current Synthetic and Systems Biology Curr Synthetic Sys Biol 0.8
Pharmaceutica Analytica Acta Pharm Anal Acta 1.83
Hereditary Genetics: Current Research Hereditary Genet 1.2
Pharmaceutical Regulatory Affairs: Open
International Journal of Emergency Mental Pharm Regul Aff 1.88
Int J Emerg Ment Health 6.5 Access
Health and Human Resilience
J Pharmacogenomics
Spine J Spine 1.9 Pharmacogenomics & Pharmacoproteomics 1.69
Pharmacoproteomics
Cloning & Transgenesis Clon Transgen 1.5
Pharmacovigilance J Pharmacovigil 2.65
Journal of Medical Microbiology & Diagnosis J Med Microb Diagn 1.9
J Phylogenetics Evol
Biosensors Journal Biosens J 0.33 Phylogenetics & Evolutionary Biology 2.76
Biol
Defense Management J Def Manag 0.5 Proteomics & Bioinformatics J Proteomics Bioinform 2.55
Review of Public Administration and Review Pub
0.2 Advances in Automobile Engineering Adv Automob Eng 1.750
Management Administration Manag
Advances in Robotics & Automation Adv Robot Autom 0.813
Single cell biology Single Cell Biol 1
Arts and Social Sciences Journal Arts Social Sci J 1.231
Gerontology & Geriatric Research J Gerontol Geriatr Res 1
Neuroinfectious Diseases J Neuroinfect Dis 2.4 Bioceramics Developments and Applications Bioceram Dev Appl 0.958
Cell Science & Therapy J Cell Sci Ther 1.37 Business & Financial Affairs J Bus & Fin Aff 2.000
Molecular Biomarkers & Diagnosis J Mol Biomark Diagn 2.1 J Generalized Lie
Generalized Lie Theory and Applications 1.750
Brain Disorders & Therapy Brain Disord Ther 1.6 Theory Appl
Clinical Case Reports J Clin Case Rep 1.2 Irrigation & Drainage Systems Engineering Irrigat Drainage Sys Eng 4.286
Gene Technology Gene Technol 0.83 Industrial Engineering & Management Ind Eng Manage 0.474
Socialomics J Socialomics 2.3 J Aeronaut Aerospace
Aeronautics & Aerospace Engineering 1.407
Journal of Trauma and Treatment J Trauma Treat 0.6 Eng
Translational Biomedicine Transl Biomed 1.06 Applied & Computational Mathematics J Appl Computat Math 0.581
Journal of Neurology and Neuroscience J Neurol Neurosci 0.88 Architectural Engineering Technology J Archit Eng Tech 1.071
Research & Reviews: Journal of Botanical Accounting & Marketing J Account Mark 0.500
J Bot Sci 0.33 J Aquac Res
Sciences Aquaculture Research & Development 1.272
Journal of Psychiatry J Psychiatry 2.32 Development
Anaplastology Anaplastology 0.73 Bioengineering & Biomedical Science J Bioeng Biomed Sci 1.235
Tropical Medicine & Surgery Trop Med Surg 0.4 Biometrics & Biostatistics J Biomet Biostat 1.272
Orthopedic & Muscular System: Current Biosensors & Bioelectronics J Biosens Bioelectron 2.137
Orthop Muscular Syst 0.32
Research Civil & Environmental Engineering J Civil Environ Eng 1.294
Pediatrics & Therapeutics Pediat Therapeut 1.32 Cytology & Histology J Cytol Histol 0.569
J Sports Med Doping Civil & Legal Sciences J Civil Legal Sci 0.286
Sports Medicine & Doping Studies 1.45
Stud Ecosystem & Ecography J Ecosyst Ecogr 1.806
Journal of Oral Hygiene & Health J Oral Hyg Health 0.52 Electrical & Electronic Systems J Elec Electron Syst 0.533
Emergency Medicine Emerg Med (Los Angel) 0.875 Earth Science & Climatic Change J Earth Sci Clim Change 2.082
Journal of Transplantation Technologies & J Transplant Technol Geography & Natural Disasters J Geogr Nat Disast 0.800
1.39
Research Res Hotel & Business Management J Hotel Bus Manage 1.600
Journal of Hypertension: Open Access J Hypertens (Los Angel) 0.92 Information Technology & Software
International Journal of Waste Resources Int J Waste Resour 1.95 J Inform Tech Soft Engg 2.789
Engineering
Surgery: Current research Surgery Curr Re 0.587 Molecular Imaging & Dynamics J Mol Imaging Dynam 2.091
Page 12
Earth Science & Climatic Change J Earth Sci Clim Change 2.082 Pain & Relief J Pain Relief 1.14
Geography & Natural Disasters J Geogr Nat Disast 0.800 Palliative Care & Medicine J Palliat Care Med 0.88
Hotel & Business Management J Hotel Bus Manage 1.600 Steroids & Hormonal Science J Steroids Horm Sci 0.65
Information Technology & Software Gastrointestinal & Digestive System J Gastrointest Dig Syst 0.43
J Inform Tech Soft Engg 2.789
Engineering Hair: Therapy & Transplantation 0.6
Molecular Imaging & Dynamics J Mol Imaging Dynam 2.091 Andrology Andrology (Los Angel) 1.16
Petroleum & Environmental Engineering J Pet Environ Biotechnol 2.839 Endocrinology & Metabolic Syndrome Endocrinol Metab Syndr 1.12
Stock & Forex Trading J Stock Forex Trad 0.300 Internal Medicine 2.48
Textile Science & Engineering J Textile Sci Eng 0.667 Sleep Disorders & Therapy J Sleep Disord Ther 0.5
Tourism & Hospitality J Tourism Hospit 1.190 Nuclear Medicine & Radiation Therapy J Nucl Med Radiat Ther 0.88
J Telecommun Syst Alternative & Integrative Medicine Altern Integr Med 1.11
Telecommunications System & Management 0.800
Manage Pulmonary & Respiratory Medicine J Pulm Respir Med 1.01
Physical Mathematics J Phys Math 4.500 Occupational Medicine Health Affairs Occup Med Health Aff 0.85
Nanomedicine & Nanotechnology J Nanomed Nanotechnol 4.68 Reproductive System & Sexual Disorders Reprod Syst Sex Disord 1.25
Arabian Journal of Business and Medical Diagnostic Methods 0.29
Arab J Bus Manage Rev 1.42
Management Review
Blood Disorders & Transfusion J Blood Disord Transfus 0.5
Research and Reviews: Journal of Engineering and
0.14 General Medicine Gen Med (Los Angel) 0.86
Engineering and Technology Technology
Bioenergetics: Open Access Bioenergetics 3.1
Journal of Material Sciences & Engineering J Material Sci Eng 1.31
Chemotherapy (Los
Journal of Mass Communication & J Mass Communicat Chemotherapy: Open Access 1.8
0.62 Angel)
Journalism Journalism
Clinical & Experimental Pathology J Clin Exp Pathol 1.54
Journal of Powder Metallurgy & Mining J Powder Metall Min 0.71
Carcinogenesis & Mutagenesis J Carcinog Mutagen 1.9
Journal of Applied Mechanical Engineering J Appl Mech Eng 1.65
Clinical Research & Bioethics J Clinic Res Bioeth 0.95
Archives of Clinical Microbiology 0.35
Vaccines & Vaccination J Vaccines Vaccin 1.8
Dentistry Dentistry 1.22
Immunome Research Immunome Res 7.1
Journal of Diabetes & Metabolism J Diabetes Metab 1.77
Clinical & Experimental Ophthalmology J Clin Exp Ophthalmol 1.11
Otolaryngology: Current Research Otolaryngol (Sunnyvale) 0.22
Clinical & Experimental Dermotology
Journal of Metabolic Syndrome J Metabolic Synd 1.27 J Clin Exp Dermatol Res 0.5
Research
Journal of Primatology J Primatol 0.53
Clinical & Experimental Cardiology J Clin Exp Cardiolog 1.33
Journal of Thyroid Disorders & Therapy Thyroid Disorders Ther 0.43
Clinical Microbiology: Open Access Clin Microbiol 0.7
Jounal of Novel Physiotherapies J Nov Physiother 1.24
Anesthesia & Clinical research J Anesth Clin Res 0.7
Journal of Stem Cell Research & Therapy J Stem Cell Res Ther 2.78
Mycobacterial Diseases Mycobact Dis 0.9
Anatomy & Physiology: Current Research Anat Physiol 1
Clinical Toxicology J Clin Toxicol 1.39
Pancreatic Disorders & Therapy Pancreat Disord Ther 0.54
Clinical Trials & Research J Clin Trials 1.33
Journal of Cancer Science & Therapy J Cancer Sci Ther 4.203
Antivirals & Antiretrovirals J Antivir Antiretrovir 1.27
Journal of Biomedical Sciences 0.2
Fermentation Technology Ferment Technol 3.44
Journal of Nutritional Disorders & Therapy J Nutr Disord Ther 1.46
Clinical & Cellular immunology J Clin Cell Immunol 2.019
Medical & Surgical Urology Med Surg Urol 0.3
Allergy & Therapy J Allergy Ther 0.762
Journal of Biochips & Tissue Chips J Biochip Tissue Chip 1.7
Bacteriology & Parasitology J Bacteriol Parasitol 2.025
Journal of Liver J Liver 0.08
Rheumatology
Journal of Family Medicine and Medical Rheumatology: Current Research 1.522
Fam Med Med Sci Res 0.78 (Sunnyvale)
Research
Virology & Mycology Virol Mycol 0.69
Gynecol Obstet
Gynecology & Obstetrics 0.52 Clinics Mother Child
(Sunnyvale) Clinics in Mother and Child Health 0.432
Health
Journal of Integrative Oncology J Integr Oncol 1.67
Womens Health Care J Womens Health Care 0.79
Journal of Neonatal Biology J Neonatal Biol 0.55
Marine Science: Research & Development J Marine Sci Res Dev 0.45
Journal of Glycobiology J Glycobiology 0.8
Plant Pathology & Microbiology J Plant Pathol Microbiol 1.75
Journal of Blood & Lymph J Blood Lymph 0.12
Geology & Geophysics J Geol Geophys 0.91
Journal of Arthritis J Arthritis 1.87
FisheriesSciences J Fisheries Sci 0.51
Journal of Membrane Science & Technology J Membra Sci Technol 1.18
Fisheries and Aquaculture Journal Fish Aquac J 0.69
Med Chem (Los
Medicinal Chemistry 2.64 Bioremediation & Biodegradation J Bioremediat Biodegrad 2.1
Angeles)
Advances in Crop Science and Technology Adv Crop Sci Tech 0.39
Journal of Physical Chemistry & Biophysics J Phys Chem Biophys 0.75
Journal of Remote Sensing & GIS J Geophys Remote Sens 0.77
Organic Chemistry: Current Research Organic Chem Curr Res 1.94
Biofertilizers & Biopesticides J Biofertil Biopestic. 1.19
Journal of Bioprocessing & Biotechniques J Bioprocess Biotech 1.74
Hydrology: Current Research Hydrol Current Res 1.12
Journal of Environmental & Analytical
J Environ Anal Toxicol 2.58 Probiotics & Health J Prob Health 0.69
Toxicology
Journal of Chemical Engineering & Process J Chem Eng Process Veterinary Science & Technology J Veterinar Sci Technolo 2.5
1.21 Medicinal & Aromatic Plants Med Aromat Plants 2.02
Technology Technol
Journal of Computer Science & Systems Forest Research Forest Res 1.69
J Comput Sci Syst Biol 1.62
Biology International Journal of Sensor Networks Sensor Netw Data
1.66
Journal of Analytical & Bioanalytical and Data Communications Commun
J Anal Bioanal Tech 2.16
Techniques Innovative Energy Policies Innov Energ Policies 0.88
Journal of Plant Biochemistry & Physiology J Plant Biochem Physiol 2.28 J Biodivers Endanger
Biodiversity & Endangered Species 0.25
Journal of Chromatography & Separation Species
J Chromatogr Sep Tech 1.78
Techniques Biosafety Biosafety 0.49
Journal of Thermodynamics & Catalysis 0.91 Agrotechnology Agrotechnol 0.69
J Community Med Journal of Traditional Medicine and Clinical J Tradition Med Clin
Community Medicine & Health Education 1.27 0.49
Health Educ Naturopathy Naturopth
Epidemiology Nutrition & Food Sciences J Nutr Food Sci 1.14
Epidemiology: Open Access 1.35
(Sunnyvale) Entomol Ornithol
Entomology, Ornithology & Herpetology 1.26
J Obes Weight Loss Herpetol
Obesity & Weight Loss Therapy 0.94
Ther
Impact Factor Calculation:

Impact Factor was established by dividing the number of articles published in 2012 and 2013 with the number of times they are cited in 2014 based on Google search and
the Scholar Citation Index database. If ‘X’ is the total number of articles published in 2012 and 2013, and ‘Y’ is the number of times these articles were cited in indexed
journals during 2014 than, impact factor = Y/X
Page 13
EPIGENETICS 2018
Page 14

September 03-05, 2018 | London, UK
Supporting Journals
EPIGENETICS 2018
Page 15
Supporting Journals

www.omicsonline.org/archive-hereditary-genetics-open-access.php
Journal of Cancer Science & Therapy

www.omicsonline.org/cancer-science-therapy.php
Journal of Carcinogenesis & Mutagenesis

www.omicsonline.org/carcinogenesis-mutagenesis.php
EPIGENETICS 2018
Page 16
Agri, Food, Aqua & Veterinary 22nd International Conference on
Food Processing & Analysis
October 11-13, 2018 Moscow, Russia
E: eurofoodprocessing@foodtechconferences.com
W: foodprocessing.foodtechconferences.org
6th Global Summit on Plant Science

21st Euro-Global Summit on Food and Beverages October 29-30, 2018 Valencia, Spain
March 08-10, 2018 Berlin, Germany E: plantscience@plantscienceconferences.com
E: eurofood@foodtechconferences.com W: plantscience.global-summit.com
W: food.global-summit.com/europe
9th European Food Safety & Standards Conference
10th Euro-Global Summit on Aquaculture & Fisheries November 29-30, 2018 Dublin, Ireland
May 28-29, 2018 London, UK E: eurofoodsafety@foodtechconferences.com
E: aquaeurope@aquaconferences.com W: foodsafety-hygiene.conferenceseries.com/europe
W: aquaculture-fisheries.conferenceseries.com/europe
3rd International Conference on Food Microbiology
8 International Conference on
th November 26-28, 2018 Dublin, Ireland
Food Safety & Regulatory Measures E: foodmicrobiology@foodtechconferences.com
June 11-12, 2018 Barcelona, Spain W: foodmicrobiology.conferenceseries.com
foodsafety@foodtechconferences.com
W: foodsafety-hygiene.conferenceseries.com
Alternative Healthcare
11th International Veterinary Congress
July 02-03, 2018 Berlin, Germany
E: veterinary@veterinaryseries.com
W: veterinary.conferenceseries.com
3rd International Conference on

Food and Beverage Packaging 9th International Conference and Exhibition on
July 16-18, 2018 Rome, Italy Chinese Medicine, Ayurveda & Acupuncture
E: foodpackaging@foodtechconferences.com March 12-13, 2018 Barcelona, Spain
E: chinesemedicine@healthconferences.org
W: foodpackaging.conferenceseries.com W: chinesemedicine.conferenceseries.com
5th Annual Congress on
Plant & Soil Science 5th International Conference and Exhibition on
August 16-17, 2018 London, UK Herbal and Traditional Medicine
E: plant-soil@plantscienceconferences.com June 14-15, 2018 Rome, Italy
E: herbalmedicine@annualconferences.org
W: plantscience-biology.agriconferences.com W: herbalconference.annualcongress.com
13th International Conference on
Agriculture & Horticulture 8th International Conference & Exhibition on
September 10-12, 2018 Zurich, Switzerland Traditional & Alternative Medicine
E: agri@foodtechconferences.com November 01-03, 2018 Valencia, Spain
E: traditionalmedicine@healthconferences.org
W: agriculture-horticulture.conferenceseries.com W: traditionalmedicine.conferenceseries.com
21st International Conference on
Food Technology & Processing
October 02-04, 2018 London, UK
E: foodtechnology@foodtechconferences.com
W: foodtechnology.conferenceseries.com
Page 17
Biochemistry Cardiology

24th Annual Cardiologists Conference
Enzymology and Molecular Biology
June 11-13, 2018 Barcelona, Spain
March 05-06, 2018 London, UK
E: cardiologists@cardiologyconference.org
E: enzymology@annualconferences.org
W: annualmeeting.conferenceseries.com/cardiologists
W: enzymology.conferenceseries.com
13th International Conference on 26th Annual Conference on
Metabolomics and Systems Biology Clinical & Medical Case Reports in Cardiology
June 11-12, 2018 London, UK July 05-06, 2018 Berlin, Germany
E: eurometabolomics@annualconferences.org E: cardiologycasereports@annualconferences.org
W: europe.metabolomicsconference.com W: casereports.cardiologymeeting.com
4th International Conference on 3rd International Conference on
Lipid Science & Technology Cardiovascular Medicine and Cardiac Surgery
July 23-24, 2018 Birmingham, UK July 05-06, 2018 Berlin, Germany
E: lipids@biochemconferences.org E: cardiovascular@cardiologyconference.org
W: lipids.conferenceseries.com W: cardiovascular.conferenceseries.com
4th Glycobiology World Congress
Hypertension & Healthcare
September 17-19, 2018 Rome, Italy
September 10-11, 2018 Zurich, Switzerland
E: glycobiology@annualconferences.org
E: hypertension@cardiologymeetings.com
W: glycobiology.conferenceseries.com
W: hypertension.conferenceseries.com
14th International Conference on Structural Biology 27th European Cardiology Conference

September 24-26, 2018 Berlin, Germany October 22-24, 2018 Rome, Italy
E: structuralbiology@biochemconferences.org E: eurocardiology@cardiologyconference.org
W: structuralbiology.conferenceseries.com W: cardiology.conferenceseries.com/europe

29th World Cardiology Conference
Advancements in Bioinformatics and Drug Discovery
November 19-20, 2018 Edinburg, Scotland
November 29-30, 2018 Dublin, Ireland
E: worldcardiology@annualconferences.org
E: bioinformatics@annualconferences.org
W: worldcardiology.conferenceseries.com
W: bioinformatics.conferenceseries.com
12th International Conference and Expo on
Proteomics and Molecular Medicine
E: proteomics@annualconferences.org
W: www.proteomicsconference.com
Page 18
Chemical Engineering Chemistry

Petroleum Engineering 4th European Organic Chemistry Congress
May 17-18, 2018 Rome, Italy March 01-03, 2018 London, UK
E: petroleumengineering@chemseries.com E: euroorganicchemistry@chemistryconference.org
W: petroleumengineering.conferenceseries.com W: organicchemistry.conferenceseries.com/europe
8th World Congress on 6th International Conference and Exhibition on

Biopolymers Materials Science and Chemistry
June 28-30, 2018 Berlin, Germany May 17-18, 2018 Rome, Italy
E: biopolymercongress@chemseries.com E: materialschemistry@chemistryconference.org
W: biopolymers.conferenceseries.com W: materialschemistry.conferenceseries.com
11th World Bioenergy Congress and Expo 4th International Conference on

July 02-04, 2018 Berlin, Germany Electrochemistry
E: bioenergy@chemseries.com June 11-12, 2018 Rome, Italy
W: bioenergy.conferenceseries.com E: electrochemistry@chemistryconference.org
W: electrochemistry.conferenceseries.com
12th Global Summit and Expo on 10th World Congress on
Biomass and Bioenergy Medicinal Chemistry and Drug Design
September 04-05, 2018 Zurich, Switzerland June 14-15, 2018 Barcelona, Spain
E: eurobiomass@chemseries.com E: medicinalchemistry@chemistryconference.org
W: materials.conferenceseries.com W: medicinalchemistry.pharmaceuticalconferences.com/europe
13th World Congress on 7th World Congress on
Biofuels and Bioenergy Mass Spectrometry
September 04-06, 2018 Zurich, Switzerland June 20-22, 2018 Rome, Italy
E: biofuelscongress@chemseries.com E: euromassspectrometry@chemistryconference.org
W: biofuels-bioenergy.conferenceseries.com/europe W: massspectra.com/europe
5th International Conference on 6th International Conference and Exhibition on
Advances in Chemical Engineering & Technology Advances in Chromatography & HPLC Techniques
October 04-05, 2018 London, UK August 02-03, 2018 Barcelona, Spain
E: eurochemengineering@chemseries.com E: hplc@chemistryconference.org
W: chemicalengineering.conferenceseries.com/europe W: hplc.conferenceseries.com
7th International Conference and Exhibition on
Pain Research and Management
E: painmanagement@chemistryconference.org
W: painmanagement.conferenceseries.com
Page 19
9th International Conference and Expo on 4th International Conference on
Separation Techniques Dental and Clinical Dentistry
September 13-14, 2018 Zurich, Switzerland September 10-11, 2018 Copenhagen, Denmark
E: separationtechniques@chemistryconference.org E: clinicaldentistry@dentistryconferences.com
W: separationtechniques.conferenceseries.com W: clinicaldentistry.dentistryconferences.com
Environmental Chemistry and Engineering Advanced Dental Education
September 20-22, 2018 Berlin, Germany November 15-16, 2018 Edinburgh, Scotland
E: environmentalchemistry@chemistryconference.org E: advdentaleducation@annualconferences.org
W: environmentalchemistry.conferenceseries.com W: advanced-dental-education.dentistryconferences.com
5th International Conference on 26th Euro Congress and Expo on
Physical and Theoretical Chemistry Dental and Oral Health
October 11-13, 2018 Edinburgh, Scotland December 10-11, 2018 Rome, Italy
E: physicalchemistry@chemistryconference.org E: eurodentalcongress@dentistryconferences.com
W: physicalchemistry.conferenceseries.com W: www.dentalcongress.com/europe
Dermatology
Pharmaceutical Chemistry
October 29-31, 2018 Brussels, Belgium
E: pharmaceuticalchemistry@pharmaceuticalconferences.org
W: pharmaceuticalchemistry.conferenceseries.com
Dentistry
13th Global Dermatologists Congress
July 23-24, 2018 Moscow, Russia
E: dermatologists@dermatologyconference.org
W: annualmeeting.conferenceseries.com/dermatologists

24th Global Dentists and Pediatric Dentistry Annual Meeting
Cosmetic Dermatology and Hair Care
June 11-12, 2018 London, UK
August 13-14, 2018 Madrid, Spain
E: dentists@dentalcongress.com
E: cosmeticdermatology@dermatologyconference.org
W: annualmeeting.conferenceseries.com/dentists/
W: cosmeticdermatology.conferenceseries.com
25th World Congress on
Diabetes
Dentistry and Oral Health
E: dentistrycongress@dentistryconferences.com
W: dentalevent.conferenceseries.com
Dentistry and Dental Materials
July 19-20, 2018 Rome, Italy
27th European Diabetes Congress
E: dentalmaterials@dentalcongress.com
June 20-21, 2018 Rome, Italy
W: dentalmaterials.dentistryconferences.com
E: eurodiabetes@endocrineconferences.com
W: www.diabetesexpo.com/europe
Page 20
3rd International Conference on 4th International Conference and Exhibition on
Metabolic Syndrome & Clinical Management Satellite & Space Missions
June 18-19 , 2018 Dublin, Ireland June 18-20, 2018 Rome, Italy
E: metabolicsyndrome@endocrineconferences.com E: satellite@annualconferences.org
W: metabolicsyndromes.conferenceseries.com W: satellite.conferenceseries.com
29th International Congress on 5th International Conference on
Prevention of Diabetes and Complications Big Data Analysis and Data Mining
September 27-28, 2018 Berlin, Germany June 20-21, 2018 Rome, Italy
E: diabetesmeeting@endocrineconferences.org E: bigdata@enggconferences.com
W: diabetesmeeting.conferenceseries.com W: datamining.conferenceseries.com
4th Global Summit and Expo on
13th European Diabetes and Endocrinology Congress
Multimedia & Artificial Intelligence
July 19-21,2018 Rome, Italy
E: euroendocrinology@endocrineconferences.com
E: multimedia@enggconferences.com
W: europe.endocrineconferences.com
W: multimedia.global-summit.com
International Conference on
Engineering
Aerospace and Aerodynamics
August 02-03, 2018 Barcelona, Spain
E: aerospace@annualconferences.org
W: aerospace-engineering.conferenceseries.com
9th Euro Biosensors and Bioelectronics conference

September 13-14, 2018 London, UK
2nd International Conference on
E: eurobiosensors@conferenceseries.net
3D Printing Technology and Innovations
W: biosensors.conferenceseries.com/europe
E: 3dprinting@conferenceseries.net
W: 3dprinting.conferenceseries.com
Automobile Engineering
4th International Conference and Business Expo on September 20-21, 2018 Rome, Italy
Wireless, Telecommunication & IoT E: automobile@enggconferences.com
May 28-29 2018 London, UK W: automobile.conferenceseries.com/europe
E: wireless@enggconferences.com
W: wirelesscommunication.conferenceseries.com
Cloud Computing and Data Analysis
2nd World Congress on September 06-07, 2018 London, UK
Wind and Renewable Energy E: cloudcomputing@annualconferences.org
June 14-15, 2018 London, UK W: cloud-computing.conferenceseries.com
E: windenergy@enggconferences.com
W: winenergy.conferenceseries.com
Battery and Fuel Cell Technology
3rd International Conference on September 10-11, 2018 London, UK
Power and Energy Engineering E: batterytech@enggconferences.com
June 18-19, 2018 Rome, Italy W: batterytech.conferenceseries.com
E: powerengineering@annualconferences.org
W: power-energy.conferenceseries.com
Page 21
2nd International Conference on 5th World Congress and Expo on
Membrane Science and Technology Green Energy
September 13-14, 2018 London, UK June 14-16 ,2018 London, UK
E: membranescience@annualconferences.org E: greenenergycongress@earthscienceconferences.com
W: membranescience.conferenceseries.com W: greenenergy.conferenceseries.com/europe
2nd International Conference on 4th International Conference on
Mechatronics, Automation and Control Systems Pollution Control and Sustainable Environment
September, 17-18, 2018 Berlin, Germany July 26-28, 2018 Rome, Italy
E: mechatronics@enggconferences.com E: pollutioncontrol@conferenceseries.net
W: mechatronics.conferenceseries.com W: pollutioncontrol.conferenceseries.com
3rd International Conference on 5th World Conference on
Fluid Dynamics & Aerodynamics Climate Change
October 25-26, 2018 Berlin, Germany October 04-06, 2018 London, UK
E: fluiddynamics@enggconferences.com E: climatechange@annualconferences.org
W: fluid-aerodynamics.global-summit.com W: climatechange.conferenceseries.com
Gastroenterology
Agricultural Engineering and Food Security
November 12-13,2018 Frankfurt, Germany
E: foodsecurity@annualconferences.com
W: agri-foodsecurity.agriconferences.com
Design and Production Engineering
December 03-04, Valencia, Spain
12th Global Gastroenterologists Meeting
E: productionengineering@annualconferences.org
March 15-16, 2018 Barcelona, Spain
W: design-production.conferenceseries.com
E: gastro@gastroconferences.org
W: gastro.conferenceseries.com
Environmental Sciences
Hepatitis & Liver Diseases
June 18-20, 2018 Dublin, Ireland
E: hepatitis@gastroconferences.com
W: hepatitis.conferenceseries.com
World Conference on Ecology 13th Euro-Global Gastroenterology Conference

March 19-20, 2018 Berlin, Germany August 20-21, 2018 Rome, Italy
E: ecology@annualconferences.org E: gastrocongress@gastroconferences.com
W: ecology.conferenceseries.com W: gastroenterology.conferenceseries.com/europe
8th World Congress and Expo on 3rd International conference on

Recycling Digestive Diseases
June 25-26, 2018 Berlin, Germany October 22-24, 2018 Berlin, Germany
E: recyclingexpo@conferenceseries.net E: digestivediseases@gastroconferences.com
W: recycling.conferenceseries.com W: digestivediseases.conferenceseries.com
Page 22
Genetics and Molecular Biology 21st Euro Biotechnology Congress
E: eurobiotechnology@geneticconferences.com
W: www.biotechnologycongress.com/europe

Tissue Engineering & Regenerative Medicine
October 18-20, 2018 Rome, Italy
7th International Conference and Exhibition on E: regenerativemedicine@geneticconferences.com
Cell and Gene Therapy W: tissuescience-regenerativemedicine
March 15-17, 2018 London,UK
E: celltherapy@conferenceseries.net Geology and Earth Sciences
W: cellgenetherapy.conferenceseries.com
20th Global Congress on
Biotechnology
E: biotechcongress@geneticconferences.com
W: biotechnology.conferenceseries.com 2nd Annual Congress on
Soil and Water Sciences
Integrative Biology
E: soilscience@annualconferences.org
May 21-23, 2018 Barcelona, Spain
W: soilscience.conferenceseries.com
E: integrativebiology@conferenceseries.net
W: integrativebiology.conferenceseries.com 4th International Conference on
GIS and Remote Sensing
September 27-28, 2018 Berlin, Germany
Genomics and Molecular Biology
E: giscongress@earthscienceconferences.com
May 21-23, 2018 Barcelona, Spain
W: gis-remotesensing.conferenceseries.com/europe
E: genomics@conferenceseries.net |
W: genomics.conferenceseries.com Healthcare
Synthetic Biology and Tissue Engineering
E: syntheticbiology@conferenceseries.net
W: syntheticbiology.conferenceseries.com
4th International Conference on 3rd World Congress on
Bioscience Public Health & Nutrition
July 02-03, 2018 Vienna, Austria February 26-28, 2018 London, UK
E: bioscience@conferenceseries.net E: publichealthcongress@healthconferences.org
W: bioscience.conferenceseries.com W: publichealth.global-summit.com
10th Annual Conference on 5th International Conference on
Stem Cell and Regenerative Medicine Tropical Medicine & Infectious Diseases
August 13-14, 2018 London, UK May 21-22, 2018 Barcelona, Spain
E: stemcellcongress@conferenceseries.net E: tropicalmedicine@healthconferences.org
W: stemcell-regenerativemedicine.conferenceseries.com W: tropicalmedicine.annualcongress.com
Page 23
13th World Congress on 7th International Conference on
Healthcare & Technologies Medical & Nursing Education
June 14-15, 2018 Dublin, Ireland October 29-30, 2018 Brussels, Belgium
E: healthcaresummit@healthconferences.org E: medicaleducation@healthconferences.org
W: healthcare.global-summit.com/europe W: medicaleducation.conferenceseries.com
2nd International Conference on 5th International Conference on
Social Sciences & Interdisciplinary Studies Healthcare and Hospital Management
June 18-19, 2018 Rome, Italy December 03-05, 2018 Rome, Italy
E: socialsciences@healthconferences.org E: hospitalmanagement@healthconferences.org
W: socialsciences.conferenceseries.com W: hospital-management.healthconferences.org
Immunology
Medical Informatics & Telemedicine
E: medicalinformatics@healthconferences.org
W: medicalinformatics.conferenceseries.com
Geriatrics Gerontology & Palliative Nursing
July 30-31, 2018 Barcelona, Spain
9th Molecular Immunology & Immunogenetics Congress
E: geriatrics@healthconferences.org
W: geriatrics-gerontology.conferenceseries.com
E: molecularimmunology@immunologyconferences.org
3rd Internationl Conference on W: molecularimmunology.conferenceseries.com
General Practice & Primary Care
9th European Immunology Conference
E: generalpractice@healthconferences.org
W: generalpractice.conferenceseries.com
E: euroimmunology@conferenceseries.net
4th World Congress on Health Economics, Health W: immunology.conferenceseries.com/europe
Policy and Healthcare Management
September 13-14, 2018 Zurich, Switzerland 10th International Conference on
E: health-economics@healthconferences.org Clinical and Cellular Immunology
W: healtheconomics.healthconferences.org August 06-07, 2018 Madrid, Spain
E: immunologyworld@annualconferences.org
W: immunology.immunologyconferences.org
Epidemiology & Public Health
September 17-19, 2018 Rome, Italy 11th Annual Congress on
E: epidemiology@healthconferences.org Immunology & Immunotechnology
W: epidemiology.conferenceseries.com September 13-14, 2018 Zurich, Swtizerland
E: immunologycongress@annualconferences.org
W: immunologycongress.immunologyconferences.org
Environmental Health & Preventive Medicine
October 15-16, 2018 Warsaw, Poland 12th International Conference on
E: environmentalhealth@healthconferences.org Allergy, Asthma & Clinical Immunology
W: environmentalhealth.conferenceseries.com October 01-02, 2018 Moscow, Russia
E: allergy@immunologyconferences.org
W: allergy.conferenceseries.com
Advances in Skin, Wound Care and Tissue Science
October 18-19, 2018 Rome, Itlay
E: woundcongress@healthcarevents.com
W: woundcare.conferenceseries.com/europe
Page 24
3rd International Conference on 13th World Congress on
Autoimmunity Infection Prevention and Control
November 26-27, 2018 Dublin, Ireland October 11-12, 2018 Moscow, Russia
E: autoimmunity@immunologyconferences.org E: ipcc@infectiousconferences.com
W: autoimmunity.conferenceseries.com W: infectionprevention.conferenceseries.com
7th International Chronic Obstructive
Infectious Diseases
Pulmonary Disease Conference
E: copdconferences@annualconferences.org
W: copd.conferenceseries.com/europe
Materials Science
Infectious Diseases
March 01-02, 2018 Berlin, Germany
E: infectioncongress@infectiousconferences.com
W: infectioncongress.conferenceseries.com
3rd Annual Conference and Expo on
Biomaterials
Rare Diseases and Orphan Drugs
E: biomaterials@materialsconferences.org
E: rarediseasecongress@infectiousconferences.com
W: biomaterials.conferenceseries.com
W: rarediseases.conferenceseries.com/europe
Emerging Materials and Nanotechnology
Influenza and Zoonotic Diseases
July 02-03, 2018 Vienna, Austria
E: emergingmaterialscongress@materialsconferences.org
E: influenza@infectiousconferences.com
W: emergingmaterials.materialsconferences.com
W: influenza.conferenceseries.com
Ceramics and Composite Materials
Emerging Infectious Diseases
May 14-15, 2018 Rome, Italy
August 27-28, 2018 Zurich, Switzerland
E: ceramics@materialsconferences.org
E: emerginginfections@annualconferences.org
W: ceramics.conferenceseries.com
W: emerging-diseases.infectiousconferences.com
Materials Science and Engineering
Control and Prevention of HIV/AIDS, STDs & STIs
E: materialscongress@materialsconferences.org
E: std@infectiousconferences.com
W: materialsscience.conferenceseries.com/europe
W: globalhiv-aids-std.infectiousconferences.com
7th International conference on
10th Euro-Global Conference on Infectious Diseases Smart Materials and Structures
September 27-29, 2018 Rome, Italy July 02-03, 2018 Vienna, Austria
E: europe@infectiousconferences.com E: smartmaterialscongress@annualconferences.org
W: smartmaterials.materialsconferences.com
W: infection.conferenceseries.com/europe
Page 25
20th International Conference on 47th World Congress on Microbiology
Advanced Energy Materials and research September 10-11, 2018 London, UK
August 13-14, 2018 Dublin, Ireland
E: advancedenergymaterials@annualconferences.org E: microbiology@microbiologyconferences.org
W: energymaterials.materialsconferences.com W: microbiology.conferenceseries.com/europe
21st International Conference on 9th international summit on

Advanced Materials & Nanotechnology Clinical Microbiology
September 04-06, 2018 Zurich, Switzerland October 08-09, 2018 Zurich, Switzerland
E: materials@materialsconferences.org E: microbiologysummit@microbiologyconferences.org
W: materials.conferenceseries.com W: clinicalmicrobiology.conferenceseries.com/europe
International Conference on 5th World Congress and Expo on
Advanced Materials and Simulations Applied Microbiology
September 11-12, 2018 University of Derby, UK November 15-16, 2018 Frankfurt, Germany
E: materialssimulation@materialsconferences.org E: appliedmicrobiology@microbiologyconferences.org
W: advanced-materials-simulation.materialsconferences.com W: microbiology.conferenceseries.com
Nanotechnology
Graphene, Carbon Nanotubes, and Nanostructures
E: carboncongress@materialsconferences.org
W: carbon.materialsconferences.com
Microbiology
Nanomaterials and Nanotechnology
E: nanomaterials@nanotechconferences.org
W: nanomaterials.conferenceseries.com
16th International Pharmaceutical Microbiology and
24th World Nano Conference
Biotechnology Conference
May 07-08 | 2018 Rome, Italy
May 21-23, 2018 Vienna, Austria
E: nano@nanotechconferences.org
E: pharmaceutical@microbiologyconferences.org
W: nano.conferenceseries.com
W: pharmaceuticalmicrobiology.conferenceseries.com/europe
10th International Virology Congress and Expo 25th Nano Congress for Future Advancements
July 02-04, 2018 Vienna, Austria August 16-17, 2018 Dublin, Ireland
E: eurovirology@microbiologyconferences.org E: nanocongress@nanotechconferences.org
W: virology.conferenceseries.com/europe W: nanocongress.conferenceseries.com

Microbial Interactions and Microbial Ecology Advanced Nanotechnology
July 19-20, 2018 Rome, Italy October 04-05, 2018 Moscow Russia
E: microbialinteraction@microbiologyconferences.org E: advancednano@nanotechconferences.org
W: microbialinteraction.conferenceseries.com W: advancednano.nanotechconferences.org
Page 26
3rd World Congress and Expo on 22nd International Conference on
Graphene and 2D Materials Neurology & Neurophysiology
November 26-28, 2018 Barcelona, Spain April 23-24, 2018 Rome, Italy
E: graphene@nanotechconferences.org E: neurophysiology@neuroconferences.com
W: graphene.conferenceseries.com/europe W: neurophysiology.conferenceseries.com
Nanosciences and Nanotechnology Neurology and Neurosurgery
November 26-28, 2018 Barcelona, Spain April 23-24, 2018 Rome, Italy
E: nanoscience@nanotechconferences.org E: neurosurgery@neuroconferences.org
W: nanotechnology.conferenceseries.com W: neurosurgery.conferenceseries.com
Nephrology
Neuroscience and Neurochemistry
May 21-22, 2018 Birmingham, UK
E: neurochemistry@neuroconferences.com
W: neurochemistry.conferenceseries.com
Alzheimers Disease & Dementia
17th International Conference on May 24-25, 2018 Vienna, Austria
Nephrology & Urology E: dementiacongress@neuroconferences.com
March 12-13, 2018 London, UK W: alzheimers-dementia.neurologyconference.com
E: nephrology-urology@annualconferences.org
W: nephrology-urology.nephroconferences.com 3rd International Conference on Spine and Spinal Disorders
19th Global Nephrologists Annual Meeting E: spine@neuroconferences.com
May 14-15, 2018 Rome, Italy W: spine.conferenceseries.com
E: nephrologists@nephroconferences.com
W: annualmeeting.conferenceseries.com/nephrologists/
25th World Congress on Neurology & Neuroscience
22nd European Nephrology Conference E: neurosciencecongress@neuroconferences.com
October 15-16, 2018 Warsaw, Poland W: neuroscience.neurologyconference.com
E: euronephrology@nephroconferences.com
W: nephrology.conferenceseries.com/europe
27th Euro-Global Neurologists Meeting
Neuroscience E: neurologistsconference@neuroconferences.com
W: neurologists.neurologyconference.com
11th International Conference on Vascular Dementia

E: vasculardementiacongress@neuroconferences.com
W: vasculardementia.neurologyconference.com
21st World Congress on Neurology and Therapeutics
March 15-17, 2018 London, UK 7th World Congress on
E: neurology@neuroconferences.com Addictive Disorders & Addiction Therapy
W: neurologyconference.com July 16-18, 2018 London, UK
E: addiction@neuroconferences.com
W: addictiontherapy.conferenceseries.com/europe
Page 27
26th European Neurology Congress 4th International Conference on Spine and Spinal Disorders
August 6-8, 2018 Madrid, Spain November 12-13, 2018 Frankfurt, Germany
E: neurologycongress@neuroconferences.com E: spinecongress@neuroconferences.com
W: neurologyconference.com/europe W: spine.conferenceseries.com/europe

4th International Conference on Epilepsy & Treatment
Central Nervous System Disorders & Therapeutics
August 29-30, 2018 Zurich, Swtizerland
November 12-14, 2018 Edinburgh, Scotland
E: epilepsy@neuroconferences.com
E: cns@neuroconferences.com
W: epilepsytreatment.conferenceseries.com
W: cns.conferenceseries.com
4th World Congress on Parkinsons & Huntington Disease Nursing

E: parkinson@neuroconferences.com
W: parkinsons.neurologyconference.com

Brain Disorders and Therapeutics
September13-15, 2018 Copenhagen, Denmark
E: braindisorders@neuroconferences.com 47th Global Nursing & Healthcare Conference
W: braindisorders.conferenceseries.com March 01-03, 2018 London, UK
E: nursingglobal@nursingconference.com
7th International Conference on Neurological Disorders & Stroke W: global.nursingconference.com/europe
E: strokecongress@neuroconferences.com 7th World Congress on Breast Cancer
W: stroke.neurologyconference.com May 10-11, 2018 Frankfurt, Germany
E: breastcancer@conferenceseries.net
27th International Conference on W: breastcancer.conferenceseries.com
Neurology and Cognitive Neuroscience
October 18-19, 2018 Warsaw, Poland 3rd International Conference on
E: neurocognitive@neuroconferences.com Reproductive Health and Medicine
W: neurocognitivedisorders.conferenceseries.com May 21-22, 2018 Vienna, Austria
12th International Conference on E: reproductivemedicine@healthconferences.org
Alzheimer’s Disease & Dementia W: reproductivehealth.conferenceseries.com/europe
October 29-31, 2018 Valencia, Spain 48th World Congress on
E: dementia@neuroconferences.com Advanced Nursing Research
W: alzheimers-dementia.conferenceseries.com June 14-15, 2018 Dublin, Ireland
E: nursingresearch@annualconferences.org
4th International Conference on Spine Surgery W: nursingresearch.nursingmeetings.com
November 1-2, 2018 Brussels, Belgium
E: spinesurgeryconference@neuroconferences.com 2nd World Congress on
W: spinalsurgery.neurologyconference.com Patient Safety & Quality Healthcare
28th Global Neurologists Annual Meeting on E: patientsafety@healthconferences.org
Neurology and Neurosurgery W: patientsafety.conferenceseries.com
E: neurologists@neuroconferences.com
W: annualmeeting.conferenceseries.com/neurologists
Page 28
51st World Nursing Leadership & Management Conference
Nursing Care Plan and Health
16 -18 July 2018 Rome, Italy
E: nursingleadership@annualconferences.org
E: nursingcareplan@annualconferences.org
W: nursingleadership.nursingmeetings.com
W: nursingcareplan.nursingmeetings.com
50th World Congress On Men in Nursing
Gynecology and Obstetrics
October 8-10, 2018- Zurich, Switzerland
mennursing@annualconferences.org
E: gynecology@nursingconference.com
W: men.nursingmeetings.com
W: gynecology.conferenceseries.com
33rd Euro Nursing & Medicare Summit
Emergency Nursing & Critical Care
October 8-10, 2018 Edinburgh, Scotland
July 16-17, 2018 London, UK
E: euronursing@nursingconference.com
E: emergencynursing@annualconferences.org
W: europe.nursingconference.com
W: emergency.nursingmeetings.com
26th Cancer Nursing & Nurse Practitioners Conference 27th World Nursing Education Conference
July 16-17, 2018 London, UK November 12-14, 2018 Frankfurt, Germany
E: cancernursing@nursingconference.com E: nursingeducation@nursingconference.com
W: cancernursing.nursingconference.com W: nursingeducation.nursingconference.com
31st World Congress on

Nutrition
Advanced Nursing Practice
E: nursingpractice@nursingconference.com
W: nursingpractice.nursingconference.com
Pediatric Nursing & Healthcare
15th International Conference on Clinical Nutrition
E: pediatricnursing@nursingconference.com
May 24-26, 2018 Vienna, Austria
W: pediatric.nursingconference.com
E: clinicalnutrition@nutritionalconference.com
17th World Congress on W: clinicalnutrition.conferenceseries.com
Clinical Nursing and Practice
21st European Nutrition and Dietetics Conference
E: clinicalnursing@annualconferences.org
W: clinical.nursingmeetings.com
E: nutritioncongress@nutritionalconference.com
5th World Congress on W: nutritionalconference.com/europe
Midwifery & Women’s Health
September 13-14, 2018 Frankfurt, Germany 14th International Congress on Advances in Natural
E: euromidwifery@nursingconference.com Medicines, Nutraceuticals & Neurocognition
W: midwifery.conferenceseries.com/europe July 19-20, 2018 London, UK
E: nutraceuticals@nutritionalconference.com
24th World Nursing and Healthcare Conference W: nutraceuticals.pharmaceuticalconferences.com
September 13-15, 2018 Copenhagen, Denmark
E: worldnursing@annualconferences.org
W: world.nursingconference.com
Page 29
6th International Conference on 6th International Congress on
Sports Nutrition & Fitness Gynecology & Gynecologic Oncology
August 16-17, 2018 Dublin, Ireland July 23-24, 2018 Rome, Italy
E: sports-nutrition@annualconferences.org E: gynecologyconference@annualconferences.org
W: sportsnutrition.nutritionalconference.com W: gynecologyconference.annualcongress.com
17th World Congress on 29th Euro-Global Summit on
Nutrition and Food Chemistry Cancer Therapy & Radiation Oncology
September 13-15, 2018 London, UK July 23-25, 2018 Rome, Italy
E: nutri-foodchemistry@nutritionalconference.com E: eurocancer@oncologyseries.com
W: nutrition-foodchemistry.conferenceseries.com W: cancer-radiationoncology.conferenceseries.com
22nd European Nutritional Science Congress 28th Euro Congress on Cancer Science & Therapy
November 26-27, 2018 Barcelona, Spain August 09-10, 2018 Madrid, Spain
E: nutritionalscience@nutritionalconference.com E: cancerscience@oncologyseries.com
W: nutritionalscience.nutritionalconference.com W: cancerscience.conferenceseries.com

Obesity
Medical Imaging and Clinical Research
September 03-04, 2018 London, UK
E: medicalimaging@oncologyseries.com
W: clinical-medicalimaging.conferenceseries.com
Epigenetics and Chromatin
11th International Conference on September 03-04, 2018 London, UK
Childhood Obesity and Nutrition E: epigenetics@oncologyseries.com
March 15-16, 2018 Barcelona, Spain W: epigenetics.conferenceseries.com
E: childhoodobesity@annualconferences.org
W: childhoodobesity.conferenceseries.com 3rd Cancer Diagnostics Conference & Expo
14th Euro Obesity and Endocrinology Congress E: cancerdiagnotics@oncologyseries.com
September 13-14, 2018 London, UK W: cancerdiagnostics.conferenceseries.com
E: euroobesity@obesityconference.org
W: obesity.nutritionalconference.com
36th World Cancer Conference
October 11-13, 2018 Zurich, Switzerland
Oncology & Cancer E: worldcancer@annualconferences.org
W: cancer.global-summit.com
13th World Biomarkers Congress

E: worldbiomarkers@oncologyseries.com
W: molecular-cancer-biomarkers.conferenceseries.com
12th World Hematologists Congress
Ophthalmology
E: hematologists@oncologymeet.com
W: hematology.conferenceseries.com/europe
Page 30
19th Ophthalmology Summit
Surgical Pathology & Cancer Diagnosis
Feb 26-27, 2018 Berlin Germany
May 17-18, 2018 Rome, Italy
E: ophthalmologysummit@ophthalmologyconferences.com
E: surgicalpathology@annualconferences.org
W: ophthalmologysummit.conferenceseries.com
W: surgicalpathology.conferenceseries.com
8th European Conference on Predictive, Preventive, Personalized
3rd Global Pediatric Ophthalmology Congress
Medicine & Molecular Diagnostics
August 20-21, 2018 Rome, Italy
E: pediatricophthalmology@ophthalmologyconferences.com
E: europersonalizedmedicine@conferneceseries.net
W: pediatricophthalmology.conferenceseries.com
W: personalizedmedicine.conferenceseries.com/europe
2nd International Conference on
Pediatrics
Cataract and Advanced Eye Care
E: cataract@ophthalmologyconferences.com
W: cataract.conferenceseries.com
2nd Global Meeting and Expo on
Vision Science & Eye
August 29-30, 2018 Zurich, Swizeland
3rd International Conference on Pediatric Surgery
E: visionscience@ophthalmologyconferences.com
May 7-8, 2018 Frankfurt, Germany
W: visionscience.conferenceseries.com
E: pediatricsurgery@annualconferences.org
3rd International Conference and Expo on W: pediatricsurgery.conferenceseries.com
Optometry and Vision Science
October 8-9, 2018 Edinburg, Scotland
17th International Conference on Clinical Pediatrics
E: optometry@ophthalmologyconferences.com
W: optometry.conferenceseries.com
E: clinicalpediatrics@pediatricsconferences.org
17th International Conference on W: clinicalpediatrics.conferenceseries.com
Clinical & Experimental Ophthalmology
Advances in Neonatal and Pediatric Nutrition
E: ophthalmology@ophthalmologyconferences.org
W: ophthalmology.conferenceseries.com
E: neonatalnutrition@annualconferences.org
W: pediatricnutrition.pediatricsconference.com
28th European Ophthalmology Congress
E: ophthalmologycongress@ophthalmologyconferences.com
Pediatrics Primary Care
W: ophthalmology.conferenceseries.com/europe
September 03-04 2018 Zurich, Switzerland
E: pediatricprimarycare@annualconferences.org
Pathology W: primarycare.pediatricsconferences.com
Pediatrics Health
E: pediatricshealth@annualconferences.org
W: health.pediatricsconferences.com
24th European Pediatrics Conference
Laboratory Medicine and Pathology
June 25-26, 2018 Berlin, Germany
E: europediatrics@pediatricsconferences.org
E: laboratorymedicine@pathologyconferences.org
W: pediatrics.conferenceseries.com/europe
W: laboratorymedicine.conferenceseries.com
Page 31
24th World Pediatrics Conference
Pharmaceutical Sciences and Innovations in Pharma Industry
October 18-20, 2018 Warsaw, Poland
February 26- 27, 2018 London, UK
E: worldpediatrics@annualconferences.org
E: pharmaindustry@pharmaceuticalconferences.org
W: worldpediatrics.pediatricsconferences.org
W: industry.pharmaceuticalconferences.com
26th International Conference on 16th International Conference and Exhibition on
Neonatology and Perinatology Pharmaceutics & Novel Drug Delivery Systems
November 15-17 2018 Edinburgh, Scotland March 19-21, 2018 Berlin, Germany
E: neonatology@pediatricsconferences.com E: pharmaceutica@pharmaceuticalconferences.org
W: neonatology.conferenceseries.com W: novel-drugdelivery-systems.pharmaceuticalconferences.com
Petroleum 11th European Biosimilars Congress

April 26-27, 2018 Rome, Italy
E: eurobiosimilars@pharmaceuticalconferences.org
W: biosimilars-biologics.pharmaceuticalconferences.com/europe
15th Annual European Pharma Congress

May 07-09, 2018 Frankfurt, Germany
9th International Conference and Expo on E: pharmaeurope@pharmaceuticalconferences.org
Oil and Gas W: europe.pharmaceuticalconferences.com
4th World Congress and Exhibition on
E: petroleum@oilgasconferences.org
Antibiotics and Antibiotic Resistance
W: oil-gas.conferenceseries.com
E: antibiotics@pharmaceuticalconferences.org
Physical Therapy & Rehabilitation
W: antibiotics.pharmaceuticalconferences.com
Pharmacovigilance
E: pharmacovigilance@pharmaceuticalconferences.org
W: pharmacovigilance.pharmaceuticalconferences.com
Novel Physiotherapies
Natural Products, Medicinal Plants & Marine Drugs
E: novelphysiotherapies@annualconferences.org
E: naturalproducts@pharmaceuticalconferences.org
W: novelphysiotherapies.conferenceseries.com
W: naturalproducts.pharmaceuticalconferences.com
6th International Conference & Exhibition on
Physiotherapy & Physical Rehabilitation
Pharmaceutical Formulations
August 13-14, 2018 London, UK
E: physiotherapy@annualconferences.org
E: formulations@pharmaceuticalconferences.org
W: physiotherapy.annualcongress.com
W: formulation.pharmaceuticalconferences.com
Pharma
10th World Congress on Pharmacology
July 30-Aug 01, 2018 Barcelona, Spain
E: pharmacology@pharmaceuticalconferences.org
W: pharmacology.pharmaceuticalconferences.com
Page 32
4th International Conference and Expo on 5th International Conference on
Drug Discovery, Designing & Development Theoretical and Applied Physics
September 06-07, 2018 London, UK July 02-03, 2018 Vienna, Austria
E: drugdiscovery@pharmaceuticalconferences.org E: appliedphysics@annualconferences.org
W: drug-discovery.pharmaceuticalconferences.com W: appliedphysics.physicsmeeting.com
6th International Conference on 9th International Conference on
Advanced Clinical Research and Clinical Trials Optics, Photonics & Lasers
September 10-11, 2018 Zurich, Switzerland July 02-04, 2018 Berlin, Germany
E: clinicalresearch@pharmaceuticalconferences.org E: eurooptics@annualconferences.org
W: clinicalresearch.pharmaceuticalconferences.com W: optics.physicsmeeting.com
18th World Pharma Congress
Condensed Matter and Materials Physics
August 16-17, 2018 London, UK
E: pharmacongress@pharmaceuticalconferences.org
E: materialsphysics@annualconferences.org
W: world.pharmaceuticalconferences.com
W: materialsphysics.physicsmeeting.com
18th Annual Pharmaceutical and Chemical Analysis Congress 3rd International Conference on
November 05-06, 2018 Madrid, Spain Quantum Optics and Quantum Computing
E: analysis@pharmaceuticalconferences.org September 10-11, 2018 London, UK
W: analysis.pharmaceuticalconferences.com E: quantumoptics@annualconferences.org
W: quantumoptics.physicsmeeting.com
Generics Drugs and Biosimilars 4th International Conference on Physics
November 15-17, 2018 Frankfurt, Germany September 17-18, 2018 Berlin, Germany
E: genericpharma@pharmaceuticalconferences.org E: physics@physicsconferences.org
W: generic-market.pharmaceuticalconferences.com W: physics.conferenceseries.com
9th Global Experts Meeting on
Neuropharmacology
Quantum Physics and Quantum Technology
November 15-16, 2018 Frankfurt, Germany
E: neuro@pharmaceuticalconferences.org
E: quantumphysics@physicsconferences.org
W: neuro.pharmaceuticalconferences.com
W: quantumphysics.conferenceseries.com
Pharmaceutical Biotechnology
Astronomy and Space Science
December 10-11, 2018 Rome, Italy
E: pharmabiotech@pharmaceuticalconferences.org
E: astrospace@physicsconferences.org
W: biotech.pharmaceuticalconferences.com
W: astronomy-space.physicsmeeting.com
Physics 3rd International Conference on
Magnetism and Magnetic Materials
E: magneticmaterials@annualconferences.org
W: magneticmaterials.physicsmeeting.com
High Energy & Particle Physics
3rd International Conference on Nuclear and Plasma Physics December 03-04, 2018 Valencia, Spain
June 07-08, 2018 London, UK E: highenergy@physicsconferences.org
E: plasmaphysics@annualconferences.org W: highenergyphysics.conferenceseries.com
W: plasmaphysics.physicsmeeting.com
Page 33
Psychiatry
Metabolic and Bariatric Surgery
March 15-16, 2018 Barcelona, Spain
E: bariatricsurgery@annualconferences.org
W: bariatricsurgery.conferenceseries.com
7th International Conference and Exhibition on Surgery

4th International Conference on E: surgery@surgeryconferences.org
Mental Health & Human Resilience W: sugery.conferenceseries.com
April 26-27, 2018 Rome, Italy
E: mentalhealth@conferenceseries.net 3rd International Conference on Anesthesia
W: mentalhealth.conferenceseries.com June 21-22, 2018 Dublin, Ireland
4th International Conference on E: anesthesia@annualconferences.org
Depression, Anxiety and Stress Management W: anesthesia.conferenceseries.com
May 10-11, 2018 Frankfurt, Germany 13th International Conference on
E: stress@psychiatrycongress.com Arthroplasty and Orthopedics
W: stressmanagement.global-summit.com August 08-09, 2018 Rome, Italy
27th World Congress on E: arthroplasty@annualconferences.org
Psychiatry & Psychological Syndromes W: orthopedics.surgeryconferences.com
June 21-23, 2018 London, UK 8th International Conference and Expo on
E: psychiatrycongress.com Cosmetology, Trichology & Aesthetic Practices
28th Euro Congress on
E: cosmetologycongress@surgeryconferences.org
Psychiatrists and Psychologists
W: cosmetology.surgeryconferences.com
E: europsychiatry@psychiatrycongress.com World Congress on
W: psychiatry.global-summit.com/europe Neurology and Neuromuscular Disorders
September 13-14, 2018 Frankfurt, Germany
E: neuromuscular@annualconferences.org
Adolescent Medicine & Child Psychology
W: neuromuscular.neuroconferences.com
Sep 04-05, 2018 Zurich, Switzerland
E: childpsychology@conferenceseries.net 3rd European Otolaryngology-ENT Surgery Conference
W: childpsychology.conferenceseries.com October 08-10, 2018 London, UK
E: ent@surgeryconferences.org
W: ent.conferenceseries.com
Psychiatry & Psychosomatic Medicine
November 01-03, 2018 Brussels, Belgium 2nd International Conference on
E: psychosomaticmedicine@psychiatrycongress.com Craniofacial Surgery
W: psychosomatic.conferenceseries.com October 08-09, 2018 London, UK
E: craniofacial@annualconferences.org
Surgery W: craniofacial.surgeryconferences.com
9th European Congress of Rheumatology,
Autoimmunity and Orthopedics
E: rheumatology@annualconferences.org
W: rheumatology.conferenceseries.com
Page 34
Toxicology Vaccines

15 Euro-Global Summit on
th
Vaccines and Immunization
Toxicology and Applied Pharmacology March 19-20, 2018 London, UK
July 02-04, 2018 Berlin, Germany E: vaccinessummit@immunologyconferences.org
E: eurotoxicology@annualconferences.org W: vaccines-immunization.conferenceseries.com
W: toxicology.global-summit.com/europe
31st Euro Global Summit and Expo on
16 Annual Meeting on
th
Vaccines & Vaccination
Environmental Toxicology and Life Sciences June 14-16, 2018 Barcelona, Spain
August 13-14, 2018 London, UK E: eurovaccines@vaccineconference.com
E: euroenvitox@annualconferences.org W: europe.vaccineconferences.com
W: environmentaltoxicology.toxicologyconferences.com
Page 35
EPIGENETICS 2018
Page 36

Exhibitors
EPIGENETICS 2018
Page 37
© Alain Janssens
Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample
preparation, and diagnostic assays based in Liège, Belgium and Denville, NJ, USA. The company has developed
both (1) shearing solutions for a number of applications, as well as a comprehensive approach to gain new
insights into epigenetic studies and (2) innovative products for the infectious diseases market. The company
offers innovative Bioruptor® and Megaruptor®shearing devices, IP-Star® automation instrument, reagent kits,
and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. Along with highly
trusted and cost-effective In Vitro Diagnostic (IVD) kits for the detection of viruses, bacteria and parasites in a
wide number of diseases.
From Diagenode’s founding in 2003 in Liège as a local biotechnology startup, the company has expanded rapidly.
Diagenode opened its US branch in 2006 and developed a global distribution and partnering network including
relationships in Japan and other Asia-Pacific countries.
1 EPIGENETICS RESEARCH
Epigenetics plays a revolutionary role in life sciences research.
2 MOLECULAR DIAGNOSTICS
The field of human disease diagnostics is also changing and
Rapid progress in this field is driving the need for new kinds of growing at a rapid rate. Diagenode offers amplification and
research tools and new standards for understanding the epigenetic quantification methods for DNA targets of human infectious
control mechanisms involved in various biological phenomena disease. We also provide guidance to diagnostics companies
such as disease development and drug mechanisms of action. developing epigenetics-based diagnostics. Our products are
Genome-wide tools which can assess global epigenetic changes designed to make diagnostic assays simpler, faster, and more
at the histone or DNA level (such as Next Generation Sequencing) convenient, with the highest levels of quality. Our kits are CE-
dramatically advance the understanding of epigenetic mechanisms. marked and certified ISO 9001 and ISO 13485.
Epigenetics research will identify new biomarkers for earlier-
stage disease diagnosis and enable development of effective new
therapeutics.
Epigenetic assays are complex and necessitate high-quality

reagents, robust protocols, and comprehensive data analysis.
Diagenode continually innovates solutions and provides the highest
quality epigenetics tools available.
Please contact us for more information www.diagenode.com www.diagenodediagnostics.com

Europe Diagenode sa / LIEGE SCIENCE PARK / Rue Bois Saint-Jean, 3 / 4102 Seraing (Ougrée) / Belgium / Phone: (+32) 4 364 20 50 / E-mail: info@diagenode.com
USA Diagenode Inc. / 400 Morris Avenue, Suite 101 / Denville, NJ 07834 / USA / Phone: (+1) 862 209-4680 / Mail: info.na@diagenode.com
Page 38
Page 39
Page 40

Keynote Forum
Day 1
EPIGENETICS 2018
Page 41
conferenceseries.com Marvin H Caruthers, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Epigenetics & Chromatin September 03-05, 2018 | London, UK
Marvin H Caruthers
University of Colorado, USA
DNA analogues for CRISPER/CAS fidelity and exon skipping
N ew thiomorpholino oligonucleotide analogues (TMO) containing morpholino and deoxyribonucleoside joined through
thiophosphate-phosphor inter nucleotide linkages were chemically synthesized. These analogues have higher melting
temperatures when compared to natural DNA/RNA and DNA/RNA duplexes. Moreover, the TMO/RNA duplexes exhibit the
A-form structure and are RNase H1 active. Treatment of HeLa cells with fluorescently labeled TMO and TMO/DNA chimeras
demonstrated that these analogues were efficiently taken up by cells and stimulates biological activity in a HeLa cell dual luciferase
assay. Recently thiomorpholino oligonucleotides were found to be more active than any other tested analogue in exon skipping
assays with a mouse model for Duchenne muscular dystrophy. Recently imidoamidate DNA was synthesized. Imidoamidate DNA
forms duplexes with complementary DNA, is positively charged and can be transfected in the absence of lipid, and is RNase H1
active. In collaboration with Agilent Technologies, we have developed methods and instruments for the chemical synthesis on glass
chips of DNA and RNA containing upto 300 nucleotides per segment. RNA containing phosphonoacetate nucleotides at the 3’/5’
ends have much higher fidelity than any other analogue in the CRISPER/CAS system.
Figure 1: Imidoamidate DNA. Figure 2: Thiomorpholino DNA
Recent Publications
1. Shang et al. (2016) Peptide substituted oligonucleotide synthesis & non-toxic passive cell delivery. Signal Transduction &
Targeted Therapy 1:e16019.
2. Paul et al. (2015) Oxidative substitution of borane-phosphonate di-esters as a route to post-synthetic modified DNA.
Journal of the American Chemical Society 137(9):3253-3264.
3. Caruthers M (2013) The chemical synthesis of DNA/RNA: our gift to science. Journal of Biological Chemistry 288(2):1420-
1427.
4. Dellinger et al. (2011) Streamlined process for the chemical synthesis of RNA using 2’-O-thionocarbamate protected
nucleoside phosphoramidites in the solid phase. Journal of the American Chemical Society 133:11540-11556.
5. Le Proust E et al. (2010) Synthesis of high quality libraries of long (150mer) oligonucleotides by a novel depurination
controlled process. Nucleic Acids Research 38(8):2522-2540.

ISSN: 2161-1041
EPIGENETICS 2018 Volume 7

Page 42
Biography
Marvin H Caruthers is a distinguished Professor at the University of Colorado. He is a Guggenheim Fellow, completed PhD at Northwestern University and Post-doctoral
Studies at MIT. His interests include nucleic acids chemistry and biochemistry. Approximately 35 years ago, the methodologies for chemically synthesizing DNA/RNA were
developed in his laboratory and incorporated into instruments for synthesizing DNA/RNA as used by biochemists, biologists and molecular biologists. He is the recipient
of several academic and research awards including The National Academy of Sciences Award in the Chemical Sciences, The Prelog Medal, The Economists Award in
Biotechnology and The US National Medal of Science. He is an elected member of The US National Academy of Sciences, The American Academy of Arts & Sciences, The
National Inventors Hall of Fame and a Corresponding Member of the German Academy of Science Gottingen. He is also a co-founder of Amgen and Applied Biosystems.
Notes:

ISSN: 2161-1041

Page 43
conferenceseries.com Alexey V Fedulov, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Alexey V Fedulov
Alpert School of Medicine of Brown University–Rhode Island Hospital, USA
Maternal exposure to environmental particles leads to transgenerational epigenetic transmission of

asthma risk
Statement of the Problem: Allergic asthma has origins early in life and results from a complex interaction of genome, epigenome and
environment. Maternal asthma history and especially gestational environmental exposures increase the risk of asthma in humans
and animal models. Exposure of pregnant mice to diesel exhaust particles (DEP) or concentrated urban air particles (CAP) results in
an increase in asthma susceptibility in F1 pups in our model. Here, we sought to test the hypothesis that this transmission continues
trans-generationally and occurs via epigenetic mechanisms.
Methodology & Theoretical Orientation: After the pregnant dams received intranasal instillations of particle suspensions or
control, their F1, F2 and F3 offspring were tested for ovalbumin allergy predisposition. We treated a subset of mice at F1 with a
DNMT inhibitor to test if this would abrogate the transmission of the phenotype. Moreover, we have previously shown that dendritic
cells (DCs) in the F1 progeny are key to the phenotype because they convey the disease predisposition upon isogenic transplant and
harbor DNA methylation aberrations; we therefore analyzed the DCs’ methylome (eRRBS) in this transgenerational study in all
three generations.
Findings: We found that the elevated asthmatic susceptibility after maternal exposure to particles during pregnancy persists into
F2 and with more variability, into F3 generations: low dose ovalbumin increased levels of eosinophils, IL-5 and IL-13 in broncho-
alveolar lavage and histopathologic changes of allergic airway disease, not seen/minimal in controls. The DCs in these generations
continued to display DNA methylation changes in several thousand loci, the number was diminishing towards F3. Lineages treated
with DNMT inhibitor at F1 no longer showed asthma susceptibility at F2 or F3.
Conclusion & Significance: The data indicate that pregnancy airway exposure to particles triggers transgenerationally transmitted
asthma susceptibility and suggests a mechanistic role for epigenetic alterations in DCs in this process.
Figure 1: Schematic of the transgenerational protocol.

ISSN: 2161-1041

Page 44
Recent Publications
1. Shang et al. (2016) Peptide substituted oligonucleotide synthesis & non-toxic passive cell delivery. Signal Transduction &
Targeted Therapy 1:e16019.
2. Paul et al. (2015) Oxidative substitution of borane-phosphonate di-esters as a route to post-synthetic modified DNA.
Journal of the American Chemical Society 137(9):3253-3264.
3. Caruthers M (2013) The chemical synthesis of DNA/RNA: our gift to science. Journal of Biological Chemistry 288(2):1420-
1427.
4. Dellinger et al. (2011) Streamlined process for the chemical synthesis of RNA using 2’-O-thionocarbamate protected
nucleoside phosphoramidites in the solid phase. Journal of the American Chemical Society 133:11540-11556.
5. Le Proust E et al. (2010) Synthesis of high quality libraries of long (150mer) oligonucleotides by a novel depurination
controlled process. Nucleic Acids Research 38(8):2522-2540.
Biography
Alexey V Fedulov has his expertise in Epigenetic Engineering and Transgenerational Epigenetic Studies. His lab has built a model of targeted reactivation of epigenetically
silenced genes by fusion complexes comprised of DNA demethylase enzymes and sequence-specific DNA binding domains. His laboratory studies are in immune and
epigenetic mechanisms of lung disease including early life asthma origins. The ultimate goal of the studies is to find novel therapeutic approaches by modulating epigenetic
control of gene expression.

ISSN: 2161-1041

Page 45
conferenceseries.com Anne Clémence Veillard, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Anne Clémence Veillard

Diagenode, Belgium
ChIPmentation: An innovative technology for fast and high quality ChIP-seq
E pigenetics is crucial for the regulation of gene expression and has broad relevance in biological processes like development, disease
and response to the environment. Epigenomics, the study of the epigenetic state of the genome, is therefore a fast growing field.
Diagenode, as a long time expert and leader in developing optimized tools to study epigenetic marks such as histone post translational
modifications and DNA methylation, continuously innovates further to study the epigenetics. Diagenode’s latest innovation,
ChIPmentation, integrates both chromatin immunoprecipitation (ChIP) and library preparation within the same protocol to ensure
successful next-generation sequencing experiments. Chromatin immuno precipitation coupled with high throughput sequencing
(ChIP-seq) has become the gold standard for whole genome mapping of protein DNA interactions. ChIPmentation, developed by
Diagenode in collaboration with the CeMM (Vienna-Austria) is based on tagmentation technology and is a robust ChIP-seq solution
that permits the integration of sequencing library preparation into the ChIP experiment. This approach significantly reduces the
number of steps in the process. In addition, ChIPmentation has been integrated into the work flow of Diagenode’s IP-Star automated
platform for greater ease of use, simplicity and reproducibility. ChIPmentation is a robust technology that will enable the generation
of data quickly and reliably for epigenomics research.
Figure 1: Classical ChIP-seq and ChIPmentation workflows. Schematic representation of the work flow used by the ChIPmentation protocol and comparison with the
classical workflow for ChIP-seq. The main steps of ChIPmentation are automated on Diagenode IP-Star® as indicated by the IP-Star® symbol.
Recent Publications
1. Laczik M (2016) Iterative fragmentation improves the detection of ChIP-seq peaks for inactive histone marks. Bioinformatics
and Biology Insights 10:209-224.
2. Veillard A C (2016) Diagenode® premium RRBS technology: cost-effective DNA methylation mapping with superior
coverage. Nature Methods 13:184.
3. Schmidl C (2015) ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. Nat. Methods
12:963–965.
4. Veillard A C (2014) Stable methylation at promoters distinguishes epiblast stem cells from embryonic stem cells and the in
vivo epiblasts. Stem cells and Development 23(17):2014–2029.

ISSN: 2161-1041

Page 46
Biography
Anne Clémence Veillard is working in Diagenode s.a. (Belgium), to develop innovative technologies to study DNA methylation and histone marks since 2014. She is
fascinated by how epigenetics makes the link between the history and faith of a cell and its gene expression. That is why she studied DNA methylation profile of several
types of pluripotent stem cells during her PhD, at the National Institute of Agronomical Research (INRA-France). She believes that good technical tools are necessary to
support exciting research projects.
Notes:

ISSN: 2161-1041

Page 47
EPIGENETICS 2018
Page 48

Scientific Tracks & Abstracts

Day 1
EPIGENETICS 2018
Page 49
Day-1
Sessions
Epigenetics | Cancer Epigenetics | DNA Methylation
Chair: Michelle M. Hanna, Ribomed Biotechnologies, USA

Co-Chair: Charles De Smet, De Duve Institute - University of Louvain, Belgium
Session Introduction
Title: Evaluating drug-chromatin interactions using novel methods for target engagement studies
Marta Rucka, Promega, UK
Title: Targeting a lncRNA – epigenetic factor complex to inhibit colon cancer metabolism
Maria Hatziapostolou, Nottingham Trent University, UK
Title: Epigenetic regulation of leukemia

Andreas Lennartsson, Karolinska Institute, Sweden
Title: Methylation pattern switch between low and high grade cervical intraepithelial neoplasia:
implications for progression models, robust triage and cancer risk
Belinda Nedjai, Barts and the London School of Medicine and Dentistry - Queen Mary University, UK
Title: Special Session | The genetics of common diseases

Kari Stefansson, deCODE Genetics, Iceland
Title: Generation of long acting therapies using glycosylated linkers

Abdulrahman Alshehri, University of Sheffield, UK
Title: Synergistic pharmacology: targeting two epigenetic enzyme targets in a protein complex
Sriram Raja Gopal, Jubilant Drug Discovery and Development Center, India
Title: Alterations of DNA methylation seem to be an early event in the development of tumors from the
upper aerodigestive tract
Sheila Coelho Soares Lima, Brazilian National Cancer Institute, Brazil
Title: Robust joint statistical tests for DNA methylation data

Xiaogang Steven Wang, York University, Canada
Title: Role of DNA methylation in sperm nuclear-encoded of oxidative phosphorylation pathway

regulation and embryo development
Mahmoud Hashemitabar, Ahvaz Jundishapur University of Medical Sciences, Iran
Page 50
conferenceseries.com Marta Rucka, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Evaluating drug-chromatin interactions using novel methods for target engagement studies
Marta Rucka
Promega, UK
R egulation of gene expression is a dynamic process orchestrated and maintained by a large variety of chromatin-interacting
proteins. Understanding these chromatin-protein complexes and their binding kinetics is crucial for development
of the small-molecule drugs. Promega has developed NanoBRET™ technology, which allows for dynamic measurement of
protein:protein interactions (PPIs) in living cells. This proximity-based assay measures energy transfer from a bioluminescent
protein donor (NanoLuc® fusion protein) to a fluorescent protein acceptor (HaloTag® fusion protein) under physiological
conditions. Furthermore, the assessment of chromatin-protein interaction reversibility is also possible allowing for identification
of compounds that either induce or inhibit the target complex. Evaluating the engagement of these small molecules with
chromatin regulatory proteins provides useful information for chemical probe optimization and further pharmaceutical
development. In addition to the specificity and affinity of target engagement, binding dynamics under non-equilibrium
conditions may also underlie the therapeutic potential of the drugs. Promega has developed NanoBRET™ Target Engagement
system, wherein the apparent binding affinity and permeability of test compound is measured by competitive displacement of
a broad-coverage NanoBRET™ Tracer reversibly bound to a NanoLuc fusion protein in cells. As both the compound and tracer
compete directly for the same binding site it enables quantification of drug residence time on the targets. During this talk the
author will discuss the work they have completed using histone deacetylases (HDACs) and bromodomain (BRD)-containing
proteins as the targets in our NanoBRET PPI and target engagement studies.
Recent Publications
1. Machleidt et al. (2015) NanoBRET ¬– A novel BRET platform for the analysis of protein-protein interactions. ACS Chem
Biol. 10(8):1797-804.
2. Roberts et al. (2015) Target engagement and drug residence time can be observed in living cells with BRET. Nat Commun.
6:10091.
3. Warning et al. (2016) Potent and selective bivalent inhibitors of BET bromodomains. Nat Chem Biol. 12(12):1097-1104.
Biography
Marta Rucka received a PhD from University of Southampton in 2014. Her PhD and Postdoctoral research focused on dissecting the role of transcriptional co-repressors in
the regulation of tumour cell motility. Currently, she looks after cellular analysis and proteomics portfolio at Promega UK. Promega continues to develop novel and exciting
methods designed to enhance drug discovery and life science research, including NanoLuc-based technology for direct assessment of target engagement and residence
time in live cells.

ISSN: 2161-1041

Page 51
conferenceseries.com Maria Hatziapostolou, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Targeting a lncRNA – epigenetic factor complex to inhibit colon cancer metabolism

Maria Hatziapostolou
Nottingham Trent University, UK
L ncRNAs (long non-coding RNAs) have recently occurred as new epigenetic regulators contributing to human diseases. We
found that the lncRNA HOTAIR is up-regulated in colon cancer and associates with poor patient survival. HOTAIR directly
interacts with the histone acetyltransferase PCAF (KAT2B) to regulate H3K27 acetylation and transcriptional activation.
Hence, the HOTAIR/PCAF complex induces cell metabolic reprogramming and oncogenic transformation of colon epithelial
cells. We have characterized the interface of HOTAIR/PCAF complex and developed a specific inhibitor (CPDI-1) that disrupts
their interaction. This inhibitor reverses the HOTAIR/PCAF-induced metabolic rewiring and inhibits tumorigenesis in vivo.
Disruption of an lncRNA/epigenetic factor interaction may offer an alternative approach to target cancer metabolism and
progression.
Recent Publications
1. Vorvis C, Hatziapostolou M, Mahurkar Joshi S, Koutsioumpa M, Williams J, Donahue TR, Poultsides G A, Eibl G
and Iliopoulos D (2016) Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in
pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 310(11):G1124-37.
2. Polytarchou C, Hommes D W, Palumbo T, Hatziapostolou M, Koukos G, van der Meulen de Jong A E, Oikonomopoulos
A, van Deen W K, Vorvis C, Koutsioumpa M, Birli E, Choi J, Chang L, Anton P A, Pothoulakis C, Verspaget H W and
Iliopoulos D (2015) Therapeutically targeting miR-214 circuit in ulcerative colitis and colitis-associated colon cancer.
Gastroenterology 149(4):981-992.
3. Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt M B, Hatziapostolou M, Lim E, Tam W L, Ni M, Chen Y, Mai J, Shen
H, Hu D Z, Adoro S, Hu B, Song M, Tan C, Landis M D, Ferrari M, Shin S J, Brown M, Chang J C, Liu X S and Glimcher
L H (2014) XBP1 promotes triple negative breast cancer by controlling the HIF1A pathway. Nature 508(7494):103-7.
4. Sanidas I, Polytarchou C, Hatziapostolou M, Ezell S A, Kottakis F, Hu L, Guo A, Xie J, Comb M, Iliopoulos D and Tsichlis
P N (2014) Phosphoproteomics screen reveals Akt isoform-specific signals linking RNA processing to lung cancer. Mol.
Cell. 53(4):577-90.
5. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides G A, Jaeger S A, Ogata H, Karin M, Struhl K,
Hadzopoulou Cladaras M and Iliopoulos D (2011) An HNF4A-microRNA inflammatory feedback circuit regulates
hepatocellular oncogenesis. Cell 147(6):1233-47.
Biography
Maria Hatziapostolou explores novel areas of basic research and specifically works on projects that span from tumour-stroma interactions, to the implications of epigenetic
machinery and non-coding RNAs in oncogenesis and chemoresistance. She uses high-throughput approaches, sophisticated molecular techniques, and functional in vitro
and in vivo approaches focusing on basic research outcomes that can be translated in potential clinical applications. Her research in Hatziapostolou laboratory focuses on
the molecular interplay between the genome and the epigenome during oncogenic transformation, cancer growth and metastasis. She has her interest in cancers of those
of the gastrointestinal tract with an emphasis on pancreatic, liver and colon cancer.
Notes:

ISSN: 2161-1041

Page 52
conferenceseries.com Andreas Lennartsson, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Epigenetic regulation of leukemia

Andreas Lennartsson
Karolinska Institute, Sweden
A cute myeloid leukemia (AML) has a poor prognosis in both adults and children, with a long-term survival of only 25% and
60% respectively. No major development has occurred of the treatment since, the last decades and the majority of treatments
for AML consist of cytotoxic drugs with low specificity. AML is associated with perturbed epigenetic regulation, with early
mutations in and chromosomal translocations of different epigenetic regulators. This indicates that epigenetic mechanisms
may play an essential role in the development of AML and are potentially very potent drug targets. A network of epigenetic
factors regulates DNA methylation, post-translational histone modifications and chromatin structure and relays information
to the transcriptional program that dictates hematopoietic cell fate and differentiation. We have previously demonstrated the
importance of epigenetic mechanisms in hematopoietic differentiation and AML development. Especially we have showed that
epigenetic regulation of enhancer activity is crucial for normal myelopoiesis and AML. We have recently demonstrated that
the generation of leukemic - specific gene expression involves interplay of combinational epigenetic mechanisms at specific
enhancer elements with their cognate promoters. Our results suggest that the normal epigenetic remodeling of enhancers is
perturbed during the evolution of leukemia and contribute to the leukemic phenotype.
Biography
Andreas Lennartsson has a Master’s Degree in Biotechnology from Lund University in Sweden. He did his PhD in Experimental Hematology also at Lund University. After
his PhD, he continued at the Omics Science Center at RIKEN in Japan for Post-doc training in Piero Carninci's group. He carried out his second Post-doc in Karl Ekwall's
group at Karolinska Institute, where he is now leading a sub-group in Professor Ekwall's laboratory.
Notes:

ISSN: 2161-1041

Page 53
conferenceseries.com Nedjai B et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Methylation pattern switch between low and high grade cervical intraepithelial neoplasia: Implications
for progression models, robust triage and cancer risk
Nedjai B, Reuter C, Ahmad A, Kleeman M, Banwait R, Warman R, Carton L, Sabrina Boer S, Vasiljevic N, Cuzick J and Lorincz A
Barts and the London School of Medicine and Dentistry–Queen Mary University, UK
T he evolution of precancerous cervical lesions is poorly understood. One hypothesis, the molecular switch model, states that
CIN3 could evolve straight from normal epithelium after an HPV infection without progressing through the CIN1 and
CIN2 stages. To shed light on this process, we compared DNA methylation of selected biomarkers and HPV type in two groups
of CIN1: CIN1 that were adjacent to CIN3 (adjacent-CIN1) and CIN1 that were the principal lesions with no CIN3 present
(principal-CIN1). 354 CIN (CIN1 and CIN3) and normal tissue were macrodissected and typed for HPV from 127 women
who underwent loop electrosurgical excision procedures (LEEP). Methylation of genes EPB41L3 and the viral regions of
HPV16-L1/L2, HPV18-L2, HPV31-L1 and HPV33-L2 were determined by quantitative pyrosequencing of bisulfite converted
DNA. Corresponding HPV types were also obtained on paired exfoliated specimens collected before treatment. There was a
highly significant trend of increased methylation with disease progression from normal to CIN3 (p<0.0001). CIN1 adjacent
or near CIN3 (adjacent-CIN1) predominantly shared the same HPV types as the CIN3. In contrast, methylation differed
substantially between adjacent-CIN1 and CIN3 (p=0.008); however, diagnostically principal-CIN1 had indistinguishable
methylation compared to adjacent-CIN1 (EPB41L3: p=0.49; HPVme-All: p=0.11). HPV types and methylation levels in LEEP
and corresponding exfoliated cells were similar, with 99% of CIN3 and 88% of CIN1 containing matching HPV types. Our
results suggest that progression from normal epithelium to CIN1 or CIN3 can be promoted by the same persistent HPV type
but occurs via distinct DNA epigenotypes, thus supporting the molecular switch model.
Figure 1: Flow chart showing the number of cases and dissected areas used for the main study (LEEP tissues, centre main panel) and the punch biopsy pilot
study (top main panel). For some cases several CIN1 or CIN3 areas were dissected per cervix. Sections of five CIN1 and eight CIN3 cases had no normal
epithelium. Sections of ten CIN3 cases had no adjacent- CIN1 lesions. Mean methylation levels were averaged per lesion type. HPV genotyping was done
separately for all lesions. Our study also included a comparison of HPV typing data from the 127 LEEP to corresponding exfoliated cell specimens (right panel).
Recent Publications
1. Bagnati M, Ogunkolade B W, Marshall C, Tucci C, Hanna K, Jones TA, Bugliani M, Nedjai B, Caton P W, Kieswich J,
Yaqoob M M, Ball G R, Marchetti P, Hitman G A and Turner M D (2016) Glucolipotoxicity initiates pancreatic β-cell
death through TNFR5/CD40-mediated STAT1 and NF-κB activation. Cell Death & Differentiation 7(8):e2329.
2. Nedjai B, Viney J M, Li H, Hull C, Anderson C A, Horie T, Horuk R, Vaidehi N and Pease J E (2015) CXCR3 antagonist
VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779. British Journal of
Pharmacology 172(7):1822-33.
3. Turner M D, Nedjai B, Hurst T and Pennington D J (2014) Cytokines and chemokines: At the crossroads of cell signalling
and inflammatory disease. Biochimica et Biophysica Acta 1843(11):2563-2582.
4. Turner M D, Chaudhry A and Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS
door to pro-inflammatory cytokine secretion. Bioscience Reports 32(2):105-12.

ISSN: 2161-1041

Page 54
5. Nedjai B, Li H, Stroke I L, Wise E L, Webb M L, Merritt J R, Henderson I, Klon A E, Cole A G, Horuk R, Vaidehi N and
Pease J E (2012) Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and
CXCL11 are allosteric ligands of CXCR3. British Journal of Pharmacology 166(3):912-23.
Biography
Nedjai B as a Senior Research Fellow co-leads the Molecular Epidemiology Lab (MEL) Research Team in Epigenetics of prostate, breast and cervical cancer. She holds a
PhD in functional genomics and her aim is to identify and develop cost-effective tests for the early detection and the prediction of outcomes in cancer patients. Her recent
successes include the identification of methylation biomarkers to manage women infected by papillomavirus and an alternative epigenetic approach for management of
men with prostate cancer. She is an expertise in biomarkers identification and validation using deep sequencing and high through put techniques (WES, RNA seq, miRNA
and methylome). Her future research will include discovery of biomarkers for early detection of epithelial cancer using a Pan Cancer approach. We have already identified
a few methylation biomarkers able to predict cancer at early stage in several epithelial cancers and another aim would be to refine such biomarkers in various ethnic groups
to increase the early detection potential.
Notes:

ISSN: 2161-1041

Page 55
conferenceseries.com Kari Stefansson, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
The genetics of common diseases

Kari Stefansson
deCODE genetics, Iceland
A t deCODE genetics in Iceland we have sequenced the whole genomes of 50.000 Icelanders or 12.5% of the nation and
genotyped 180.000 or 60% of the nation. In addition we have the genealogy of the entire nation going centuries back
in time on a computer database. This allows us to impute sequence variants with allelic frequency down to about 0.01% into
all genotyped individuals and their first and second degree relatives. We are in the privileged position of being able to phase
the entire genomes of all Icelanders. This has allowed us to determine whether there is a difference in the impact of sequence
variants depending on the parent it is inherited from. Taking advantage of this we have found sequence variants that increase
the risk of disease when it is inherited from one sex and protect against the same when it is inherited from the other sex.
Furthermore, we have discovered a number of sequence variants where there is a difference in the size of the effect depending
on the parent of origin. Hence, a parent of origin analysis of associations between variants in the sequence and diversity in
phenotypes is a part of our daily routine. Furthermore, we have combined whole genome oxidative bisulfite sequencing of 285
individuals and allele specific RNA sequencing of 11,617 blood samples with parnet-of-orgin phased haplotyes, to produce a
new map of imprinted methylation and gene expression pattern across the human genome. Through this we have, for example,
gained new insights into parent of origin specific effects on phenotypes.
Biography
Kári Stefánsson, M.D., Dr. Med. has served as President, Chief Executive Officer and a Director since he founded deCODE genetics in August 1996. Dr. Stefánsson
was appointed the Chairman of the Board of Directors of deCODE genetics in December 1999. From 1993 until April 1997, Dr. Stefánsson was a professor of Neurology,
Neuropathology and Neuroscience at Harvard University. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University
of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States.
He has published numerous articles on the genetics of common/complex diseases and has been among the leaders of the world in the discovery of variants in the
sequence of the human genome that associate with the risk of common/complex traits. Dr. Stefánsson was chosen by Time magazine as one of the 100 most influential
men of the year for 2007 and by Newsweek as one of the 10 most important biologists of the 21 century.
He was the recipient of the Jakobus Award 2007, The World Glaucoma Association Award for present scientific impact 2007, The European Society of Human Genetics
Award 2009, and The Andre Jahre Award 2009.

ISSN: 2161-1041

Page 56
conferenceseries.com Abdulrahman Alshehri et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Generation of long acting therapies using glycosylated linkers

Abdulrahman Alshehri, R J Ross and I R Wilkinson
University of Sheffield, UK
Rationale: The current therapeutic drugs such as, growth hormone (GH), granulocyte colony stimulating factor (GCSF) and
leptin require once daily injections, which are inconvenient and expensive. Therefore, a number of approaches to reducing
therapeutic regimens clearance have been tried mainly through conjugation with another moiety. One such technology already
being employed is PEGylation; however this has been shown to be non-biodegradable and toxic. A previous study by Asterion
has shown that the use of glycosylated linkers between two GH ligands to create protein tandems resulted in their glycosylation
and an increased molecular weight (MW) whilst maintaining biological activity. The use of this technology using GCSF as an
example will be presented, but can be easily applied to other molecules such as leptin.
Hypothesis: The incorporation of variable glycosylated linkers between two GCSF ligands will create a construct with high
molecular weight and protected from proteolysis resulting in reduced clearance without blocking bioactivity.
Methodology: GCSF tandems with linkers containing between 2‐8 NAT glycosylation motifs and their respective controls
(Q replaces N in the sequence motif NAT so there is no glycosylation) were cloned, and sequenced. Following expression in
Chinese hamster ovary (CHO) cells, expressed protein was analysed by SDS PAGE to confirm molecular weights. In vitro
bioactivity was tested using an AML‐193 proliferation assay. Immobilized metal affinity chromatography (IMAC) was used to
purify the protein. Pharmacokinetic and pharmacodynamics properties of the purified GCSF tandem proteins were measured
in normal Sprague Dawley rats with full ethical approval.
Results: Purified glycosylated tandems show increased molecular weight above that of controls when analysed by SDS PAGE.
All GCSF tandems show increased bioactivity in comparison to native GCSF. Following intravenous administration to rats,
GCSF2NAT, GCSF4NAT, GCSF8NAT containing 2, 4 & 8 glycosylation sites respectively and GCSF8QAT (non-glycosylated
GCSF tandem control) showed approximately 3‐fold longer circulating half‐life compared to that reported for the native GCSF
(1.79 hours). Both GCSF2NAT and GCSF4NAT show a significant increase in the percentage of neutrophils over controls at
12 hours post injection. This effect however is short lived as the counts at 24+ hours are not significantly different to controls.
GCSF8NAT shows an increase in the percentage of neutrophils that is only significant at 48 hours.
Conclusion: Results show that the use of glycosylated linkers to generate GCSF tandems results in molecules with increased
molecular weight, improved in vitro bioactivity, longer circulating half‐lives and enhanced neutrophilic population when
compared to both native GCSF and the non‐glycosylated tandem protein
Figure 1: An example of 2NAT glycosylation motifs and its control 2QAT within a flexible linker (Gly4Ser)n between two GCSF ligands. (A) The
glycosylation motif 2NAT inserted to the linker (glycosylated linker). (B) Non-‐glycosylation motif 2QAT control
Recent Publications
1. Li H and D'anjou M (2009) Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol
20(6):678-‐84.

ISSN: 2161-1041

Page 57
2. Chung H K, Kim S W, Byun S J, Ko E M, Chung H J, Woo J S, Yoo J G, Lee H C, Yang B C, Kwon M, Park S B, Park J K
and Kim K W (2011) Enhanced biological effects of Phe140Asn, a novel human granulocyte colony-‐stimulating factor
mutant, on HL60 cells. BMB Rep 44(10):686-91.
3. Cooper K L, Madan J, Whyte S, Stevenson M D and Akehurst R L (2011) Granulocyte colony-‐stimulating factors for
febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-‐analysis. BMC Cancer 11:404.
4. Cory A H, Owen T C, Barltrop J A and Cory J G (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell
growth assays in culture. Cancer Commun 3:207-12.
5. Cox G N, Chlipala E A, Smith D J, Carlson S J, Bell S J and Doherty D H (2014) Hematopoietic properties of granulocyte
colony-‐stimulating factor/immunoglobulin (G-‐CSF/IgG-‐Fc) fusion. PLoS One 9(3):e91990
Biography
Abdulrahman Alshehri is working at Security Forces Hospital, Makkah, Saudi Arabia for 12 years. He did his PhD at Sheffield University, UK and has been working in
creating long acting therapies using different strategies such as, glycosylated linkers using multiple techniques like PCR, gene cloning, cell culture, pharmacodynamic and
pharmacokinetic to generate these therapies. This research has awarded the prize for the best research amongst 500 researches around the world from the Society for
Endocrinology conference held in Edinburgh in November 2015.
Notes:

ISSN: 2161-1041

Page 58
conferenceseries.com Sriram Rajagopal, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Synergistic pharmacology: Targeting two epigenetic enzyme targets in a protein complex

Sriram Rajagopal
Jubilant Drug Discovery and Development Center, India
C ancer patient treatment with single agent or single target modulation leads to poor clinical outcome. This is due to tumor
cell heterogeneity, pathway redundancy in cancer cells and presence of cancer stem cells that are difficult to eradicate. In
a clinical setting, drug cocktail is the preferred choice of treatment to address this but has its limitation. Therefore targeting
epigenetic pathways has the ability to modulate number of disease specific genes and offers the opportunity to address
multifactorial diseases. In this regard, a single small molecule inhibitor modulating two or more disease relevant protein
pathways overcome regulatory and developmental hurdles of cocktail drug development in a clinical trial. Hence, a targeted
therapy with poly pharmacology will be beneficial and better tolerated for cancer patients. Many epigenetic targets are
over expressed in human cancer tissue as compared to normal tissue. Epigenetic alterations of the genome are through the
modification of the DNA/ histone proteins that lead to modulation of oncogenes and tumor suppressor genes that regulate
cancer specific processes. A histone modification influences the recruitment of other epigenetic/ transcription factor proteins
that in turn influence the gene expression. Understanding the targets of such multi protein complex regulates gene expression
can help in building targeted pharmacological approaches leading to the design of compounds with better efficacy. In my
presentation, I will cover our approach in testing this hypothesis with few epigenetic targets and tool compounds using
mechanistic studies and preclinical models.
Figure 1: Interplay of Epigenetic targets and Transcription Factors
Recent Publications
1. Jay H Kalin (2018) Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature
Communication 9(1):53.
2. Perri F, et al. (2017) Epigenetic control of gene expression: Potential implications for cancer treatment. Critical Reviews
in Oncology/Hematology 111:166–172.
3. Po-Hsien Haung, et al. (2011) Histone deacetylase inhibitors stimulate histone h3 lysine 4 methylation in part via
transcriptional repression of histone h3 lysine 4 demethylases. Molecular Pharmacology 79(1):197–206.
Biography
Sriram Rajagopal—PhD—has 25 years of research experience in Oncology/Diabetes/ Antibacterial Drug Discovery. He received his PhD in 1989 from Anna University,
Chennai, India and carried out Post-doctoral research work at University of Washington, School of Medicine, Neuroscience Department, Seattle, USA. He moved to M.
D. Anderson Cancer Center, Houston, Texas as Junior Faculty and worked on different types of cancer using primary cancer and cell line to understand how to sensitize
cancer cells to current anticancer drugs. After 15 years of academic work in USA, he moved to India and started his drug discovery work with Indian pharma industry.
Thorough his understanding of the complete R&D value chain he has built and managed effective research teams for in-house, collaborative integrated drug discovery and
functional services. He has to his credit in identifying 15 preclinical candidates out of which six have moved to different stages of clinical development.

ISSN: 2161-1041

Page 59
conferenceseries.com Sheila Coelho Soares Lima, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Alterations of DNA methylation seem to be an early event in the development of tumors from the
upper aero digestive tract
Sheila Coelho Soares Lima
Brazilian National Cancer Institute–INCA, Brazil
Statement of the Problem: Tumors from the upper aerodigestive tract (UADT) rank among the 10 most frequent neoplasias
worldwide. These tumors are more prevalent in developing countries, arising from a squamous epithelium and are usually
associated with tobacco, alcohol consumption and HPV infection. The most common histological type is squamous cell
carcinoma and the most commonly affected sub sites include larynx, oral cavity, pharynx and esophagus. Although they share
similarities, UADT cancer comprises a group of neoplasias with high clinical and phenotypic heterogeneity and inspite of
the recent advances in the identification of biomarkers and new therapeutic targets, no significant gains in overall survival
have been observed. Between the associated causes, the development of second primary tumors in the UADT stands out. It is
hypothesized that the squamous epithelium lining the affected organs goes through a process known as cancerization field, in
which different morphologically normal areas acquire molecular alterations, making them prone to become neoplastic. Based
on this, we have been interested in understanding the epigenetic mechanisms that lead to the development of each of these
tumors.
Methodology & Theoretical Orientation: Microarrays have been used to determine the DNA methylation signature of UADT
tumors with further validation by pyro-sequencing in independent samples.
Findings: Interestingly, we showed that each subtype of UADT cancer carries a specific DNA methylation signature. They
differ in terms of hyper/hypomethylation frequency; affected genomic regions, genes and pathways and transcription factor
networks. We have also shown that aberrant DNA methylation of genes involved in epithelium protection and in apoptosis
control is an early event in the development of UADT tumors. Therefore, our data indicates that these neoplasias show an
epigenetic convergence with respect to early changes, but also diverge in terms of carcinogenic pathways, which may have an
impact on prognosis and response to therapy.
Figure 1: Epigenetic alterations involved in the development of UADT tumors.
Recent Publications
1. Degli Esposti D, et al. (2017) Unique DNA methylation signature in HPV-positive head and neck squamous cell
carcinomas. Genome Medicine 9:33.
2. Herceg Z, et al. (2017) Roadmap for investigating epigenome deregulation and environmental origins of cancer.
International Journal of Cancer 142(5): 874-882.
3. Gonzaga I M, et al. (2017) TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and
histologically normal tumor surrounding esophageal cells. Clinical Epigenetics 9:130.
4. Lima S, et al. (2011) Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential
epigenetic biomarkers. Epigenetics 6(10):1217-1227.

ISSN: 2161-1041

Page 60
Biography
Sheila Coelho Soares Lima is a Researcher at the Brazilian National Cancer Institute, where she is the Head of the Epigenetics group. She has her expertise in evaluating
alterations of DNA methylation in tumors with the objective of understanding molecular carcinogenic mechanisms, identifying biomarkers of diagnosis, prognosis and
response to therapy and determining new therapeutic strategies. Based on this, she aims to improve cancer patient diagnosis, treatment and life quality. She has shown
some of the first evidences of the epigenetic cancerization field in the upper aerodigestive tract and is currently working on tumor stem cells and epigenetic therapy.
Notes:

ISSN: 2161-1041

Page 61
conferenceseries.com Xiaogang Steven Wang, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Robust joint statistical tests for DNA methylation data

Xiaogang Steven Wang
York University, Canada
T he detection of differential methylation between the control and case group of a disease of interest remains a challenging
task. Reliable result depends on a correct employment of robust statistical tests. In the past, the hypothesis testing for
methylation data is mainly focused on the equality of means while the intrinsic variability in the methylation data has often
been ignored. Many statistical tests that could incorporate the variability into the testing procedure rely on the assumption of
either normality or absence of outliers. Consequently, these tests are not very robust when applied to real data. In this talk, we
will present three robust statistical tests that can test the equality of both means and variances simultaneously. Results from
simulation studies and real data analyses suggest that our proposed methods are more powerful and robust in comparison with
other three bench mark testing procedures.
Recent Publications
1. Gold N, Frasch M, Herry C, Richardson B and Wang X (2018) A doubly stochastic change point detection algorithm for
noisy biological signals. Frontiers in Computational Physiology and Medicine 8:1112.
2. Li X, Qiu W, Morrow J, Weiss J, Fu Y and Wang X (2015) A comparative study of tests for homogeneity of variances with
application of DNA methylation data. PLOS One 10(12):e0145295.
3. Wang Q, Gold N, Frasch M, Huang H Â and Wang X (2015) Mathematical model of cardiovascular and metabolic
responses to umbilical cord occlusions in fetal sheep. Bulletin of Mathematical Biology 77(12):2264-2293.
Biography
Xiaogang Steven Wang is currently a Professor in Statistics at the Department of Mathematics and Statistics, York University, Toronto, Canada. He was an expertise in
bioinformatics, data mining, machine learning and biostatistics. He developed several effective clustering algorithms including one for categorical data and one for protein
data. He also worked on developing algorithms for handling nonstationary biological times series data. Besides of machine learning, he has been working on analyzing
DNA methylation data.

ISSN: 2161-1041

Page 62
conferenceseries.com Mahmoud Hashemitabar, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Role of DNA methylation in sperm nuclear-encoded of oxidative phosphorylation pathway regulation

and embryo development
Mahmoud Hashemitabar
Ahvaz Jundishapur University of Medical Sciences, Iran
Statement of the Problem: DNA methylation functions through the imprinting control regions (ICRs). It is a parental allelic
specific modification process through the differentially methylated regions (DMRs) can specify cell lineage commitment
during the embryo development. Paternal methylation changes in the promoter loci of (IGF2/H19 CTCF6) are associated
with male infertility, failure in the transition from the 8-cell stage to the morula and embryo loss. But it’s unclear existence of
differentially methylation signature for promoter loci of nuclear-encoded (ncDNA) of oxidative phosphorylation (OXPHOS).
Here we illuminate the role of COX6b2 as one of the ncDNA of OXPHOS protein in sperm function and fertilization.
Methodology & Theoretical Orientation: COX6B2 assessment was performed by immunofluorescent assays and by
solubilizing sperm protein for 2D- gel electrophoresis and western blotting and also by sperm RNA extraction for real-time
PCR to determine the difference of COX6B2 protein and gene expression between asthenozoospermia and normal fertile
groups. Also, a meta-analysis through the PubMed, Cochrane central register and EMBASE was performed to reveal the
paternally DMRs loci in OXPHOS gene regulation.
Findings: The percentage of COX6B2+ in midpiece of the sperm was lower in asthenozoospermia than normal group. The
COX6B2 level by 2-D gel electrophoresis and western blotting and COX6B2 gene expression in the asthenozoospermic samples
were significantly lower than the normal fertile group. Meta-analysis revealed that DMRs in both sperm and oocyte (stemness
transcriptome point of view) are closely similar to embryonic stem (ES) cells, show largely unmethylated DMRs loci e.g. for
Rhox homeobox gene. The OXPHSO pathways are regulated mainly via the sperm-specific differentially methylation pattern
in the post-implantation.
Conclusion & Significance: Understanding the epigenetic differences between gametes and after fertilization, with the
comparison of DMRs among the fertile and infertile couples, help to achieve the new biomarkers for predicting infertility
and IVF/ICSI success. Compensation of insufficient IVF/ICSI cycle condition may be ameliorated abnormal de novo DNA
methylation in association with inhibition in early embryonic arrest.
Recent Publications
1. Hashemi Tabar M, Tabandeh M R, Moghimipour E, Dayer D, Ghadiri A A, Allah Bakhshi E, et al. (2018) The combined
effect of Pdx1 overexpression and Shh manipulation on the function of insulin‐producing cells derived from adipose‐
tissue stem cells. FEBS Open Bio 8(3):372-82.
2. Hashemitabar M, Bahmanzadeh M, Mostafaie A, Orazizadeh M, Farimani M and Nikbakht R (2014) A proteomic
analysis of human follicular fluid: comparison between younger and older women with normal FSH levels. International
Journal of Molecular Sciences 15(10):17518-40.

ISSN: 2161-1041

Page 63
3. Rezaei M, Zeidooni L, Hashemitabar M, Razzazzadeh S, Mahdavinia M and Ghasemi K (2014) Gamma-tocopherol

enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29). Nutrition and Cancer 66(8):1386-
93.
4. Khodaei F, Ahmadi K, Kiyani H, Hashemitabar M and Rezaei M (2018) Mitochondrial effects of teucrium polium and
prosopis farcta extracts in colorectal cancer cells. Asian Pacific Journal of Cancer Prevention: APJCP 19(1):103-109.
5. Houshmand G, Mansouri M T, Naghizadeh B, Hemmati A A and Hashemitabar M (2016) Potentiation of indomethacin-
induced anti-inflammatory response by pioglitazone in carrageenan-induced acute inflammation in rats: Role of PPARγ
receptors. International Immunopharmacology 38:434-42.
Biography
Mahmoud Hashemitabar has his expertise in differentiating of embryonic stem cells toward insulin producing cells (IPCs). He has been developing different sources of
pluripotent stem cell and improving different IPCs protocols for treatment of diabetic type 1 animal models. His experience as a senior clinical embryologist in IVF center
provides a context to overcome in male and female infertile/sub fertile and also presenting this experience in advising of a lot of PhD students interested in the field of
infertility treatment, research and teaching both in hospital and educational university.
Notes:

ISSN: 2161-1041

Page 64

Keynote Forum
Day 2
EPIGENETICS 2018
Page 65
conferenceseries.com Michelle M Hanna, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Michelle M Hanna
Ribomed Biotechnologies, USA
Simultaneous measurement of MGMT methylation and determination of IDH1 R132H and CpG
island methylator phenotype (CIMP) in gliomas using coupled abscription PCR signaling (CAPS)
I n 2016, the World Health Organization announced new guidelines for the stratification of brain tumors (gliomas) before
treatment. In addition to MGMT methylation, molecular biomarkers now recommended include mutations in IDH1 and IDH2
(primarily IDH1 R132H) that cause the glioma CpG island methylator phenotype (G- CIMP). The methylated phenotype correlates
with longer survival. Tumor samples received by clinical laboratories often contain insufficient DNA to measure gene-specific
DNA methylation for even a single target with bisulfite or methylation-sensitive restriction enzyme (MSRE) based methods,
so it has become practice to infer CIMP from the presence of the IDH1 R132H mutation identified by sequencing. This can
cause CIMP to be missed. To simultaneously measure DNA methylation and associated mutations, even in challenging samples
of low concentration or damaged DNA, a new method, coupled abscription PCR signaling (CAPS), was developed. Samples
from patients with recurrent high-grade glioma (HGG) were analyzed using CAPS to measure: MGMT promoter methylation;
methylation of a three-gene panel for G-CIMP, and; the IDH1 R132H mutation. IDH1 was also sequenced. In 26/26 samples,
results for R132H with CAPS matched sequencing. In 25/26, CIMP status from the three-gene methylation panel correlated
with the R132H status. In one case, both CAPS and sequencing scored negatively for R132H, but the tumor was clearly CIMP+
based on DNA methylation. Additional sequencing showed this sample contains the IDH1 R132S mutation, which also induces
CIMP. Additionally, some samples were negative for any IDH mutation but were highly methylated, indicating that CIMP was
epigenetically imprinted, followed by loss of the mutation. CAPS detection makes it possible to now analyze multiple methylation
biomarkers, even with limited FFPE tumor material. This MGMT/CIMP/IDH1 R132H diagnostic (GliomaSTRAT) increases the
applicability and reliability for prognostic assessment of patients diagnosed with brain cancer compared to currently available
assays and allows CIMP to be determined definitively.
Figure 1: Representative GliomaSTRAT results.
Recent Publications
1. Timothy F Cloughesy et al. (2016) Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high
grade glioma (2016) Science Translational Medicine 8:341RA75.
2. McCarthy D, W Pulverer, A Weinhaeusel, O Diago, D Hogan, D Ostertag and Michelle Hanna (2016) MethylMeter®:
bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples. Epigenomics
8(6):947-969.

ISSN: 2161-1041

Page 66
3. McCarthy David R, P Cotter and Hanna Michelle M (2012) A quantitative, sensitive, and bisulfite-free method for
analysis of DNA methylation in DNA Methylation ¬– From Genomics to Technology, Dr. Tatiana Tatarinova (Ed.), DOI:
10.5772/36090.
Biography
Michelle M Hanna, the founder and CEO of Ribomed Biotechnologies, received her PhD in Chemistry from the University of California, Davis and did her Postdoctoral
work in Biochemistry and Molecular Genetics as an American Cancer Society Postdoctoral Fellow at the University of California, Berkeley. She was an Assistant Professor
of Biological Chemistry at the University of California, Irvine, College of Medicine, where she received Young Investigator awards from the American Cancer Society and
the Beckman Foundation, and an Associate Professor of Biochemistry until she founded Ribomed. She is the Inventor of the Abscription/CAPS technology. She has
been awarded over $10 million in grants and contracts and her work has resulted in numerous publications and patents. She also serves on the Grant Review Board for
Praespero, an autoimmune disease foundation.
Notes:

ISSN: 2161-1041

Page 67
conferenceseries.com Tao Liu, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Tao Liu
Histone Modification Group Children's Cancer Institute, Australia
The histone H3K79 methyltransferase DOT1L regulates gene transcription and promotes
neuroblastoma tumourigenesis
M yc oncoproteins exert tumorigenic effects by regulating the expression of target oncogenes. Histone H3 lysine 79 (H3K79)
methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional
activation. DOT1L is the only known histone methyltransferase that catalysis H3K79 methylation. Here, we showed that N-Myc
up-regulated DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. Knocking down DOT1L reduced
mRNA and protein expression of the N-Myc target genes ODC1 and E2F2. DOT1L and N-Myc formed a protein complex, and
knocking down DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters
and reduced neuroblastoma cell proliferation. Ablating DOT1L expression with doxycycline significantly reduced ODC1 and
E2F2 expression, reduced tumor progression and improved overall survival in mice xenografted with neuroblastoma cells stably
expressing doxycycline-inducible DOT1L small hair-pin RNA. In addition, high levels of DOT1L gene expression in human
neuroblastoma tissues correlated with high levels of MYCN, ODC1 and E2F2 gene expression, and independently correlated with
poor patient survival. Taken together, our data identify DOT1L as a novel co-factor in N-Myc-mediated transcriptional activation
of target genes and neuroblastoma oncogenesis, and as a target for novel therapeutic strategies against neuroblastoma.
Biography
Tao Liu originally trained as a Medical Practitioner specializing in Neurology. He studied PhD degree at UNSW Australia on the role of inflammatory mediators in chronic
pain due to nerve injury. He then worked on the role of MIC-1, a new member of the transforming growth factor beta superfamily, in cancer cell proliferation, survival/
apoptosis and metastasis at St Vincent's Centre for Applied Medical Research. He moved to Children's Cancer Institute as a Senior Research Officer in 2003. Since 2004,
he has been focusing his research on the roles of histone deacetylases, histone demethylases, histone methyl transferases and long noncoding RNAs in modulating gene
transcription and tumourigenesis, and the roles of histone deacetylase inhibitors and histone methyltransferase inhibitors as anticancer agents. He was promoted to Project
Leader in 2009 and Group Leader in 2011. Over the past decade, he has authored a number of peer-reviewed publications in high impact scientific journals including
Lancet, Journal of the National Cancer Institute, Proceedings of the National Academy of Sciences USA, Nature Reviews Cancer, Nature Communications, Journal of
Clinical Oncology, PLOS Genetics, Cell Death & Differentiation, and Cancer Research.

ISSN: 2161-1041

Page 68
conferenceseries.com Jiangwen Zhang, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Jiangwen Zhang
University of Hong Kong, Hong Kong
Identification of DNA methylation of distal regulatory regions with causal effect on tumorigenesis
A berrant promoter methylation is a common mechanism for tumor-suppressor inactivation in cancer. However, the exact role
of DNA methylation at enhancers remains to be elucidated. We have developed a set of tools to genome-wide identify DNA
methylation in distal regions with causal effect on tumorigenesis. Novel oncogenes/tumor-suppressors and their putative enhancers
can be identified together based on this strategy. Many predictions were directly demonstrated by dCas9-based epigenetic editing
with strong evidence to support the accuracy and efficiency of our tool. Our study reveals the prevalent regulation of genome-
wide putative enhancers by DNA-methylation with causal effect on cellular malignancy and patient survival. Mechanistically,
oncogenic and lineage-specific transcriptional-factors aberrantly shaped the methylation landscape with diverged tumor-subtype
core regulatory circuitry. Notably, the gene regulatory networks orchestrated by enhancer methylation across different cancer
types converged on a common architecture, highlighting general organization principle for such networks regulated by DNA
methylation of distal regulatory regions.
Biography
Jiangwen Zhang graduated from Johns Hopkins University with a PhD. He has worked at Harvard University Genome Centre as Senior System Biologist for years before
joining the University of Hong Kong in 2013. His lab has broad interest in genetic and epigenetic regulation in development and diseases. Currently, his lab is focusing on
epigenetic regulation of tumorigenesis. His lab employs high through-put “omics” assays and large scale computation to dissect the gene regulatory network and signaling
pathways involved in oncogenesis.

ISSN: 2161-1041

Page 69
EPIGENETICS 2018
Page 70


Day 2
EPIGENETICS 2018
Page 71
Day- 2
Sessions
Epigenetics | Chromatin
Chair: Marvin H Caruthers, University of Colorado, USA

Co-Chair: Xiaogang Steven Wang, University of Colorado, USA
Title: The centenarian epigenome: DNA methylation and chromatin formation of the oldest old
Danielle Gutman, University of Haifa, Israel
Title: Activation of epigenetics pass way for improving traits in different cultivars
Avner Shenfeld, Epigenetics Ltd, Israel
Title: Epigenetic editing in the promoter of CXCL11 gene

Alexey V. Fedulov, Brown University, USA
Title: Transcriptional regulation by histone modifications using yeast model

Jung Shin Lee, Kangwon National University, South Korea
Page 72
conferenceseries.com Danielle Gutman, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
The centenarian epigenome: DNA methylation and chromatin formation of the oldest old
Danielle Gutman
University of Haifa, Israel
Statement of the Problem: The aging process is generally associated with multi system deterioration that leads to the
development of various chronic diseases which greatly affect the lifespan as well as quality of life of the aging individual.
Advances in medical care have promoted lifespan beyond twice as much as reproductive age, yet a genomic explanation to the
survival of centenarians is not yet available, despite extensive genomic research performed. We hypothesize that the centenarian
epigenome might offer an explanation through epigenetic flexibility of methylation and chromatin structure. Such an approach
is novel and has not yet been implemented on human populations.
Aim: The aim of our study is to characterize the aging epigenome and chromatin configuration in order to demonstrate this
epigenetic flexibility which possibly allows crafting an appropriate genomic response, best fit to the environment.
Methodology & Theoretical Orientation: Three groups of participants are currently being recruited (up to 100 participants
each); centenarians (95+ yo), offspring of centenarians, controls (65-80 yo). Peripheral blood is drawn from all participants for
epigenetic analyses. Illumina Infinium Methylation EPIC array is used on DNA from CD34+ cells of all participants and Hi-C
analyses are performed on age and sex matched grouped white blood cell samples.
Findings: Based on previous work led by Prof. Gil Atzmon we expect to find differential methylation patterns among the
groups. Specifically, we observe ENCODE hot spots among centenarians and offspring, which are distinctly different in
methylation status from controls. In addition, using unrelated samples we aim to highlight structural differences between the
centenarian and non-centenarian related controls’ chromatin. Our approach avoids small scale variance and emphasizes the
bigger biological differences in chromatin formation associated with age.
Figure 1: Unsupervised clustering of methylation data (25,000 loci) from CD34+ cells shows differences in methylation between Centenarians and Controls. The
heat map shows hypomethylated loci in red, hypermethylated in yellow. Distinct patterns are obvious between those over 100 and those who are 80 or 60 years old.
Recent Publications:
1. Ben-Avraham D, Govindaraju D R, Budagov T, Fradin D, Durda P, Liu B, Ott S, Gutman D, and Atzmon G (2017)
The GH receptor axon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH
sensitivity and taller stature. Science Advances 3(6):e1602025.
2. Ben-Avraham D, Karasik D, Verghese J, Lunetta K L, Smith J A, Eicher J D, Vered R, Deelen J, Arnold A M, Buchman
A S, Tanaka T, Faul J D, Nethander M, Fornage M, Adams H H, Matteini A M, Callisaya M L, Smith A V, Yu L, De
Jager P L, Evans D A, Gudnason V, Hofman A, Pattie A, Corley J, Launer L J, Knopman D S, Parimi N, Turner S T,
Bandinelli S, Beekman M, Gutman D and Atzmon G (2017) The complex genetics of gait speed: genome-wide meta-
analysis approach. Aging 9(1):209-246.

ISSN: 2161-1041

Page 73
3. Sharvit L, Gutman D, Adwan H, Vered R and Atzmon G (2016) Genetics of age-dependent human disease. Hazzard’s
Geriatric Medicine and Gerontology, 7e, chapter 2.
4. Gutman D, Sharvit L and Atzmon G (2014) Possible Mechanisms for Telomere Length Maintenance in Extremely Old
People. Hereditary Genet 3:e111.
Biography
Danielle Gutman completed her undergraduate studies of Biology and Mathematics and MSc in Human biology with honors at the University of Haifa. Her MSc
work and a project from her PhD lab were both presented as posters in international conferences. She is currently working on her PhD which includes recruiting and
collecting all samples from a unique human population cohort, processing samples in the lab and analyzing all the data. This cohort is the first of its kind in Israel
and she is the driving force behind it, coordinating between all aspects. Along-side her studies, she works as a genetics lab instructor at the University of Haifa,
coordinating, planning and teaching 60 students every year for five years.
Notes:

ISSN: 2161-1041

Page 74
conferenceseries.com Avner Shenfeld, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Activation of epigenetics passway for improving traits in different cultivars

Avner Shenfeld
Epigenetics Ltd., Israel
Improvement of agricultural methods and productivity is seen as one of the greatest challenges of the 21st century. In about
two decades from now, the world population will be increased dramatically. This in turn will force food production to its limit.
One potential solution for increasing food supply is by using epigenetics techniques. By applying moderate stress on plants plus
specific selection process, we were able to apply phenotypic changes without affecting the plant genotyping. We, at Epigenetics,
developed a non-GMO platform for improving seed traits, based on treatment and selection cycles. Results show an increase
in yield potential of row crops, vegetables and ornamentals (Soybean, Corn, Pepper, Tomato, Chrysanthemum, Echinacea,
Stevia and other). Indications show that Epigenetics treatment may expose a new source of genetic diversity through heritable
epigenomic modifications. We concentrated our attention to the increased plant's growth and yield by manipulating genes
that control the level of photosynthesis activity (photosynthetic rate). Increase energy supply (up to 80 to 100%) allows the
plant to activate many new traits such as increase bio-mass, resistant to abiotic stress, resistance to herbicide side effects and
better growth potential which associate with increased fruit to canopy fresh weight ratio. After activation of the epigenetics
biochemical pass way, we introduced a selection process directed towards a chosen trait, toward biomass and yield increased.
Our technology is blind to the origin of the plants: non-GM or GM, untouched their original properties while increasing their
yield.
Figure 1: Effect of epigenetic treatment of soybean plants. First picture: control plant, next pictures: treated plants
Figure 2: Effect of epigenetic treatment of tomato plants. First picture: control plant, next pictures: treated plants
Biography
Avner Shenfeld is a founder VP, CTO, Chairman of the board and acting CEO of four start-ups that he founded. He earned his PhD in Biochemistry & Biophysics,
from the Weizmann Institute of Science. He has proven experience at four biotech companies that he has founded since 1991 (Modus Biological Membranes Ltd.,
Lipogen Ltd., Lean-ex Ltd., and Epigenetics Ltd.,) all based on his own inventions, where he directed new products through all stages of development, clinical trials,
approval and registration. His scientific activities covered many areas such as improving photosynthetic rates in different crops via epigenetics effects, metabolic
diseases, anti-obesity drug, treatment of withdrawal symptoms from various addictions – structural changes in nerve cells, memory enhancement among elderly –
effect of phospholipids on nerve cell membranes and development of a new diagnostic kit for clinical microbiology samples. His basic expertise is in cell membranes
and lipids.

ISSN: 2161-1041

Page 75
conferenceseries.com Alexey V Fedulov, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Epigenetic editing in the promoter of CXCL11 gene

Alexey V Fedulov
Alpert School of Medicine of Brown University–Rhode Island Hospital, USA
Statement of the Problem: Epigenetic engineering (editing) is an exciting path to novel therapeutics. Custom-designed
demethylases allow gene-specific reactivation of epigenetically silenced genes. Progress in this area depends in great part on
the choice of enzymatic effectors and their targeted binding to promoters. Here we report a successful use of a combination of
TDG and Tet1 to enhance transcriptional responsiveness of CXCL11 gene in a murine fibroblast line.
Methodology & Theoretical Orientation: We designed multiple fusion constructs (n=6) aimed to bind in relative vicinity of
each other in the key regulatory areas of mCXCL11. Zinc-finger protein arrays served as DNA-binding domains; murine TDG
isotype 2 and human Tet1CD were the enzymatic effectors. Constructs with catalytically inactive single aminoacid mutant
enzymes served as controls. The constructs were delivered into 3T3 fibroblasts via lentiviral transduction.
Findings: After 2 weeks of constitutive expression the pyrosequencing analysis demonstrated a decrease in CpG methylation by
up to 40 percentage points in several loci in the targeted area. This was associated with a nearly 5-fold increase in transcriptional
responsiveness of CXCL11 after stimulation with a combination of IFNγ and LPS. The maximum transcriptional responsiveness
measured ~X 2000 times over baseline, vs. ~X 400 times in the control.
Conclusion & Significance: We conclude that a combination of multiple TDG and Tet1 complexes with zinc-finger arrays is a
promising approach in targeted demethylation and that CXCL11 is a rewarding target for future experimentation.
Figure 1: Example of a fusion demethylase complex bound to the DNA target.
1. Gregory D J, Zhang Y, Kobzik L and Fedulov A V (2013) Specific transcriptional enhancement of inducible nitric
oxide synthase by targeted promoter demethylation. Epigenetics 8(11):1205-12.
2. Gregory D J, Mikhaylova L and Fedulov A V (2012) Selective DNA demethylation by fusion of TDG with a sequence-
specific DNA-binding domain. Epigenetics 7(4):344-9.
3. Gregory D J, Kobzik L, Zhang Y, McGuire C C and Fedulov A V (2017) Transgenerational transmission of asthma risk
after exposure to environmental particles during pregnancy. Am J Physiol Lung Cell Mol Physiol. 313(2):L395-L405.
4. Mikhaylova L, Zhang Y, Kobzik L and Fedulov A V (2013) Link between epigenomic alterations and genome-wide
aberrant transcriptional response to allergen in dendritic cells conveying maternal asthma risk. PLoS One 8(8):e70387.
5. Fedulov A V and Kobzik L (2011) Allergy risk is mediated by dendritic cells with congenital epigenetic changes. Am
J Respir Cell Mol Biol. 44(3):285-92.
Biography
Alexey V Fedulov has his expertise in Epigenetic Engineering and Transgenerational Epigenetic Studies. His lab has built a model of targeted reactivation
of epigenetically silenced genes by fusion complexes comprised of DNA demethylase enzymes and sequence-specific DNA binding domains. His laboratory
studies are in immune and epigenetic mechanisms of lung disease including early life asthma origins. The ultimate goal of the studies is to find novel therapeutic
approaches by modulating epigenetic control of gene expression.

ISSN: 2161-1041

Page 76
conferenceseries.com Jung Shin Lee, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Transcriptional regulation by histone modifications using yeast model

Jung Shin Lee
Kangwon National University, South Korea
T he methylation of the fourth lysine on histone H3 (H3K4me) is a well-known mark of transcription activation and the
ubiquitination of the 123rd lysine of on histone H2B monoubiquitination (H2Bub1) is the prerequisite for H3K4 me in
Saccharomyces cerevisiae. All three types of H3K4 methylation, including mono, di and tri-methylation, occur by sole H3K4
methyltransferase, Set1 in S. cerevisiae. We created the strain defective bulk level of H3K4me3 even when H2Bub1 signal is
normal without any mutation of proteins. We found that some oxidation reduction related genes are less expressed in H3K4me3
defective strain comparing the strains bearing normal level of H3K4me3 by RNA-sequence analysis. Also, Candida albicans,
which is the most common fungal pathogen in human has Set1 complex as its methyltransferase for the H3K4. It is previously
described that Set1 deleted mutant shows attenuated virulence and pathogenesis in C. albicans. However, it is unclear why Set1
is important for virulence of C. albicans. In this study, we performed RNA sequencing of wild type and Δset1 strain to identify
the role of Set1 in C. albicans pathogenesis. In Δset1, the 156 genes are down regulated more than 2-fold. The Gene Ontology
(GO) enrichment analysis revealed that the significant number of these genes has oxidoreductase activity. Indeed, the Δset1
strain is more sensitive to hydrogen peroxide or menadione which induces oxidative stress. The survival assay in macrophages
indicated that the survival rate of Δset1 in macrophages is less than wild type strain. These results show that the Set1 is required
for the survival in host cells by regulating the expression of genes whose products defend against an oxidative stress.
1. Kim J, Lee J E and Lee J S (2015) Histone deacetylase-mediated morphological transition in Candida albicans. Journal
of Microbiology 53(12):805-811
2. Lee J E, Oh J H, Ku M, Kim J, Lee J S and Kang S O (2015) Ssn6 has dual roles in Candida albicans filament development
through the interaction with Rpd31. FEBS Letters 589(4):513-520.
3. Lee J S, Garrett A, Yen K, Takahashi Y H, Hu D, Jackson J, Seidel C, Pugh B F and Shilatifard A (2012) Co-dependency
of H2B monoubiquitination and nucleosome re-assembly on Chd1. Genes and Development 26(9):914-919.
4. Lee J S, Smith E and Shilatifard A (2010) The language of histone crosstalk. Cell 142(5):682-685.
5. Lee J S, Shukla A, Schneider J, Floresn L, Swanson S K, Washburn M P, Bhaumik S R, and Shilatifard A (2007) Histone
crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 131(6):1084-1096.
Biography
Jung Shin Lee is a Biochemist and Molecular Biologist studying to understand the molecular mechanism of the epigenetic regulation by histone modifications. She
suggested the molecular mechanism of how the ubiquitination of histone H2B regulate the methylation of histone H3 lysine 4 when during her Post-doctorate. These
two histone modifications are abundant within the actively transcribed genes and are considered to be important for the transcription. She started her own lab in
2012 and her group is studying mainly how histone modifications regulate epigenetically the gene expression and subsequently have effects on the physiological
change.

ISSN: 2161-1041

Page 77
EPIGENETICS 2018
Page 78

Keynote Forum
Day 3
EPIGENETICS 2018
Page 79
conferenceseries.com Charles De Smet, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Charles De Smet
De Duve Institute–University of Louvain, Belgium
Transcriptional overlap links DNA hypo-methylation and hyper-methylation of contiguous promoters

in cancer
D NA methylation is an epigenetic mark associated with gene repression. It is now well established that alterations in DNA
methylation patterns contribute to tumor development. Both gains (hyper-methylation) and losses (hypo-methylation) of
DNA methylation marks are frequently observed in tumors. The mechanisms underlying these two are opposite, yet co-existing,
alterations in tumors remain, however unclear. Our recent work reveals an unsuspected connection between DNA hypo- and hyper-
methylation in tumors. We show indeed that DNA hypo-methylation in tumors can lead to the activation of long non-coding
transcripts that overlap downstream promoters and trigger their hyper-methylation. Promoters that have gone through this process
of hyper-methylation are characterized by an enrichment of H3K36me3, a histone mark known to be deposited during progression
of the transcription machinery and to attract DNMT3A/B DNA methyltransferases. Finally, we show that this process of inter
dependent epigenetic alteration contributes to the repression of a tumor suppressor gene, RERG, in non-small cell lung carcinomas.
Recent Publications
1. Van Tongelen A, Loriot A and De Smet C (2017) Oncogenic roles of DNA hypomethylation through the activation of
cancer-germline genes. Cancer Letters 396:130-137.
2. Cannuyer J, Van Tongelen A, Loriot A and De Smet C (2015) A gene expression signature identifying transient DNMT1
depletion as a causal factor of cancer-germline gene activation in melanoma. Clinical Epigenetics 7:114.
3. Loriot A, Van Tongelen A, Blanco J, Klaessens S et al. (2014) A novel cancer-germline transcript carrying prometastatic
miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics 9(8):1163-1171.
4. Cannuyer J, Loriot A, Parvizi K G and De Smet C (2013) Epigenetic hierarchy within the MAGEA1 cancer-germline gene:
promoter DNA methylation directs local histone modifications. PLoS ONE, 8(3):e58743.
5. De Smet C and Loriot A (2010) DNA hypomethylation in cancer: epigenetic scars of a neoplastic journey. Epigenetics
5(3):206-13.
Biography
Charles De Smet is a Professor of Molecular Biology and Embryology at the School of Medicine and Biomedical Sciences of the University of Louvain, Belgium. He is
leading the Group of Epigenetics at the de Duve Institute in Brussels. His research has led to the demonstration, that DNA hypomethylation in tumors causes the aberrant
activation of a group of germline-specific genes, the so-called cancer-germline genes. Due to their highly restricted expression, these genes are being exploited as targets
of anti-cancer vaccinations.

ISSN: 2161-1041

Page 80
conferenceseries.com Alvaro Macieira Coelho, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-001
Alvaro Macieira Coelho

French National Institute of Health, France
The decline of the prevalence of cancers during organism senescence
I n general the scientific literature reports that aging favors the development of cancers. Each type of cancer however, initiates and
evolves differently and their natural history can start way back at earlier ages before their clinical manifestations. The incidence
of cancers is spread through the human life span, it is the result of pre- and post-natal aggressions, individual susceptibility, and
developmental changes that evolve continuously from the beginning to the end. Finally during human senescence the incidence
declines for all cancers. Frequently the progression of cancers is also slower in the old. There are several possible explanations for
this decline at the tissue, cellular, and molecular levels. It is time to ask why some tumors are characteristic of the young, others of
maturity, others of the time of the decline of the reproductive period, and finally why the incidence of cancers declines late during
senescence of the human organism. These questions should be answered before the origin of cancers can be understood.
Biography
Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the
University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and
at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France)
and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received
the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science” Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping,
Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).
Notes:

ISSN: 2161-1041

Page 81
EPIGENETICS 2018
Page 82


Day 3
EPIGENETICS 2018
Page 83
Day-3
Sessions
Genomics | Biomarkers | Histone Proteins
Chair: Jiangwen Zhang, University of Hong Kong, Hong Kong

Co-Chair: Tao Liu, Histone Modification Group Children’s Cancer Institute, Australia
Title: Detection of tumor-related DNA methylation biomarkers in liquid biopsies from metastatic
castration resistant prostate cancer patients to improve treatment decisions
Madonna R Peter, University of Toronto, Canada
Title: Emergence of novel CpG islands and genomic imprinting in mammalian evolution
Shunsuke Suzuki, Shinshu University, Japan
Title: TRF1 suppresses Break Induced Replication and early onset of ALT induction
Jean-Baptiste Vannier, Imperial College London, UK
Page 84
conferenceseries.com Madonna R Peter et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Detection of tumor-related DNA methylation biomarkers in liquid biopsies from metastatic castration
resistant prostate cancer patients to improve treatment decisions
Madonna R Peter1, 2, Misha Bilenky3, Ruth Isserlin4, Anthony M Joshua5, Aaron R Hansen5, Gary Bader4, Neil E Fleshner6, Martin Hirst3 and Bharati
Bapat1,2,6
1
Lunenfeld-Tanenbaum Research Institute, Canada
2
University of Toronto, Canada
3
Canada's Michael Smith Genome Sciences Centre - British Columbia Cancer Agency, Canada
4
The Donnelly Centre for Cellular and Biomolecular Research - University of Toronto, Canada
5
Princess Margaret Cancer Centre, Canada
6
University Health Network, Canada
Background: Liquid biopsies are emerging as an important source of minimally invasive biomarkers, especially in metastatic
castration resistant prostate cancer (mCRPC), where tumors are often inaccessible for biopsy based strategies. In particular,
circulating cell free nucleic acids, such as cfDNA, can harbor tumor specific genomic and epigenomic changes. Tumor related
DNA methylation markers are detectable in circulation of mCRPC patients; however, genome wide changes in the cfDNA
methylome of mCPRC patients undergoing current androgen targeting therapies have not been extensively investigated.
Methods/Results: In collaboration with the University Health Network Genitourinary Biobank (Toronto, Canada), we
prospectively collected a cohort of mCRPC patients that received treatment with either enzalutamide or abiraterone acetate.
Plasma cfDNA was isolated at baseline (prior to starting treatment), week-12 and clinical progression. As cfDNA methylation
detection can be challenging due to low yield and quality, we optimized a protocol that involves methylated DNA immuno
precipitation (MeDIP) followed by next generation sequencing (NGS). Overall, we are able to obtain good quality NGS data
with high mappability to the genome as well as >5x coverage of 46-51% CpGs in the genome. We applied this MeDIP-seq
protocol to cfDNA samples from 11 enzalutamide treated and 5 abiraterone treated patients that completed all study visits. We
performed within patient analysis to identify differentially methylated regions (DMRs) associated with treatment and clinical
progression. Overall, there were a number of DMRs identified through our established pipeline, with known mCRPC genes
implicated, such as members of the HOX family of transcription factors and Wnt pathway members.
Conclusions: Overall, we are able to detect methylation signals from low yields of cfDNA and potentially tumor specific
methylation markers. We are currently performing pathway analysis and correlation with clinical parameters. Validation of
these methylation markers in mCRPC could further shed light on underlying disease mechanisms and novel biomarkers.
Biography
Madonna R Peter is currently a PhD student at the University of Toronto, Department of Laboratory Medicine & Pathobiology and under the Supervision of Dr. Bharati Bapat
(Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada). Previously, she completed her MSc in the Department of Immunology (University of
Toronto).

ISSN: 2161-1041

Page 85
conferenceseries.com Shunsuke Suzuki, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
Emergence of novel CpG islands and genomic imprinting in mammalian evolution

Shunsuke Suzuki
Shinshu University, Japan
Genomic imprinting is an epigenetic regulatory mechanism which induces parent of origin dependent expression to a subset of
genes. In higher vertebrates, genomic imprinting has been observed only in viviparous mammals (eutherians and marsupials)
and some imprinted genes have essential roles associated with fetal and placental development and control of post natal care as
well as lactation, suggesting the correlation between the evolution of genomic imprinting and these characteristics of mammals.
Therefore, to study how imprinted loci arose during mammalian evolution would be of great importance to understand how
these mammalian traits evolved. Parent of origin dependent expression of imprinted genes is mostly controlled by parental
allele-specific DNA methylation of the CpG islands called differentially methylated regions (DMRs). Although the essential role
of DMRs for genomic imprinting mechanism has been well established, little is known about how they evolved. Comparative
genome analysis of the SGCE-PEG10 imprinted domain revealed that PEG10, a retro transposon-derived imprinted gene
essential for placental development, was acquired in the common ancestor of marsupials and eutherians. Furthermore, in
marsupials, both imprinting and differential DNA methylation were restricted to PEG10 unlike eutherians, suggesting that
the insertion of PEG10 was the origin of imprinting in this imprinted domain. Also, comparative genome analyses in other
imprinted domains showed that most DMRs have emerged as novel CpG islands during mammalian evolution. We presume
that the emergence of novel CpG island consequent of retro transposon insertion was key genomic change for the acquisition
of DMRs that evolved imprinted loci in mammalian genomes.
Recent Publications
1. Mori S, Hayashi M, Inagaki S, Oshima T, Tateishi K, Fujii H and Suzuki S (2016) Identification of multiple forms of RNA
transcripts associated with human-specific retrotransposed gene copies. Genome Biology and Evolution 8(8):2288-2296.
2. Suzuki S, Shaw G and Renfree M B (2013) Postnatal epigenetic reprogramming in the germline of a marsupial, the tammar
wallaby. Epigenetics & Chromatin 6(1):14.
3. Renfree M B, Suzuki S and Kaneko-Ishino T (2013) The origin and evolution of genomic imprinting and viviparity in
mammals. Philosophical Transactions of the Royal Society B: Biological Sciences 368(1609):20120151.
4. Suzuki S, Shaw G, Kaneko Ishino T, Ishino F and Renfree M B (2011) The origin and evolution of genomic imprinting and
viviparity in mammals. Genome Biology and Evolution 3:1276-1283.
5. Suzuki S, Ono R, Narita T, Pask A J, Shaw G, et al. (2007) Retro transposon silencing by DNA methylation can drive
mammalian genomic imprinting. PLOS Genetics 3(4):e55.
Biography
Shunsuke Suzuki completed his PhD from Tokyo Institute of Technology in 2006 and Postdoctoral Studies at Tokyo Medical and Dental University during 2006–2009 and
The University of Melbourne, Australia during 2009–2012. He is now an Assistant Professor at the Department of Agriculture and Life Sciences, Shinshu University, Japan.
His work is focused on the role of retro transposons in the evolution of gene regulatory mechanisms in mammals.

ISSN: 2161-1041

Page 86
conferenceseries.com Jean Baptiste Vannier, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-002
TRF1 suppresses break induced replication and early onset of ALT induction
Jean Baptiste Vannier
MRC-LMS, Imperial College London, Hammersmith Hospital Campus, UK
Persistent during DNA replication or inappropriately processed, telomere DNA secondary structures can have pathological
consequences and are an established source of genome instability. Despite the advances on the role of DNA helicases and
shelterin proteins facilitating replication through telomeric secondary structures, the step-by-step analysis of induction of
telomere fragility remain poorly understood. TRF1 is a key factor in facilitating replication at telomeres and we took advantage
of its function to study the events happening at telomeres using an unbiased proteomic approach. Proteomic of isolated
chromatin revealed that telomeric chromatin of TRF1 deficient cells resemble ALT telomeres with the recruitment of PML
and also the enrichment of many ALT specific factors including ATRX, SMC5/6 complex. We also report for the first time that
the high levels of recombination detected by CO-FISH in TRF1-/- cells is dependent on SMC5 and is in fact a conservative
dependent DNA synthesis mediated by BIR and POLD3. Notably, we could not detect all hallmarks of ALT positive cells in our
experimental system, including no heterogeneous telomere length and no c-circle formation. Telomere fragility and common
fragile site share at least a common trigger, which is replication hindrance, both induced by aphidicolin treatment. Despite
POLD3 dependent BIR being involved in CFS expression and now observed in our study at TRF1 depleted telomeres, we claim
that this conservative DNA synthesis mechanism is not responsible for the induction of telomere fragility in TRF1 deficient
cells. Therefore, all indicate that the mechanism generating telomere fragility and CFS are different.
Recent Publications
1. León Ortiz A M, Panier S, Sarek G, Vannier J B and Boulton S J (2018) A distinct class of genome rearrangements driven by
illegitimate recombination. Mol Cell. 69(2):292-305.e6.
2. Speckmann C, Sahoo S S, Rizzi M, Hirabayashi S, Karow A, Serwas N K, Hoemberg M, Damatova N, Schindler D, Vannier J B,
Boulton S J, Pannicke U, Göhring G, Thomay K, Verdu Amoros J J, Hauch H, Woessmann W, Escherich G, Laack E, Rindle L,
Seidl M, Rensing Ehl A, Lausch E, Jandrasits C, Strahm B, Schwarz K, Ehl S R, Niemeyer C, Boztug K and Wlodarski M W (2017)
Clinical and molecular heterogeneity of RTEL1 deficiency. Front Immunol. 8:449.
3. Sarek G, Vannier J B, Panier S, Petrini J H and Boulton S J (2015) TRF2 recruits RTEL1 to telomeres in S phase to promote T-loop
unwinding. Mol Cell 57(4):622–635.
4. Vannier J B, Sarek G and Boulton S J (2014) RTEL1: functions of a disease-associated helicase. Trends in Cell Biology 24(7):416-25.
5. Vannier J B, Sandhu S, Petalcorin M I, Wu X, Nabi Z, Ding H and Boulton S J (2013). RTEL1 is a replisome-associated helicase that
promotes telomere and genome-wide replication. Science 342(6155):239–242.
Biography
Jean Baptiste Vannier has developed his expertise in telomere homeostasis during his Doctoral studies, in the laboratory of Dr. Charles White, where he implicated several
different DNA damage proteins in protecting uncapped telomeres from unscheduled recombination in plant model Arabidopsis thaliana (Vannier et al., EMBO J, 2006; Plos
Gen., 2009). During his Postdoctoral research with Dr. Simon Boulton, he established the mechanistic basis of RTEL1 DNA helicase function at mammalian telomeres
in T-loop disassembly and provided insight into the source and prevention of telomere fragility (Vannier et al., Cell, 2012; Science, 2013). His group uses epigenetic and
chromatin DNA-related methodologies to investigate the cellular response to replication stress and the enzymatic activities that result in telomere replication aberrations.
This represents an outstanding challenge that will provide a novel framework for understanding the contributions of replication factors in general DNA replication, genome
stability and cancer.

ISSN: 2161-1041

Page 87
EPIGENETICS 2018
Page 88

Posters
EPIGENETICS 2018
Page 89
conferenceseries.com Marina Amorim Rocha et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Valproic acid effects on DNA methylation during the cell cycle of HeLa cells
Marina Amorim Rocha, Veronezi G M B, Gatti M S V and Mello M L S
University of Campinas, Brazil
V alproic acid (VPA), an anticonvulsant drug that is a histone deacetylase inhibitor, also affects DNA methylation levels. In
HeLa cells, the VPA - induced DNA demethylation process involving modified cytosine is a matter of discussion, if by an
active pathway, with the participation of ten-eleven-translocation (TET) enzymes, or by a passive DNA replication-dependent
pathway. Here, this process was investigated throughout the cell cycle of synchronized and non-synchronized HeLa cells treated
with 1 mM and 20 mM VPA for 4 h and compared to the cell cycle of cells treated with 5-aza-CdR, an agent generally used as
a passive DNA demethylation control. The methodology used involved flow cytometry, immunofluorescence, ELISA assay and
real-time quantitative PCR. The drugs used did not induce cytotoxicity but affected the cell cycle progression. VPA was found
to induce over expression of TET1 and TET2 genes, decrease in 5mC abundance and increase in 5hmC abundance, either in G1
cells or in proliferative cells. These findings indicate an active pathway performed by VPA in the DNA demethylation process.
However, because VPA also affected the DNMT1 expression, it may also act in the passive DNA demethylation pathway.
Although 5-aza-CdR reduced the expression of the DNMT1 gene, depending on cell proliferation and without affecting the
TET1 and TET2 gene expression at any stage of the cell cycle, it induced an increase in 5hmC abundance. 5-aza-CdR may thus
also act on the active DNA demethylation pathway, because VPA induces reduction in the DNA methylation patterns of non-
replicating HeLa cells, a significant potential implication of its use may arise for a therapeutic reversal of DNA methylation in
tissues where no further involvement of the cell division process occurs.
Figure 1: VPA- but not 5-aza-CdR-treatment induced decrease in the nuclear abundance of 5mC in non-proliferative cells
1. Veronezi G M B, Felisbino M B, Gatti M S V, Mello M L S and Vidal B C (2017) DNA methylation changes in valproic
acid-treated HeLa cells as assessed by image analysis, immunofluorescence and vibrational microspectroscopy. PLoS
One 12(1):e0170740.
2. Han B R, You B R and Park W H (2013) Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-
dependent apoptosis. Oncology Reports 30(6):2999-3005.
3. Detich N, Bovenzi V and Szyf M (2003) Valproate induces replication-independent active DNA demethylation.
Journal of Biological Chemistry 278(30):27586-27592.
4. Desjobert C, E L Maï M, Gérard-Hirne T, Guianvarc'h D, Carrier A, Pottier C, Arimondo P B and Riond J (2015)
Combined analysis of DNA methylation and cell cycle in cancer cells. Epigenetics 10(1):82-91.
5. Sajadian S O, Ehnert E, Vakilian H, Koutsouraki E, Damm G, Seehofer D, Thasler W, Dooley S, Baharvand, Sipos B
and Nussler A K (2015) Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent
and suggests new treatment strategies against hepatocellular carcinoma. Clinical Epigenetics 7(98):1-14.

ISSN: 2161-1041

Page 90
Biography
Marina Amorim Rocha holds a bachelor's degree in Biological Sciences from the State University of Bahia (UESB) (2015), Campus Vitória da Conquista. She is a
Master's degree in Cell and Structural Biology from the State University of Campinas (UNICAMP) (2018). She is currently a PhD student at the State University of
Campinas (UNICAMP). Marina Amorim Rocha has expertise in epigenetics, cell cycle, cell proliferation and cytotoxicity and his research purpose while analyzing
the cell cycle is to understand some of the epigenetic mechanisms of the VPA action, an anticonvulsant known as a histone deacetylase inhibitor (HDACi) and also
proposed an anti-tumorigenic drug, given its ability to inhibit proliferation in some tumor types. Thus, his studies contribute to the understanding of the metabolic
pathways performed by VPA and may contribute with advances developed in therapeutic proposals regarding the use of this or similar drugs. Such an idea may
especially apply to tissues with no further participation of the cell division process, since it has been shown that in HeLa cells VPA acts independently of DNA
replication.
Notes:

ISSN: 2161-1041

Page 91
conferenceseries.com Celia M Ross, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Writing about epigenetics for allied health professionals in gerontology

Celia M Ross
Delaware Gerontology Institute, LLC, USA
Statement of the Problem: There is a need to provide medical epigenetics information to allied health professionals who
have varying educational backgrounds. Epigenetics is increasingly being recognized as being a factor in neurodegenerative
conditions. It will thus become an area of growing interest to allied health professionals working in gerontology. The purpose
of this study was to develop a strategy for communicating information about epigenetics to allied health professionals.
Methodology: Information about professional development preferences for US activity professionals was obtained through
a qualitative study of semi-structured phone interviews. This information was combined with the researcher’s extensive
experience as a volunteer molecular biology educator where she discussed genetics and epigenetics with individuals of varying
ages and educational backgrounds.
Findings: Activity professionals have greatly varying educational backgrounds and can enter the professional with non-
science college degrees such as music. However, activity professionals are interested in gaining a greater understanding of
neurodegenerative disorders both from the practical prevention/ care stand point but also from the theoretical biomedical
stand point. This thirst for information comes from both the personal satisfaction of learning and from a professional need for
it. Study participants enjoy life-long learning. Some participants were also healthcare educators.
Conclusion & Significance: Activity professionals are life-long learners; however, they come from varying academic
backgrounds. Advanced scientific concepts can be taught to diverse audiences, facilitated in part through the use of analogies.
For example; one can use a recipe book analogy for the genome, a sticky note analogy for epigenetics and a banquet analogy
for phenotype. This lays the ground work for the development of learning materials about epigenetics for diverse audiences.
Figure 1: Cooking analogy to explain epigenetics.
1. Ross C M (2017) Activity professionals are avid readers seeking more books about dementia. BAOJ Pall Medicine
3:026.
2. Ross C M (2017) Dicer and dementia: from the molecular level to a possible role in memory care activities. BAOJ
Neurology 3:49.
3. Ross C M (2018) Surgical Recovery, stress, and activities departments. BAOJ Surgery 4:031.

ISSN: 2161-1041

Page 92
4. Taher N, McKenzie C, Garrett R, Baker M, Fox N and Issaacs G D (2014) Amyloid-β alters the DNA methylation
status of cell-fate genes in an Alzheimer's disease model. Journal of Alzheimers Disease 38(4):831-44.
5. Kim-Ha J and Kim Y J (2016) Age-related epigenetic regulation in the brain and its role in neuronal diseases. BMB
Reports 49(12):671-680.
Biography
Celia M Ross, PhD, MS—is the Founder of the Delaware Gerontology Institute, LLC. In founding the institute, she drew upon her decades of experience in the
health sciences which ranged from molecular biology research to environmental health studies to healthcare to healthcare research. At the Delaware Gerontology
Institute, LLC she develops both products to meet the needs of the elderly and informative materials/health science commentary for professionals in the health field.
She also does extensive volunteer work teaching genetics, epigenetics, and other topics in biology at a local natural history museum. In addition, she is a Volunteer
of lifelong learning educator, giving lectures to the elderly at a local long-term care facility.
Notes:

ISSN: 2161-1041

Page 93
conferenceseries.com Marcela Chmelarova et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Role of DNA methylation in resistance to platinum-based chemotherapy in ovarian cancer cells

Marcela Chmelarova1, Ivana Baranova1, Helena Kovarikova1, Alena Mrkvicova1,2, Martina Rezacova2, Jan Laco1, Iva Sedlakova1 and Vladimir Palicka1
1
University Hospital Hradec Kralove, Czech Republic
2
Charles University, Czech Republic
Statement of the Problem: Ovarian cancer is the leading cause of death from gynecological tumors. The current standard
treatment consists of cyto reductive surgery followed by chemotherapy, alternatively biological treatment. For chemotherapy
treatment the combination of platinum derivatives with taxane are used. However, 20-40% of the patients exhibit primary drug
resistance. Carcinogenesis includes genetic changes but also epigenetic deregulation. One of the most commonly occurring
epigenetic events taking place in the mammalian genome is DNA methylation. Furthermore, DNA methylation in solid
tumors has been associated with resistance to therapy and poor prognosis. Hence, hypermethylation is an attractive target for
treatment in order to influence tumor biology and potentially to overcome therapy resistance. The objective of our project was
to identify DNA methylation changes associated with platinum resistance.
Methodology & Theoretical Orientation: To search for DNA methylation changes in selected genes (GATA4, HNF1B, CDH13
and CDH1) we used bisulfite next generation sequencing and then we compare the methylation status in cisplatin sensitive/
resistant A2780 ovarian cancer cell lines. Furthermore, we tested the effect of de-methylating agent (zebularine) on reversal of
platinum chemoresistance.
Findings: Our experiments detected elevated methylation in selected genes in cisplatin resistant cell line A2780cis compared
to cisplatin sensitive cell line A2780, which supports the theory that DNA methylation is connected to chemotherapeutics
resistance, especially to cisplatin. Moreover, we found that zebularine affected methylation status and sensitivity to cisplatin.
Conclusion & Significance: Epigenetic deregulation of selected adhesion molecules and transcription factors is involved in
chemoresistance of ovarian cancer. These findings could potentially be used in development of new treatment strategies for
ovarian cancer and may have implications in prediction of chemotherapy resistance in ovarian cancer patients.
Figure 1: Hypothesis of epigenetic regulation of platinum resistance in ovarian cancer cells and possible prediction of
platinum resistance in HGSCO (High-grade serous ovarian cancer)
1. Barton C A, Hacker N F, Clark S J and O'Brien P M (2008) DNA methylation changes in ovarian cancer: implications
for early diagnosis, prognosis and treatment. Gynecologic Oncology 109(1):129-39.
2. Ferlay J, Steliarova Foucher E, Lortet Tieulent J, Rosso S, Coebergh J W, Comber H, Forman D and Bray F (2013)
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer
49(6):1374-403.
3. Zeller C, Dai W, Steele N L, Siddiq A, Walley A J, Wilhelm Benartzi C S, Rizzo S, van der Zee A, Plumb J A and
Brown R (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by
methylome and expression profiling. Oncogene 31(42):4567-76.

ISSN: 2161-1041

Page 94
4. Lund R J, Huhtinen K, Salmi J, Rantala J, Nguyen E V, Moulder R, Goodlett D R, Lahesmaa R and Carpén O (2017)
DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Scientific Reports
7(1):1469.
5. Fang F, Cardenas H, Huang H, Jiang G, Perkins S M, Zhang C, Keer H N, Liu Y, Nephew K P and Matei D (2018)
Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer
Research 78(3):631-644.
Biography
Marcela Chmelarova has her expertise in cancer epigenetics. Ever since she started her PhD studies, her work has been mainly focused on evaluation of DNA
methylation changes primarily in gynecological cancer. She has years of experience in basic research, data evaluation and she actively engages in teaching in her
home institutions of University Hospital Hradec Kralove and Charles University-Faculty of Medicine in Hradec Kralove. Recently her team started more vigorously,
to explore mechanisms of platinum based resistance in ovarian cancer among other topics of cancer epigenetics.
Notes:

ISSN: 2161-1041

Page 95
conferenceseries.com Nawel Agher et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Heterogeneity, phenotypic and genotypic instability of the primary tumor and its metastasis
Nawel Agher1, 2 and A Tou1, 2
1
University Hospital Center “ Hassani Abdelkader” of Sidi Bel Abbés, Algeria
2
Djilali Liabès University, of Sidi Bel Abbés Algeria
T he heterogeneity of cancers presents one of the major problems of therapeutic management, which can explain the fall
of many cancer patients after treatment. The study of these changes at the level of the primary tumor and its metastasis
and the thorough knowledge of points of difference would improve the therapeutic choice and thus increase the survival and
quality of life of patients. The aim was to study primary cancer and its metastasis in all its aspects in order to find hypothetical
explanations on the behavior of the moving cell. We performed a comparative study between the primary tumor and its
secondary tumor in 10 cases of cancer diagnosed at the Department of Pathology, Hospital University Center, Sidi Bel Abbes,
Algeria. Our work consisted in correlating clinical data with anatomo-pathological aspects including a histopathological re-
reading of all lesions and using immuno histochemical techniques using markers: HER2, progesterone, estrogen, P53, Ki67,
cytokeratin, Kappa, Lambda, to compare between the primary tumor and its metastasis in terms of the degree of differentiation
(histopathological grade); the proliferative potential and the type of proliferation adopted by the moving cell; This variability
can explain the treatment failure and is often based on the histopathological and biological profile of the primary tumor is not
taking consideration of the tumor cells, having had the ability to depart from the primary tumor, borrow the blood stream and
proliferate in another environment than the initial environment thereby confirming their aggressive potential and that should
be taken into account in the therapeutic choice.
Fig 1: Primary and Secondary tumor image.
1. A F Chambers, A C Groom and I C MacDonald (2002) Dissemination and growth of cancer cells in metastatic sites.
Nature Reviews Cancer 2(8):563–572.
2. S A Eccles and D R Welch (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369(9574):1742–
1757.
3. I J Fidler (2003) The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nature Reviews Cancer
3(6):453–458.
4. G P Gupta and J Massague (2006) Cancer metastasis: building a framework. Cell 127(4):679–695.
5. R A Gatenby and R J Gillies (2008) A micro environmental model of carcinogenesis. Nature Reviews Cancer 8(1):56–
61.

ISSN: 2161-1041

Page 96
Biography
PhD. Nawel Agher, young researcher, obtained his Doctor in Biology of the normal and pathological cell the case of cancer. After several trips in search of science
which has been the subject of several national and international works on the behaviour of cancer cells. She published her first book under the name "Intérêt du
testing de l'HER-2 dans les cancers Estomac, Ovaire, Vessie),2017 (www.editions-ue.com/catalog/details//store/fr/book/978-3-639-54385-8/intérêt-du-testing-de-
l-her-2-dans-les-cancers) and second “Metastasis” (https://www.abebooks.fr/9786202279505/Metastasis-Nawel-Agher-Abdenacer-Tou-6202279508/plp),2018 in
Edition European University. She is Head of the Unit of Molecular Biology in Pathology Department of University Hospital Center “Hassani abdelkader”, Djilali
Liabès University, of Sidi Bel Abbés, Algeria.
Notes:

ISSN: 2161-1041

Page 97
conferenceseries.com Péter Nánási et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Doxorubicin induces large-scale histone redistribution in live cells

Péter Nánási, László Imre and Gábor Szabó
Department of Biophysics and Cell Biology, University of Debrecen, Hungary
A nthracyclines are widely used anti-cancer drugs exhibiting pleiotropic effects. At the chromatin level, their mechanism of
action includes topoisomerase inhibition, DNA intercalation and histone eviction. Anthracyclines also bind histones thus
modulating their DNA binding properties, turnover and intra-nuclear localization. Doxorubicin is an anthracycline derivative
frequently used in clinical practice. However, it is challenging to overcome its most common side-effect, cardiotoxicity. It has
also been reported previously that anthracyclines cause chromatin aggregation. We used a laser scanning microscopy based
assay to detect antibody labeled histones in doxorubicin treated and triton-permeabilized Jurkat cells. Doxorubicin was applied
in a concentration range between 1-36 μM and was detected by immunofluorescence and increment in the average nuclear
amount of histones in the case of H1 and H2A after two hours of treatment in a sub population of the cells; these cells did not
show the symptoms of apoptosis. The increase was already observed at the concentration of 1-2 µM corresponding to the usual
peak plasma concentrations of the drug reached upon intravenous infusion. At the same time, a marked decrease was observed
in the case of total H3 and the levels of H2B were not affected. These results were reproduced using different antibodies, but
not with GFP-tagged histones all of which exhibited a variable, minor decrease. The above changes can be readily interpreted
in terms of differential release from the permeabilized nuclei of the histones exhibiting different degree of aggregation. By
confocal microscopy, we detected H1 accumulation in nucleoli after doxorubicin treatment. At the same time, H2A filled
up the space between the trabecular, aggregated chromatin. We observed a marked intra-nuclear decrease and cytoplasmic
increase in antibody labeled H2B histone levels, a phenomenon undetectable using GFP-tagged H2B. The inhibition of de novo
protein synthesis had no effect on the latter phenomenon, so we propose that doxorubicin bound H2B histone levels become
diminished in the nuclei with one of the following mechanisms: either the drug-bound H2B gets ubiquitinated for proteasomal
targeting or H2B is transported out of the nucleous using nuclear export. Experiments are in progress to investigate these
alternatives. The data on H1 are in line with those on H2A and H2B were unexpected based on the previous studies.
1. Imre L and Szabo G (2017) Nucleosome stability measured in situ by automated quantitative imaging. Scientific
Reports 7(1):12734.
2. Pang B and Neefjes J (2013) Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic
effects of doxorubicin. Nature Communications 4:1908.
3. Wójcik K and Dobrucki J W (2013) Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions.
Cancer Biology & Therapy 14(9):823-32.
Biography
Peter Nanasi graduated at University of Debrecen in 2012 as a medical doctor. After 2012 he works at the Department of Biophysics and Cell Biology first as a PhD
student then as a junior research fellow. Area of research focused on chromatin architecture and nucleosome stability, which includes, studying the role of single-
strand DNA breaks in connection with higher order chromatin assembly, investigating the effect of different histone posttranslational modifications to nucleosome
stability using a salt and intercalator based assay. Laser Scanning Cytometry and Confocal Microscopy is freely accessbile in our department. Article published:
Imre L and Szabo G (2017) Nucleosome stability measured in situ by automated quantitative imaging. Scientific Reports 7(1):12734.

ISSN: 2161-1041

Page 98
conferenceseries.com László Imre et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
H2A.Z: stable or not stable that is the question

László Imre1, Gábor Szabó1, Juan Ausio2, Gergő Kalló1, Éva Csősz1, Hiroshi Kimura3 and Masahiko Harata4
1
University of Debrecen, Hungary
2
University of Victoria, Canada
3
Institute of Innovative Research - Tokyo Institute of Technology, Japan
4
Tohoku University, Japan
N ucleosomal structure is repressive therefore; the mechanisms involved in the regulation of nucleosome stability are of great
importance in the control of gene expression. It is well established that nucleosome free regions (NFRs) are generated at
the transcriptional start sites, flanked by nucleosomes with high turnover rate and of special histone composition. H2A.Z is one
of these histone variants, characteristic for the +1 and -1 nucleosomes neighbouring these NFRs, among its other preferential
locations. We have developed an in situ assay for the measurement of the intrinsic and super helicity dependent nucleosome
stability. Using this assay NFR flanking nucleosomes carrying H3K4me3 histone post-translational modification were found to
be less stable compared to nucleosomes carrying heterochromatic histone marks. Since H2A.Z can substitute canonical H2A
histones in the NFR flanking nucleosomes, we expected that the H2A.Z containing nucleosomes would also be destabilized.
Using H2A.Z specific antibodies and fluorophores tagged H2A.Z histones, we observed unusually stable. H2A.Z containing
nucleosomes that could be detected in an antibody clone/brand dependent manner. Having compared different antibodies and
H2A.Z isotypes we have shown that neither the acetylation of the N-terminal histone tail nor the isotype was responsible for
their increased stability. Through the spectacles of super-helicity dependent stability, the unusually stable nucleosomes appear
to constitute a sub population of all H2A.Z containing nucleosomes that appears to be of perinucleolar localization.
1. Imre et al. (2017) Nucleosome stability measured in situ by automated quantitative imaging. Scientific Reports
7(1):12734.
Biography
László Imre completed his MSc studies on the Eötvös Loránd University, Faculty of Science as a molecular biologist. He did his diploma work in the Agricultural
Biotechnology Institute investigating the site-specific integration system of the 16-3 phage virus. Then he started to work in the Institute of Isotopes Co., Ltd. as a
development engineer and has developed a multiplex microbead assay for the detection of changes in length or sequence of short genomic regions (patented in
Hungary). Now he works as a junior research fellow in the Department of Biophysics and Cell Biology, University of Debrecen. He will complete his PhD at the end
of 2018 with the supervision of Prof. Gábor Szabó. His field of interest include the effect of epigenetic histone modifications and histone variants on the chromatin
structure. He has developed an automated quantitative imaging based method for the evaluation of the intrinsic and superhelicity dependent nucleosome stability
and has also developed microbead assays for chromatin studies.
Notes:

ISSN: 2161-1041

Page 99
conferenceseries.com Nefertiti El-Nikhely, Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Metastasis-associated protein 2 (MTA2) as a regulator of NF-kB in lung cancer

Nefertiti El-Nikhely
Institute of Graduate Studies and Research—Alexandria University, Egypt
Statement of the Problem: Lung cancer is a multifactorial disease with poor prognosis and survival. Inflammation is an
important aspect in tumorigenesis that is gaining increasing attention in many studies. A key player of variant processes in
tumour growth is the transcription factor nuclear factor kappa B (NF-kB) which shows aberrant expression in several cancers
and plays a role in drug resistance. As NF-kB is a pleiotropic agent, it is tightly regulated on several levels.
Methodology: A transgenic animal model was used, where IKK2, the key kinase activating NF-kB, was altered (downregulated
IKK2, IKK2DN or activated IKK2; IKK2CA) in CRaf BxB-induced tumor in alveolar epithelial type-II cells (Sftpc/CRaf/IKK2DN
and Sftpc/CRaf/IKK2CA). Xenograft model was used with LLC1 cells for subcutaneous tumours whose immune cell repertoire
was analysed by flow cytometry.
Findings: We could observe impaired tumour growth when IKK2 was downregulated. Using several lung cancer cell lines,
we revealed that NF-kB is regulated by metastasis-associated protein 2 (MTA2). NF-kB activity was decreased when MTA2
was overexpressed in A549 cells. Moreover, knockdown of MTA2 by shMTA2 in LLC1 cells lead to increased subcutaneous
tumours in a xenograft model. The tumours with lower MTA2 levels included macrophages showing rather type 1 markers
which are pro-tumorigenic and thus contributing to the increased tumour sizes.
Conclusion: This study sheds more light into the epigenetic regulation of NF-kB signalling pathway. The interaction between
NF-kB and MTA2 can be subject of novel therapy modalities.
Figure 1: Mechanism of feedback regulation of NF-kB by MTA2/NuRD complex.
1. Soni Savai Pullamsetti, Baktybek Kojonazarov, Samantha Storn, Henning Gall, Ylia Salazar, Janine Wolf, Andreas
Weigert, Nefertiti El-Nikhely, Ardeschir Ghofrani, Gabriele A Krombach, Ludger Fink, Stefan Gattenlöhner, Ulf
R Rapp, Ralph Theo Schermuly, Friedrich Grimminger, Werner Seeger and Rajkumar Savai (2017) Lung cancer–
associated pulmonary hypertension: role of micro-environmental inflammation based on tumor cell-immune cell
crosstalk. Sci Transl Med. 9(416).
2. Kiehl S, Herkt S C, Richter A M, Fuhrmann L, El-Nikhely N, Seeger W, Savai R and Dammann R H (2014) ABCB4 is
frequently epigenetically silenced in human cancers and inhibits tumor growth. Sci Rep. 4:6899.
3. Kopp F, Hermawan A, Oak P S, Ulaganathan V K, Herrmann A, El-Nikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven
B, Savai R, Wagner E and Roidl A (2014) Sequential salinomycin treatment results in resistance formation through
clonal selection of epithelial-like tumor cells. Transl Oncol. 7(6):702-11.

ISSN: 2161-1041

Page 100
4. Zanucco E, El-Nikhely N, Götz R, Weidmann K, Pfeiffer V, Savai R, Seeger W, Ullrich A and Rapp U R (2014)
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity
and lung tumor growth. J Biol Chem. 289(39):26804- 16.
5. Larzabal L, El-Nikhely N, Redrado M, Seeger W, Savai R, Calvo A (2013) Differential effects of drugs targeting cancer
stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis. PLoS One 8(11):e79798.
Biography
This work was part of the PhD thesis and the work was done at the Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Nefertiti El-
Nikhely was working there as PhD graduate student and then as a postdoc. This study is novel in elucidating new epigenetic regulation mechanisms for NF-kB
in lung cancer. NF-kB is a crucial inflammatory factor that is often aberrant in many caners. Several studies attempted to use its inhibitors as adjunct therapy to
conventional cancer therapies. A better understanding of its underlying regulatory mechanisms is needed. This study paves the way for developing new therapy
interventions by addressing the interaction between NF-kB and its regulators.

ISSN: 2161-1041

Page 101
conferenceseries.com Klonou A et al., Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
Emerging role of histone lysine methyltransferase SETDB1 and repressive histone marks H3K9me3,
H4K20me3 and H3K4me3 in pediatric brain tumors
Klonou A1, Gargalionis A1, Korkolopoulou P1, Themistocleous M2, Papavassiliou A G1, Sgouros S3 and Piperi C1
1
National and Kapodistrian University of Athens, Greece
2
Agia Sofia Children’s Hospital, Greece
3
Mitera Hospital, Greece
Statement of the Problem: Brain tumors are regarded as the most prevalent solid neoplasms in children and the principal
reason of death in this population. Chromatin remodeling alterations such as histone methylation induced by their respective
histone methyltransferases are considered to have a prognostic value in gliomagenesis and in pediatric gliomas onset. The aim
of the study was to investigate the differential expression of repressive histone marks H3K9me3, H4K20me3, H3K4me3 and
linker histone H1x in pediatric gliomas. In addition, expression of lysine N-methyltransferases SETDB1 and the enhancer of
zeste homolog 2 (EZH2) was evaluated.
Methodology & Theoretical Orientation: Archival human glioma tissues and normal brain samples were provided by the
Neurosurgery Departments of “Mitera” and “Agia Sophia” Pediatric Hospitals and the study was approved by the University
of Athens, Medical School Ethics Committee. Protein expression was evaluated immunohistochemically as H-score (intensity
multiplied with cell percentage, 0–300) in 36 pediatric tumor samples (30 astrocytomas grade II-III, 6 glioblastomas; age 3–14
years old; 23 males, 13 females) and in five samples of normal brain tissue.
Findings: Increased nuclear staining of H3K9me3 and H4K20me3 repressive marks was observed in astrocytomas (median
H-score 298 and 295, respectively). Moderate nuclear staining was obtained for H3K4me3 and SETDB1 (median H-score 190
and 120 respectively), whereas EZH2 and H1x presented no significant nuclear expression. A positive association of H3K9me3
with H3K4me3 histone marks was observed (p=0.043). SETDB1 staining was significantly elevated in males as compared to
female children (p=0.007) and tended to be higher in glioblastomas compared to astrocytomas II-III (p=0.05).
Conclusion & Significance: These findings indicate the possible involvement of H3K9me3, H4K20me3 and H3K4me3 histone
marks in the pathogenesis of pediatric gliomas. The histone methyltransferase SETDB1 was found to play a significant role
in modulating gene expression, possibly by inducing H3K9me3 epigenetic mark. Future studies validating these chromatin
remodeling changes in larger cohorts are needed along with elucidation of the underlying molecular mechanisms for potential
therapeutic targeting.
Figure 1: Major histone modifications and their respective enzymes.

ISSN: 2161-1041

Page 102
1. Klonou A, Spiliotakopoulou D, Themistocleous M S, Piperi C and Papavassiliou A G (2018) Chromatin remodeling
defects in pediatric brain tumors. Ann Transl Med. 6(12):248.
2. Blionas A, Giakoumettis D, Klonou A, Neromyliotis E, Karydakis P, et al. (2018) Paediatric gliomas: diagnosis,
molecular biology and management. Ann Transl Med. 6(12):251.
3. Klonou A, Piperi C, Gargalionis A N and Papavassiliou A G (2017) Molecular basis of pediatric brain tumors.
Neuromolecular Med. 19(2–3):256–270.
4. Sepsa A, Levidou G, Gargalionis A, Adamopoulos C, Spyropoulou A, et al. (2015) Emerging role of linker histone
variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation
of H3K9 and H4K20. PLoS One. 10(1):e0115101.
5. Spyropoulou A, Gargalionis A, Dalagiorgou G, Adamopoulos C, Papavassiliou K A, et al. (2014) Role of histone lysine
methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony
formation. Neuromolecular Med. 16(1):70–82.
Biography
Klonou A is a second-year PhD candidate at the Medical School of National and Kapodistrian University of Athens. She is doing her thesis on the “Investigation
of genetic and epigenetic factors in pediatric brain tumors” in the Neuro-Oncology lab at the Department of Biological Chemistry. She investigates epigenetic
alterations which control chromatin remodeling and alter the genome by modifying the expression of important genes which are involved in brain oncogenesis
in children. Another goal of her research is the identification of major enzymes that cause histone modifications as well as the genes that are affected by the
expression of these enzymes. Finally, she aims to identify differences in the molecular mechanisms involved in brain oncogenesis between paediatric and adult
populations. She has published three review articles and she has been awarded for the best oral presentation at the 32nd Annual Congress of the Hellenic
Neurosurgical Society (Greece, May 2018).
Notes:

ISSN: 2161-1041

Page 103
EPIGENETICS 2018
Page 104

Accepted Abstracts
EPIGENETICS 2018
Page 105
conferenceseries.com Hereditary Genet Curr Res 2018, Volume 7
DOI: 10.4172/2161-1041-C1-003
DNA methylation changes associated with insufficient sleep in men

Alexandra Lahtinen1,2
1
University of Helsinki, Finland
2
National Institute for Health and Welfare, Finland
S ufficient sleep is crucial for our health. Poor sleep affects basic physiological processes, including systemic inflammatory
reaction, and leads to an increased risk for various psychiatric and somatic disorders. The assessment and early prevention
of long-term risks could be enhanced by identification of key players in molecular processes associated with insufficient sleep.
Though sleep is precisely regulated, the detailed mechanisms of brain processes during sleep remain unclear. Since DNA
methylation plays critical role in the regulation of gene expression, study of differentially methylated positions (DMPs) might
be valuable for comprehensive understanding of the mechanism underlying insomnia. The author performed epigenome-
wide association studies for two independent cohorts to identify DMPs in whole blood samples of individuals suffering from
insufficient sleep or diagnosed with shift-work disorder. Corresponding genes were analyzed by various tools to investigate
affected biological pathways in individuals lacking sleep. The data analysis showed that processes related to neuronal plasticity
and neurodegeneration were compromised in people lacking sleep, as well as there is an enrichment of genes involved in
visual processing and regulation of circadian rhythm. The results give evidence for importance of the epigenetic regulation in
mediating both brain-specific and systemic stress caused by compromised sleep and diurnal rhythm.

ISSN: 2161-1041

Page 106
DOI: 10.4172/2161-1041-C1-003
Blood transfusion in patients with immunohematological problem

Carlos A Gonzalez
Hospital Muñiz, Argentina
T he blood transfusion therapy is essential in the management of hematologic/oncologic disorders. Although transfusions
are not risk free. In fact, these patients may develop alloimmune or autoimmune process during the transfusion support.
Alloimmunization is a significant risk of transfusions and is the second leading cause of transfusion-associated death. In fact, the
transfused individuals with hematologic/oncologic disorders may develop red blood cell alloantibodies, which can complicate
pre-transfusion testing, delay blood product availability, and lead to transfusion reactions. The autoimmune hemolytic anaemia
may be produced by cold and warm autoantibodies and may mediate intravascular or extravascular autoimmune hemolysis
in hematology/oncology patients. The tests that form the basis for transfusion compatibility and antibody identification are
not always well understood, nor are their interpretations always straightforward. A better understanding of testing realized in
the immunohematology laboratory will allow hematology/oncology providers to make informed decisions on the risk/benefit
ratio of transfusion for their individual patients. Further, this understanding will allow improved communication between
hematology/oncology providers and the transfusion service in instances of transfusion histories, new antibody formation, and
unexpected adverse transfusion sequelae.

ISSN: 2161-1041

Page 107
DOI: 10.4172/2161-1041-C1-003
Transgenerational epigenetic inheritance: a drosophila tale

Filippo Ciabrelli
CRUK Cambridge Institute, UK
T ransgenerational epigenetic inheritance is a hotly debated phenomenon whereby a non-genetically determined phenotype
can be transmitted to the next generation. So far, this mode of inheritance has been described in few cases and it was
suggested that chromatin components might be involved, including Polycomb group proteins, which act as repressors of key
developmental genes and coordinate cell differentiation and proliferation. The molecular mechanisms linking Polycomb-
mediated silencing to transgenerational epigenetic inheritance are far from being understood. Therefore, we developed an
experimental system in Drosophila melanogaster to induce stable transgenerational epigenetic inheritance. After a genetic
induction, I could obtain two “epilines” that either overexpressed or hyperrepressed their reporter genes and which epigenetic
states could be stably inherited in the next generations, in the presence of the same DNA sequence. Starting from these highly
stable epilines, I could dissect their genetic and molecular properties. The induced “epialleles” can be transmitted to the
next generation from both parents in a pseudodominant manner. Moreover, the inherited epialleles display paramutagenic
properties. Because of their epigenetic nature, the epialleles can be stably reset under some specific conditions as hemizygosity,
but they can be only temporarily reset by environmental factors as temperature. One of the molecular signatures of the epialleles
is the differential presence of the Polycomb repressive complexes and their related epigenetic marks. This different distribution
is independent of the transcriptional activity of the downstream genes, at least in an early developmental stage. These results
make a case for strong and stable transgenerational epigenetic inheritance in metazoan and provide a model that is amenable
for the molecular dissection of this phenomenon..

ISSN: 2161-1041

Page 108
DOI: 10.4172/2161-1041-C1-003
Primate skeletal epigenetics: evolutionary implications of DNA methylation patterns and their
phenotypic association in primate skeletal tissues
Genevieve Housman
University of Chicago, USA
Introduction: Epigenetic signatures can be inherited and respond to environmental effects. Thus, it is difficult to determine
whether epigenetic mechanisms that contribute to the expression of diverse phenotypes across species are the result of
inheritance, environmental influences, or both. One way to better isolate these driving forces is by evaluating epigenetic patterns
and their associated phenotypes both intra- and inter-specifically. Inter-specific studies have been initiated in primates, and
some evolutionarily divergent DNA methylation patterns have been associated with phenotypes. However, this research is
limited by the inclusion of only a couple species, and the effects of intra-specific variation on phenotypes have not been readily
studied in nonhuman primates. The current study expands on this exploratory work by assessing the evolutionary relationship
of DNA methylation in the skeletal tissues of several primate species and by examining how this variation relates to aspects of
skeletal development and maintenance.
Methods: Methylation patterns were assessed in femoral bone and cartilage from five nonhuman primate species using
Infinium MethylationEPIC arrays. Nonpathological femur morphologies were measured among species, and the degree of
osteoarthritis, a disorder characterized by the breakdown of bone and cartilage, was also assessed within baboons.
Results: Several phylogenetically distinct methylation patterns are present, which may contribute to inter-specific morphological
differences. However, intra-specific methylation and morphological variation are not related. Conversely, several intra-specific
methylation changes are associated with osteoarthritis in baboons, and some patterns are conserved with those known in
humans.
Conclusions: Overall, these findings reveal a range of evolutionarily conserved and divergent methylation patterns in the
skeletal tissues of primates. Additionally, intra- and inter-specific methylation variation appears to differentially contribute to
healthy and diseased skeletal phenotypes. This work informs our understanding of how epigenome evolution relates to skeletal
phenotypes, and this research perspective may provide further insights into other healthy and disease phenotypes.

ISSN: 2161-1041

Page 109
DOI: 10.4172/2161-1041-C1-003
Epigenetics for precision health & performance

Mickra Hamilton
Apeiron Center for Human Potential, USA
A precision, whole systems genomics approach to thriving health and wellbeing has enormous clinical applications in the
emerging field of environmental epigenetics research. We can now look at all aspects of an individual’s life, their medical
and family history, occupation, their lifestyle, the environments they function in, individual systems diagnostics and genetics
along with real time markers from sensor and mobile data to provide precise lifestyle interventions to optimize and enhance
gene expression. This new precision offers high specificity on health, tracks how individual choices affect health now and how
that translates to the future. It also provides new insights about how we are interacting with our environment, in real time and
in detail. The interplay of our genes and our experiences, of nature and how it interacts with nurture, has now moved from the
mysterious to the knowable. The science of epigenetics assists us to create precise optimization strategies by taking the reigns of
gene expression to adapt and thrive under modern environmental pressures. Every decision we make contributes to this process
in some way. The food we eat, the quality of sleep we experience, the cars we drive, the products we clean with and put on our
skin, the thoughts we think, the levels of stress we carry and the chemicals and medications we dump into our water supply, all
have an effect. This discussion will detail the evidence-based use of precision epigenetics and genomics as strategies to mitigate
the effects of environmental toxins in the human system. Additionally, we will discuss actionable lifestyle modifications and
system support processes to fine tune and enhance our human experience as we interact with our environment.

ISSN: 2161-1041

Page 110
DOI: 10.4172/2161-1041-C1-003
Epigenetic adaptation in high altitude Tibetan population

Nipa Basak1,2, Sheikh Nizamuddin1 and Kumarasamy Thangaraj1
1
CSIR-Centre for Cellular and Molecular Biology, India
2
Academy of Scientific and Innovative Research, India
Statement of the Problem: High altitude adaptation stands important area of research realizing its importance on health and
diseases. A number of genetic studies have been performed in this field to elucidate the mechanism of high altitude adaptation,
but the study on epigenetic mode of adaptation is still in its infancy. Hence, our study focuses on epigenetic perspectives of high
altitude adaptation, DNA methylation in particular, among Tibetan population along with genetic aspects.
Methodology & Theoretical Orientation: The most common form of DNA methylation in vertebrates exists in the form
5-methylcytosine, predominantly observed in CpG rich promoter region. Our present study has been sketched to compare
DNA methylation signatures of Tibetan population, who were native to Ladakh (~5000 metres above sea level) for generations
but presently inhabiting low altitude in Southern India since last ~50 years, along with other Indian populations inhabiting
low altitude in India, using next-generation sequencing method. Extensive data analysis was performed using Bioconductor
and R packages.
Findings: We observed 6 significantly differentially methylated regions in Tibetans compared to other lowlanders. Amongst
them, 5 regions were hypomethylated and one was hypermethylated. Out of these regions, two are present in CYP2E1 and
CRELD1 genes, which were reported to be involved in high altitude adaptation genetically. Rest of the regions are present in
chromosome 4, 7, 11 and 15; including two novel genes, a pseudogene, and a non-genic region.
Conclusion & Significance: Our study, for the first time, explores genome-wide methylation difference between Tibetan
population and other mainland-Indians from low altitude, some of which could be important epigenetic markers of natural
selection. Comparison with native high altitude Tibetans would make the scenario clearer, which is in pipeline.

ISSN: 2161-1041

Page 111
DOI: 10.4172/2161-1041-C1-003
Investigating the nexus between DNA repair pathways and genomic instability in cancer
Sonali Bhattacharjee
Cold Spring Harbor Laboratory, USA
D NA double-strand breaks are one of the most lethal lesions to a cell that can be repaired by one of the two cellular pathways;
non-homologous end joining or homologous recombination. Homologous recombination genes are particularly attractive
targets for precision cancer therapy because these genes have altered expression patterns in cancer cells when compared with
normal cells and these genetic abnormalities can be targeted for selectively killing cancer cells while leaving normal cells
unscathed. Synthetic lethality is thought to be the new frontier of cancer therapeutics because it overcomes the limitation of
chemotherapy, which is unable to discriminate between cancer cells and normal cells. Two genes are synthetically lethal when
simultaneous disruptions of both genes gives rise to a lethal phenotype, while the disruption of either gene alone is viable. Many
homologous recombination genes have synthetic lethal relationships with oncogenes and tumor suppressor genes, which can
be targeted for the development of cancer therapy- an approach referred to as combination therapy. In this presentation, the
author will summarize recent progress in understanding both the functioning and the regulation of the DNA repair machinery
and elaborate on the clinical applications of these proteins in cancer therapy.

ISSN: 2161-1041

Page 112
DOI: 10.4172/2161-1041-C1-003
Role of epigenetic in tree phenotypic plasticity in a context of climate changes

Stéphane Maury
University Orléans - INRA, France
G lobal climate changes in progress will impact forest productivity notably through reduced water availability and heat
periods. One possibility to adapt is phenotypic plasticity for which epigenetic mechanisms are proposed to be a main
source of flexibility. Our objective is to evaluate the potential of DNA methylation to significantly participate to phenotypic
plasticity in trees, fixed and perennials organisms with major ecological roles. Over the 10 last years, using an integrative
approach with ecophysiological, biochemical, transcriptomics, epigenomics (MeDIP, WGBS, Mobilome) and reverse genetics
(RNAi lines) tools, we were able to dissect in the shoot apical meristem (center of the shoot morphogenesis) the response of
trees to environmental variations. This work was assessed in distinct experimental set-ups from greenhouse to field plantations
as well as during the stress or months post-stress. Our data (recently published and unpublished) showed that differentially
methylated regions (DMRs) are associated to active TE and differentially expressed genes with biological functions related to
stress response and phytohormone signaling. Altogether, our data proposed that DNA methylation is a source of flexibility
associated to phenotypic plasticity in trees opening perspectives for tree breeding. The role of epigenetic mechanisms in tree
adaptation and microevolution will be also presented through the results obtained in the frame of the national project EPITREE.

ISSN: 2161-1041

Page 113
DOI: 10.4172/2161-1041-C1-003
Epigenetics of autism
Sara Prada
University of Santiago de Compostela, Spain
F irst described by Kanner, 1943, autism is a neurodevelopmental disorder characterized by repetitive, stereotypical behaviours
and impaired expressive communication, which has since been folded into the broader classification of autism spectrum
disorders (ASD). There are no single known causes of ASD and there are ongoing challenges for diagnosis and treatment. One
of the most critical consequences of ASD is the deficit on social behaviour. We are trying to search for epigenetics (methylation)
patterns that could significantly differentiate between ASD and non-ASD (healthy) individuals and are associated to genes that
could be related with this impaired social communication, often attributed to misreading of emotional cues. Our research
started with the olfactory function. Olfactory function and memory are strongly related with the social communication in
mammals and is still not clear how the olfactory system is affected with ASD. Also, is still unclear why individuals with
ASD misread emotions. Recent results implicate social chemosignaling as a sensory substrate of social impairment in ASD,
implicating a difference in the way of doing an interpretation of social odors for ASD and TD (typically developed) individuals.
Research emerging within the past two decades suggests that immune dysfunction (also in mothers during pregnancy) is a
viable risk factor contributing to the neurodevelopmental deficits observed in ASD. Specific haplotypes of immune genes within
the major histocompatibility complex (MHC) of human chromosome 6 – human leukocyte antigen (HLA) and complement
– have been implicated in ASD. Using cluster analysis to separate methylation levels and an ANOVA analysis with random
subject effects, we are obtaining a quite interesting group of significant CpGs and related to genes potentially associated to ASD,
as the HLA family. Further data processing and statistical analyses are needed in order to arrive to final conclusions. Together,
these data suggest that immune dysregulation resulting from environmental exposures may underlie the pathogenesis of ASD.

ISSN: 2161-1041

Page 114
DOI: 10.4172/2161-1041-C1-003
Effects of prenatal perfluoroalkyl substances exposures on epigenetics

Chen-Yu Liu
National Taiwan University, Taiwan
Background: Perfluoroalkyl substances (PFASs) are stable and persistent in the environment, animals, and humans. PFASs can
penetrate placenta and affect fetal growth. We investigated associations between prenatal exposures to perfluorooctanoic acid
(PFOA), perfluorooctanesulfonate (PFOS), perfluorononanoic acid (PFNA), and perfluoroundecanoic acid (PFUA) and DNA
methylation changes at repeated elements and imprinted genes.
Aims & Methods: The study used the subjects from Taiwan Birth Panel birth cohort study, including all pregnant women who
gave birth between July 2004 and June 2005 in four hospitals in Taipei city and New Taipei City. A total of 363 mother-infant
pairs were included in the final analyses. PFOA, PFOS, PFNA, and PFUA were measured by UPLC-MS/MS in cord blood.
DNA methylation levels were measured in leukocytes from umbilical cord blood. LINE-1 and Alu repeated elements from cord
blood were used to represent global DNA methylation levels. Multivariable regression models were used to adjust potential
confounders.
Results: After controlling for potential confounders, each unit increase in the natural log-transformed PFOS exposure was
associated with lower methylation levels at Alu repeated elements (adjusted β=-0.33, 95% CI = (−0.63, −0.02), p=0.03) and
MEST gene (adjusted β=-2.01, 95% CI = (-3.41, -0.62), p=0.005). No significant effects between PFOA, PFNA, PFUA and
methylation levels in the multivariable regression models were observed.
Conclusions: Our findings suggest that prenatal PFOS exposure may be associated with low Alu and MEST methylation levels.

ISSN: 2161-1041

Page 115
INDEX
Abdulrahman Alshehri 57 Mahmoud Hashemitabar 63
Alexey V Fedulov 44 Marcela Chmelarova 94
Alexey V Fedulov 76 Maria Hatziapostolou 52
Alvaro Macieira Coelho 81 Marina Amorim Rocha 90
Andreas Lennartsson 53 Marta Rucka 51
Anne Clémence Veillard 46 Marvin H Caruthers 42
Avner Shenfeld 75 Michelle M Hanna 66
Celia M Ross 92 Nawel Agher 96
Charles De Smet 80 Nedjai B 54
Danielle Gutman 73 Nefertiti El-Nikhely 100
Jean Baptiste Vannier 87 Péter Nánási 98
Jiangwen Zhang 69 Sheila Coelho Soares Lima 60
Jung Shin Lee 77 Shunsuke Suzuki 86
Kari Stefansson 56 Sriram Rajagopal 59
Klonou A 102 Tao Liu 68
László Imre 99 Xiaogang Steven Wang 62
Madonna R Peter 85

ISSN: 2161-1041

Page 116
CME Credits
Physicians, Health professionals including Nurses and
Nurse practitioners, Physician assistants, Psychologists, Social workers,
Family therapists, Dieticians and Pharmacists
10th International Virology Summit

24th World Nursing and Healthcare Conference
E: eurovirology@microbiologyconferences.org
E: worldnursing@nursingconference.com
W: virology.conferenceseries.com/europe
W: world.nursingconference.com

Gynecology & Gynecologic Oncology Brain Disorders and Therapeutics
July 23-24, 2018 Rome, Italy September 13-15, 2018 Copenhagen, Denmark
E: gynecology@nursingmeetings.com E: braindisorder@neuroconferences.com
W: gynecologiccancer.conferenceseries.com W: braindisorders.conferenceseries.com

Control and Prevention of HIV/AIDS, STDs & STIs
Neurological Disorders & Stroke
E: std@infectiousconferences.com
E: stroke@annualconferences.org
W: globalhiv-aids-std.infectiousconferences.com
W: stroke.neurologyconference.com

Pediatrics & Primary Care
Prevention of Diabetes and Complications
E: pediatricprimarycare@annualconferences.org
E: diabetesmeeting@endocrineconferences.com
graciejones033@gmail.com
W: diabetesmeeting.conferenceseries.com
W: primarycare.pediatricsconferences.com
29th International Conference on 13th World Conference on

Adolescent Medicine & Child Psychology Neurology and Neuromuscular Disorders
September 04-06, 2018 Zurich, Switzerland October 01-02, 2018 Frankfurt, Germany
E: childpsychology@psychiatrycongress.com E: neuromuscular@surgerymeetings.com
W: childpsychology.conferenceseries.com W: neuromuscular.neuroconferences.com

Clinical and Experimental Ophthalmology
Hypertension & Healthcare
E: ophthalmology@ophthalmologyconferences.com
E: hypertensionconference2018@rediffmail.com
W: ophthalmology.conferenceseries.com
W: hypertension.conferenceseries.com
24th European Pediatrics Conference 5th International Conference on

September 10-11, 2018 Copenhagen, Denmark Gynecology and Obstetrics
E: europediatrics@gmail.com October 08-10, 2018 Zurich, Switzerland
europediatrics@annualconferences.org E: gynecology@nursingconference.com
W: pediatrics.conferenceseries.com/europe W: gynecology.conferenceseries.com

3rd European Otolaryngology-ENT Surgery Conference
Immunology & Immunotechnology
October 08-10, 2018 London, UK
EPIGENETICS 2018
E: entsurgery@surgeryconferences.org
E: immunologycongress@annualconferences.org
W: ent.conferenceseries.com
W: immunologycongress.immunologyconferences.org
Page 117
CME Credits
Physicians, Health professionals including Nurses and
Nurse practitioners, Physician assistants, Psychologists, Social workers,
Family therapists, Dieticians and Pharmacists

33rd Euro Nursing & Medicare Summit
Psychiatry & Psychosomatic Medicine
October 08-10, 2018 Edinburgh, Scotland
E: euronursing@nursingconference.com
E: psychosomaticmedicine@psychiatrycongress.com
W: europe.nursingconference.com
W: psychosomatic.conferenceseries.com

Central Nervous System Disorders & Therapeutics
November 12-14, 2018 Edinburgh, Scotland
E: worldcancer@meettheglobalexpert.com
E: cns@neuroconferences.com
W: cns.conferenceseries.com
25th World Pediatrics Conference 9th Global Experts Meeting on

October 18-20, 2018 Warsaw, Poland Neuropharmacology
E: worldpediatricsconference@gmail.com November 15-16, 2018 Frankfurt, Germany
W: worldpediatrics.pediatricsconferences.org E: neuropharmacology@conferenceseries.net
W: neuro.pharmaceuticalconferences.com
7th International Chronic Obstructive 29th World Cardiology Conference

Pulmonary Disease Conference November 19-20, 2018 Edinburgh, Scotland
October 22-23, 2018 Rome, Italy E: worldcardiology@cardiologymeeting.com
E: copdconference@meettheglobalexpert.com W: worldcardiology.conferenceseries.com
W: copd.conferenceseries.com/europe
27th European Cardiology Conference 22nd European Nutritional Science Congress

October 22-24, 2018 Rome, Italy November 26-27, 2018 Barcelona, Spain
E: eurocardiology@cardiologymeeting.com E: nutritionalscience@annualconferences.org
W: cardiologyconference.cardiologymeeting.com W: nutritionalscience.nutritionalconference.com

27th European Ophthalmology Congress
Alzheimer’s Disease & Dementia
October 29-31, 2018 Valencia, Spain
E: ophthalmologycongress@ophthalmologyconferences.com
E: dementia@neuroconferences.org
W: ophthalmologycongress.ophthalmologyconferences.com
W: alzheimers-dementia.neuroconferences.com
EPIGENETICS 2018
Page 118
Meet Inspiring Speakers and Experts at our 3000+ Global Events with
1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on
Medical, Pharma, Engineering, Science, Technology, Business and
700+ Open Access Journals
Conferences Publishing Global Research Business
Networking
Exhibitions Collaborations International Advertisements &

Careers Memberships Promotions
Conferences By Continent
USA & Americas
USA Brazil Canada Mexico
Asia-Pacific
Australia China India Japan Malaysia New Zealand Philippines Singapore South Korea
Europe & Middle East

Austria Denmark Finland France Germany Italy Netherlands Norway Poland
South Africa Spain Switzerland Turkey UAE UK Ukraine
Medical & Clinical Journals and Conferences

Alternative Healthcare Gastroenterology Health Policies Oncology & Cancer Physical Therapy Vaccines
Cardiology Healthcare Neuroscience Ophthalmology Rehabilitation Reproductive
Dentistry Management Nephrology Palliativecare Psychiatry Medicine &
Dermatology Hematology Nursing Pathology Pulmonology Women Healthcare
Diabetes & Infectious Diseases Obesity Pediatrics Radiology
Endocrinology Medical Ethics Surgery
Journals and Conferences by Subject

Agri, Food & Aqua Chemistry Geology & Earth Science Nanotechnology Pharma Marketing &
Biochemistry EEE & Engineering Immunology Nutrition Industry
Business & Management Environmental Science Materials Science Oncology & Cancer Pharmaceutical Sciences
Chemical Engineering Genetics & Molecular Microbiology Petroleum Physics
Biology Veterinary
Contact us
Conference Series llc LTD - UK Conference Series - Asia Pacific
47 Churchfield Road, London, W3 6AY 6th Floor, North Block, Divyasree Building, Raidurg, Hyderabad
Toll Free: +1-800-014-8923 Telangana, INDIA-500032 P: +91-40-33432300
E: europe@conferenceseries.com E: asia@conferenceseries.com
Toll Free
Australia - 1-800-651-097 | France - 0805-080048 | Hyderabad - 91-40-71279012
Hyderabad - 91-40-71279013 | UK - 0-800-014-8923
Los Angeles Downtown - 1-213-233-9462 | USA/Canada - 1-888-843-8169
Page 119
Upcoming Oncology and Cancer Conferences

3rd Cancer Diagnostics & Treatment Conference
November 29-December 01, 2018 Dublin, Ireland
W: cancerdiagnostics.insightconferences.com
13th World Biomarkers Congress
W: biomarkers.insightconferences.com
34th Euro-Global Summit on
Cancer Therapy & Radiation Oncology
W: cancer-radiationoncology.insightconferences.com
Bookmark your Dates


August 22-23, 2019 | Vienna, Austria
E: epigenetics@oncologyseries.com; epigenetics@conferenceseries.net
Website: epigenetics.conferenceseries.com

Epigenetics Congress 2018 Book

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Epigenetics Congress 2018 Book

Uploaded by

Copyright:

Available Formats

September 2018 | Volume 7

conferenceseries.com ISSN: 2161-1041

Conference Series llc LTD - UK

Exhibitors Toll Free: +1-800-014-8923

Opening Ceremony 09:30-09:55

Title: DNA analogues for CRISPER/CAS fidelity and exon skipping

Title: Maternal exposure to environmental particles leads to transgenerational epigenetic

Group Photo, Networking & Refreshments 11:20-11:50 @ Foyer

Sessions: Epigenetics | Cancer Epigenetics | DNA Methylation

Chair: Michelle M. Hanna, Ribomed Biotechnologies, USA

Lunch Break 13:05-14:05 @ Hotel Restaurants

Title: Epigenetic regulation of leukemia

Special Session | Title: The genetics of common diseases

Title: Generation of long acting therapies using glycosylated linkers

Networking & Refreshments 16:10-16:30 @ Foyer

Title: Robust joint statistical tests for DNA methylation data

Title: Role of DNA methylation in sperm nuclear-encoded of oxidative phosphorylation pathway

Networking & Refreshments 11:25 -11:45 @ Foyer

Sessions: Epigenetics | Chromatin

Chair: Marvin H Caruthers, University of Colorado, USA

Lunch Break 13:15-14:15 @ Hotel Restaurants

Title: Epigenetic editing in the promoter of CXCL11 gene

Title: Transcriptional regulation by histone modifications using yeast model

Poster Presentations 15:05-16:05

Title:Writing about epigenetics for allied health professionals in gerontology

Title: Role of DNA methylation in resistance to platinum-based chemotherapy in ovarian cancer

Title: Doxorubicin induces large-scale histone redistribution in live cells

Title: H2A.Z: stable or not stable that is the question

Title: Metastasis-associated protein 2 (MTA2) as a regulator of NF-kB in lung cancer

Title: Emerging role of histone Lysine Methyltransferase SETDB1 and repressive

Networking & Refreshments 16:05-16:25 @ Foyer

Title: The decline of the prevalence of cancers during organism senescence

Networking & Refreshments 11:25-11: 45 @ Foyer

Sessions: Genomics | Biomarkers | Histone Proteins

Chair: Jiangwen Zhang, University of Hong Kong, Hong Kong

Lunch Break 13:00-14:00 @ Hotel Restaurants

Awards & Closing Ceremony

Bookmark your Dates

Epigenetics & Chromatin

Chemical Engineering Clinical Psychiatry

Earth & Environmental Sciences Membrane Science & Technology 2155-9589

EEE Chemical Biology & Therapeutics -

Engineering Cytology & Histology 2157-7099

Biosensors Journal 2090-4967 Metabolomics: Open Access 2153-0769

Impact Factor Calculation:

4th International Congress on

Epigenetics & Chromatin

Hereditary Genetics: Current Research

Journal of Cancer Science & Therapy

Journal of Carcinogenesis & Mutagenesis

6th Global Summit on Plant Science

3rd International Conference on

3rd International Conference on

14th International Conference on Structural Biology 27th European Cardiology Conference

12th International Conference on

8th International Conference on

8th World Congress on 6th International Conference and Exhibition on

11th World Bioenergy Congress and Expo 4th International Conference on

14th International Conference and Exhibition on

9th Euro Biosensors and Bioelectronics conference

World Conference on Ecology 13th Euro-Global Gastroenterology Conference

8th World Congress and Expo on 3rd International conference on

11th International Conference on

21st International Conference on 9th international summit on